 MERGER AGREEMENT     

  

Exhibit 2.1

  

   * * *

 

  

  

  

 


 

  

AGREEMENT AND PLAN OF MERGER

  

  

Dated as of June 20, 2010,

  

  

Among

  

  

Valeant Pharmaceuticals International,

  

  

Biovail Corporation,

  

  

Biovail Americas Corp.

  

  

and

  

  

Beach Merger Corp.

  

  

  

   * * *

 

  

  

  

 

 

 

  

   

  

 

 

 

  


 

  

TABLE OF CONTENTS

  

  

Page

  

  

    

ARTICLE I

   
--- 
    
  

The Merger

   
    
  

SECTION 1.01.

  |  

The Merger

  |  

2

   
  

SECTION 1.02.

  |  

Closing

  |  

2

   
  

SECTION 1.03.

  |  

Effective Time

  |  

2

   
  

SECTION 1.04.

  |  

Effects

  |  

3

   
  

SECTION 1.05.

  |  

Certificate of Incorporation and By-Laws

  |  

3

   
  

SECTION 1.06.

  |  

Directors and Officers of Surviving Company

  |  

3

   
    
    
  

ARTICLE II

   
    
  

Effect on the Capital Stock of the Constituent Entities; Exchange of
Certificates

   
    
  

SECTION 2.01.

  |  

Effect on Capital Stock

  |  

3

   
  

SECTION 2.02.

  |  

Exchange of Certificates

  |  

5

   
    
    
  

ARTICLE III

   
    
  

Representations and Warranties of Biovail, BAC and Merger Sub

   
    
  

SECTION 3.01.

  |  

Organization, Standing and Power

  |  

9

   
  

SECTION 3.02.

  |  

Biovail Subsidiaries

  |  

9

   
  

SECTION 3.03.

  |  

Capital Structure

  |  

10

   
  

SECTION 3.04.

  |  

Authority; Execution and Delivery; Enforceability

  |  

11

   
  

SECTION 3.05.

  |  

No Conflicts; Consents

  |  

13

   
  

SECTION 3.06.

  |  

Reporting Documents; Undisclosed Liabilities

  |  

15

   
  

SECTION 3.07.

  |  

Information Supplied

  |  

17

   
  

SECTION 3.08.

  |  

Absence of Certain Changes or Events

  |  

17

   
  

SECTION 3.09.

  |  

Taxes

  |  

19

   
  

SECTION 3.10.

  |  

Employee Benefits

  |  

21

   
  

SECTION 3.11.

  |  

Litigation

  |  

22

   
  

SECTION 3.12.

  |  

Compliance with Applicable Laws

  |  

22

   
  

SECTION 3.13.

  |  

Environmental Matters

  |  

22

   
  

SECTION 3.14.

  |  

Contracts

  |  

24

   
  

SECTION 3.15.

  |  

Properties

  |  

25

   
  

SECTION 3.16.

  |  

Intellectual Property

  |  

25

   
  

SECTION 3.17.

  |  

Regulatory Matters

  |  

27

   
  

SECTION 3.18.

  |  

Insurance

  |  

31

   
  

SECTION 3.19.

  |  

Labor and Employment Matters

  |  

31

   
  

SECTION 3.20.

  |  

Brokers' Fees and Expenses

  |  

31

   
  

SECTION 3.21.

  |  

Opinion of Financial Advisor

  |  

31

   
 

  


 

  

  

 

 

 

  

 

i  

  

 

 

 

  

  

  

    

SECTION 3.22.

  |  

BAC; Merger Sub

  |  

31

   
---|---|--- 
  

SECTION 3.23.

  |  

Affiliate Transactions

  |  

31

   
  

SECTION 3.24.

  |  

No Other Representations or Warranties

  |  

32

   
    
    
  

ARTICLE IV

   
    
  

Representations and Warranties of Valeant

   
    
  

SECTION 4.01.

  |  

Organization, Standing and Power

  |  

32

   
  

SECTION 4.02.

  |  

Valeant Subsidiaries

  |  

33

   
  

SECTION 4.03.

  |  

Capital Structure

  |  

33

   
  

SECTION 4.04.

  |  

Authority; Execution and Delivery; Enforceability

  |  

35

   
  

SECTION 4.05.

  |  

No Conflicts; Consents

  |  

36

   
  

SECTION 4.06.

  |  

Reporting Documents; Undisclosed Liabilities

  |  

38

   
  

SECTION 4.07.

  |  

Information Supplied

  |  

39

   
  

SECTION 4.08.

  |  

Absence of Certain Changes or Events

  |  

40

   
  

SECTION 4.09.

  |  

Taxes

  |  

41

   
  

SECTION 4.10.

  |  

Employee Benefits

  |  

43

   
  

SECTION 4.11.

  |  

Litigation

  |  

44

   
  

SECTION 4.12.

  |  

Compliance with Applicable Laws

  |  

45

   
  

SECTION 4.13.

  |  

Environmental Matters

  |  

45

   
  

SECTION 4.14.

  |  

Contracts

  |  

46

   
  

SECTION 4.15.

  |  

Properties

  |  

47

   
  

SECTION 4.16.

  |  

Intellectual Property

  |  

47

   
  

SECTION 4.17.

  |  

Regulatory Matters

  |  

48

   
  

SECTION 4.18.

  |  

Insurance

  |  

52

   
  

SECTION 4.19.

  |  

Labor and Employment Matters

  |  

52

   
  

SECTION 4.20.

  |  

Brokers' Fees and Expenses

  |  

52

   
  

SECTION 4.21.

  |  

Opinion of Financial Advisor

  |  

52

   
  

SECTION 4.22.

  |  

Affiliate Transactions

  |  

53

   
  

SECTION 4.23.

  |  

No Other Representations or Warranties

  |  

53

   
    
    
  

ARTICLE V

   
    
  

Covenants Relating to Conduct of Business

   
    
  

SECTION 5.01.

  |  

Conduct of Business

  |  

53

   
  

SECTION 5.02.

  |  

No Solicitation by Biovail; Biovail Board Recommendation

  |  

61

   
  

SECTION 5.03.

  |  

No Solicitation by Valeant; Valeant Board Recommendation

  |  

65

   
    
    
  

ARTICLE V

   
    
  

Additional Agreements

   
    
  

SECTION 6.01.

  |  

Preparation of the Form S-4 and the Joint Proxy Statement; Stockholders
Meetings

  |  

68

   
 

  

  

  

 

 

 

  

 

ii  

  

 

 

 

  


 

  


 

  

    

SECTION 6.02.

  |  

Access to Information; Confidentiality

  |  

71

   
---|---|--- 
  

SECTION 6.03.

  |  

Required Actions

  |  

72

   
  

SECTION 6.04.

  |  

Equity Awards; Change in Control Provisions

  |  

75

   
  

SECTION 6.05.

  |  

Indemnification, Exculpation and Insurance

  |  

79

   
  

SECTION 6.06.

  |  

Fees and Expenses

  |  

81

   
  

SECTION 6.07.

  |  

Certain Tax Matters

  |  

83

   
  

SECTION 6.08.

  |  

Transaction Litigation

  |  

83

   
  

SECTION 6.09.

  |  

Section 16 Matters

  |  

84

   
  

SECTION 6.10.

  |  

Governance Matters

  |  

84

   
  

SECTION 6.11.

  |  

Financing

  |  

84

   
  

SECTION 6.12.

  |  

Public Announcements

  |  

85

   
  

SECTION 6.13.

  |  

Stock Exchange Listing

  |  

86

   
  

SECTION 6.14.

  |  

Joinder Agreement

  |  

86

   
  

SECTION 6.15.

  |  

Entity Name

  |  

86

   
  

SECTION 6.16.

  |  

Valeant Warrants and Valeant Convertible Notes

  |  

86

   
  

SECTION 6.17.

  |  

Pre-Merger Special Dividend

  |  

87

   
    
    
  

ARTICLE VII

   
    
  

Conditions Precedent

   
    
  

SECTION 7.01.

  |  

Conditions to Each Party's Obligation to Effect the Merger

  |  

88

   
  

SECTION 7.02.

  |  

Conditions to Obligations of Valeant

  |  

89

   
  

SECTION 7.03.

  |  

Conditions to Obligation of Biovail, BAC and Merger Sub

  |  

90

   
    
    
  

ARTICLE VIII

   
    
  

Termination Amendment and Waiver

   
    
  

SECTION 8.01.

  |  

Termination

  |  

91

   
  

SECTION 8.02.

  |  

Effect of Termination

  |  

93

   
  

SECTION 8.03.

  |  

Amendment

  |  

93

   
  

SECTION 8.04.

  |  

Extension; Waiver

  |  

93

   
  

SECTION 8.05.

  |  

Procedure for Termination, Amendment, Extension or Waiver

  |  

94

   
  

SECTION 8.06.

  |  

Alternative Structure.

  |  

84

   
    
    
  

ARTICLE IX

   
    
  

General Provisions

   
    
  

SECTION 9.01.

  |  

Nonsurvival of Representations and Warranties

  |  

94

   
  

SECTION 9.02.

  |  

Notices

  |  

94

   
  

SECTION 9.03.

  |  

Definitions

  |  

96

   
  

SECTION 9.04.

  |  

Interpretation

  |  

100

   
 

  

  

  

 

 

 

  

 

iii  

  

 

 

 

  


 

  

    

SECTION 9.05.

  |  

Severability

  |  

100

   
---|---|--- 
  

SECTION 9.06.

  |  

Counterparts

  |  

101

   
  

SECTION 9.07.

  |  

Entire Agreement; No Third-Party Beneficiaries

  |  

101

   
  

SECTION 9.08.

  |  

Governing Law

  |  

101

   
  

SECTION 9.09.

  |  

Assignment

  |  

101

   
  

SECTION 9.10.

  |  

Specific Enforcement

  |  

101

   
  

SECTION 9.11.

  |  

Waiver of Jury Trial

  |  

102

   
 

  


 

  


 

  

    

Exhibit A

  |  

Governance Matters

   
---|--- 
  

Exhibit B

  |  

Form of Joinder Agreement

   
  

Exhibit C

  |  

Commitment Letter

   
 

  


 

  

  

 

 

 

  

 

iv  

  

 

 

 

  

  

  

AGREEMENT AND PLAN OF MERGER (this "Agreement"), dated as of June 20, 2010,
among Valeant Pharmaceuticals International, a Delaware corporation
("Valeant"), Biovail Corporation, a Canadian corporation ("Biovail"), Biovail
Americas Corp., a Delaware corporation and a wholly owned subsidiary of
Biovail ("BAC"), and Beach Merger Corp., a Delaware corporation and a newly
formed, wholly owned subsidiary of BAC ("Merger Sub").

  

  

WHEREAS the Board of Directors of Valeant, the Board of Directors of Biovail,
the Board of Directors of BAC and the Board of Directors of Merger Sub have
approved this Agreement, determined that the merger of Merger Sub with and
into Valeant, upon the terms and subject to the conditions set forth in this
Agreement, are in the best interests of Valeant, Biovail or Merger Sub, as
applicable, and their respective stockholders and declared the advisability of
this Agreement;

  

  

WHEREAS the Board of Directors of Valeant and the Board of Directors of Merger
Sub has recommended adoption or approval, as applicable, of this Agreement by
their respective stockholders, as applicable;

  

  

WHEREAS the Board of Directors of Biovail has recommended the approval by its
stockholders of the issuance of common shares of Biovail contemplated by this
Agreement;

  

  

WHEREAS Valeant intends to declare and pay the Pre-Merger Special Dividend one
Business Day immediately prior to the Closing Date, payable to holders of
record of Valeant Common Stock as of the close of business one Business Day
immediately prior to the Closing Date;

  

  

WHEREAS the Board of Directors of Valeant and the Board of Directors of
Biovail have determined that the declaration and payment of the Post-Merger
Special Dividend will be in the best interests of the Combined Company and its
stockholders;

  

  

WHEREAS for U.S. Federal income Tax purposes, the Merger is intended (i) to
qualify as a "reorganization" within the meaning of Section 368(a) of the Code
and (ii) to not result in gain being recognized under Section 367(a)(1) of the
Code (other than for any stockholder that would be a "five-percent transferee
shareholder" (within the meaning of United States Treasury Regulations Section
1.367(a)-3(c)(5)(ii)) of Biovail following the Merger that does not enter into
a five-year gain recognition agreement in the form provided in United States
Regulations Section 1.367(a)-8(c)) (the "Intended Tax Treatment"), and this
Agreement is intended to be, and is adopted as, a "plan of reorganization" for
purposes of Sections 354 and 361 of the Code; and

  

  

  

 

 

 

  

 

1  

  

 

 

 

  

  

  

WHEREAS Valeant, Biovail, BAC and Merger Sub desire to make certain
representations, warranties, covenants and agreements in connection with the
Merger and also to prescribe various conditions to the Merger.

  

  

NOW, THEREFORE, in consideration of the foregoing, and the respective
representations, warranties, covenants and agreements set forth herein, and
intending to be legally bound, the parties hereto agree as follows:

  

  

  

ARTICLE I

  

  

The Merger

  

  

SECTION 1.01. The Merger. On the terms and subject to the conditions set forth
in this Agreement, and in accordance with the General Corporation Law of the
State of Delaware (the "DGCL"), on the Closing Date, Merger Sub shall be
merged with and into Valeant (the "Merger"). At the Effective Time, the
separate corporate existence of Merger Sub shall cease and Valeant shall
continue as the surviving company in the Merger (the "Surviving Company").

  

  

SECTION 1.02. Closing. The closing (the "Closing") of the Merger shall take
place at the offices of Cravath, Swaine and Moore LLP, Worldwide Plaza, 825
Eighth Avenue, New York, New York 10019 at 10:00 a.m., New York City time, on
a date to be specified by Valeant and Biovail, which shall be no later than
the second Business Day following the satisfaction or (to the extent permitted
by Law) waiver by the party or parties entitled to the benefits thereof of the
conditions set forth in Article VII (other than those conditions that by their
nature are to be satisfied at the Closing, but subject to the satisfaction or
(to the extent permitted by Law) waiver of those conditions), or at such other
place, time and date as shall be agreed in writing between Valeant and
Biovail; provided, however, that if all the conditions set forth in Article
VII shall not have been satisfied or (to the extent permitted by Law) waived
on such second Business Day, then the Closing shall take place on the first
Business Day on which all such conditions shall have been satisfied or (to the
extent permitted by Law) waived or at such other time and date as shall be
agreed in writing between Valeant and Biovail. The date on which the Closing
occurs is referred to in this Agreement as the "Closing Date".

  

  

SECTION 1.03. Effective Time. Subject to the provisions of this Agreement, as
soon as practicable on the Closing Date, the parties shall file with the
Secretary of State of the State of Delaware the certificate of merger relating
to the Merger (the "Certificate of Merger"), executed and acknowledged in
accordance with the relevant provisions of the DGCL, and, as soon as
practicable on or after the Closing Date, shall make all other filings
required under the DGCL or by the Secretary of State of the State of Delaware
in connection with the Merger. The Merger shall become effective at the time
specified in the Certificate of Merger, which shall be on the Business Day
following the date that the Certificate of Merger has been duly filed with the
Secretary of State of the State of Delaware, or at such later time as Valeant
and Biovail shall agree and specify in the Certificate of Merger (the time the
Merger becomes effective being the "Effective Time").

  

  

  

 

 

 

  

 

2  

  

 

 

 

  

  

  

SECTION 1.04. Effects. The Merger shall have the effects set forth in this
Agreement and Section 259 of the DGCL.

  

  

SECTION 1.05. Certificate of Incorporation and By-Laws. The certificate of
incorporation of Merger Sub, as in effect immediately prior to the Effective
Time, shall be the certificate of incorporation of the Surviving Company until
thereafter changed or amended as provided therein or by applicable Law, except
that the name of the Surviving Company shall be amended to be consistent with
the terms of Section 6.15. The by-laws of Merger Sub, as in effect immediately
prior to the Effective Time, shall be the by-laws of the Surviving Company
until thereafter changed or amended as provided therein or by applicable Law,
except that references to the name of Merger Sub shall be replaced by the name
of the Surviving Company.

  

  

SECTION 1.06. Directors and Officers of Surviving Company. The directors of
the Surviving Company shall be composed of the individuals identified on Annex
1.06 attached hereto (as it may be amended or modified from time to time after
the date hereof and prior to the Effective Time by the mutual written consent
of Biovail and Valeant) and shall continue until the earlier of their
resignation or removal or until their respective successors are duly elected
and qualified, as the case may be. The officers of Valeant immediately prior
to the Effective Time shall be the officers of the Surviving Company until the
earlier of their resignation or removal or until their respective successors
are duly elected or appointed and qualified, as the case may be.

  

  

  

ARTICLE II

  

  

Effect on the Capital Stock of the Constituent Entities; Exchange of
Certificates

  

  

SECTION 2.01. Effect on Capital Stock. At the Effective Time, by virtue of the
Merger and without any action on the part of Valeant, Biovail, BAC, Merger Sub
or the holder of any shares of Valeant Common Stock or Merger Sub Common
Stock:

  

  

(a) Conversion of Merger Sub Common Stock. Each share of common stock, par
value $0.01 per share, in Merger Sub ("Merger Sub Common Stock") issued and
outstanding immediately prior to the Effective Time shall be converted into
one fully paid and nonassessable share of common stock, par value $0.01 per
share, of the Surviving Company ("Surviving Company Common Stock") with the
same rights, powers and privileges as the shares so converted (the "Converted
Shares"). In addition to the foregoing conversion, the Surviving Company shall
issue 10,000,000 shares of Surviving Company Common Stock (the "Issued
Shares") to BAC contemporaneously with the Closing in consideration for the
deposit of the Merger Consideration by or on behalf of BAC with the Exchange
Agent. The Converted Shares and the Issued Shares shall constitute the only
outstanding shares of capital stock of the Surviving Company. From and after
the Effective Time, all certificates representing shares of Merger Sub Common
Stock shall be deemed for all purposes to represent the Converted Shares and
the Issued Shares until the Board of the Surviving Company issues new
certificates in respect of such shares.

  

  

  

 

 

 

  

 

3  

  

 

 

 

  

  

  

(b) Cancellation of Treasury Stock and Biovail-Owned Stock. Each share of
common stock, par value $0.01, of Valeant (the "Valeant Common Stock") that is
owned by Valeant as treasury stock and each share of Valeant Common Stock, if
any, that is owned by Biovail, BAC or Merger Sub immediately prior to the
Effective Time shall no longer be outstanding and shall automatically be
canceled and shall cease to exist, and no consideration shall be delivered in
exchange therefor.

  

  

(c) Conversion of Valeant Common Stock. Each share of Valeant Common Stock
issued and outstanding immediately prior to the Effective Time (other than
shares to be canceled in accordance with Section 2.01(b) and except as
provided in Section 2.01(d) with respect to the Appraisal Shares) shall be
converted into the right to receive that number of fully paid and
nonassessable common shares in the capital of Biovail (the "Biovail Common
Stock") equal to the Exchange Ratio (the "Merger Consideration"). All such
shares of Valeant Common Stock, when so converted, shall no longer be
outstanding and shall automatically be canceled and shall cease to exist, and
each holder of a certificate (or evidence of shares in book-entry form) that
immediately prior to the Effective Time represented any such shares of Valeant
Common Stock (each, a "Certificate") shall cease to have any rights with
respect thereto, except the right to receive the Merger Consideration, the
Pre-Merger Special Dividend (to the extent not previously paid) and any cash
in lieu of fractional shares of Biovail Common Stock to be issued or paid in
consideration therefor and any dividends or other distributions to which
holders become entitled upon the surrender of such Certificate in accordance
with Section 2.02, without interest. For purposes of this Agreement, the
"Exchange Ratio" means 1.7809. The Exchange Ratio shall be calculated to the
nearest one-ten-thousandth of a share of Biovail Common Stock. Notwithstanding
the foregoing, if between the date of this Agreement and the Effective Time
the outstanding shares of Biovail Common Stock or Valeant Common Stock shall
have been changed into a different number of shares or a different class, by
reason of any stock dividend, subdivision, reclassification, recapitalization,
split, combination, consolidation or exchange of shares, or any similar event
shall have occurred, then any number or amount contained herein which is based
upon the number of shares of Biovail Common Stock or Valeant Common Stock, as
the case may be, will be appropriately adjusted to provide to Biovail and the
holders of Valeant Common Stock the same economic effect as contemplated by
this Agreement prior to such event. As provided in Section 2.02(i), the right
of any holder of a Certificate to receive the Merger Consideration or other
consideration shall be subject to and reduced by the amount of any withholding
under applicable Tax Law.

  

  

  

 

 

 

  

 

4  

  

 

 

 

  

  

(d) Appraisal Rights. Notwithstanding anything in this Agreement to the
contrary, shares ("Appraisal Shares") of Valeant Common Stock issued and
outstanding immediately prior to the Effective Time that are held by any
Person who is entitled to demand and properly demands appraisal of such
Appraisal Shares pursuant to, and who complies in all respects with, Section
262 of the DGCL ("Section 262") shall not be converted into Merger
Consideration as provided in this Section 2.01, but rather the holders of
Appraisal Shares shall be entitled to payment of the fair value of such
Appraisal Shares in accordance with Section 262. At the Effective Time, all
Appraisal Shares shall no longer be outstanding, shall automatically be
canceled and shall cease to exist, and each holder of Appraisal Shares shall
cease to have any rights with respect thereto, except the right to receive the
fair value of such Appraisal Shares in accordance with the provisions of
Section 262. Notwithstanding the foregoing, if any such holder shall fail to
perfect or otherwise shall waive, withdraw or lose the right to appraisal
under Section 262, or a court of competent jurisdiction shall determine that
such holder is not entitled to the relief provided by Section 262, then the
right of such holder to be paid the fair value of such holder's Appraisal
Shares shall cease and such Appraisal Shares shall be deemed to have been
converted as of the Effective Time into, and to have become, the right to
receive the Merger Consideration as provided in this Section 2.01. Valeant
shall give prompt notice to Biovail of any demands received by Valeant for
appraisal of any shares of Valeant Common Stock, withdrawals of such demands
and any other instruments served pursuant to Section 262 received by Valeant.
Biovail shall have the right to participate in all negotiations and
proceedings with respect to such demands. Prior to the Effective Time, Valeant
shall not, without the prior written consent of Biovail (not to be
unreasonably withheld, delayed or conditioned), make any payment with respect
to, or settle or offer to settle, any such demands, or agree to do any of the
foregoing.

  

  

SECTION 2.02. Exchange of Certificates. (a) Exchange Agent. Prior to the
Effective Time, Biovail and Valeant shall agree upon and appoint a bank or
trust company to act as exchange agent (the "Exchange Agent") for the payment
of the Merger Consideration. At or prior to the Effective Time, Biovail shall
deposit on behalf of BAC, or shall cause BAC to deposit, with the Exchange
Agent, for the benefit of the holders of Certificates, for exchange in
accordance with this Article II through the Exchange Agent, certificates
representing the shares of Biovail Common Stock to be issued as Merger
Consideration and cash sufficient to make payments in lieu of fractional
shares pursuant to Section 2.02(e). All such Biovail Common Stock and cash
deposited with the Exchange Agent is hereinafter referred to as the "Exchange
Fund". As promptly as practicable after the Effective Time, and in any event
not later than the second Business Day thereafter, Biovail shall cause the
Exchange Agent to mail to each holder of record of Valeant Common Stock a form
of letter of transmittal (which shall specify that delivery shall be effected,
and risk of loss and title to any Certificates shall pass, only upon delivery
of such Certificates to the Exchange Agent and shall be in such form and have
such other provisions (including customary provisions with respect to delivery
of an "agent's message" with respect to shares held in book-entry form) as
Biovail may specify, subject to Valeant's approval), together with
instructions thereto.

  

  

  

 

 

 

  

 

5  

  

 

 

 

  

  

  

(b) Merger Consideration Received in Connection with Exchange. Upon (i) in the
case of shares of Valeant Common Stock represented by a Certificate, the
surrender of such Certificate for cancellation to the Exchange Agent, or (ii)
in the case of shares of Valeant Common Stock held in book-entry form, the
receipt of an "agent's message" by the Exchange Agent, in each case together
with the letter of transmittal, duly, completely and validly executed in
accordance with the instructions thereto, and such other documents as may
reasonably be required by the Exchange Agent, the holder of such shares shall
be entitled to receive in exchange therefor (x) the Merger Consideration into
which the shares of Valeant Common Stock have been converted pursuant to
Section 2.01 and (y) any cash in lieu of fractional shares which the holder
has the right to receive pursuant to Section 2.02(e) and in respect of any
dividends or other distributions which the holder has the right to receive
pursuant to Section 2.02(c). In the event of a transfer of ownership of
Valeant Common Stock that is not registered in the transfer records of
Valeant, a certificate representing the proper number of shares of Biovail
Common Stock pursuant to Section 2.01 and cash in lieu of fractional shares
which the holder has the right to receive pursuant to Section 2.02(e) and in
respect of any dividends or other distributions which the holder has the right
to receive pursuant to Section 2.02(c) may be issued to a transferee if the
Certificate representing such Valeant Common Stock (or, if such Valeant Common
Stock is held in book-entry form, proper evidence of such transfer) is
presented to the Exchange Agent, accompanied by all documents required to
evidence and effect such transfer and by evidence that any applicable stock
transfer Taxes have been paid. Until surrendered as contemplated by this
Section 2.02(b), each share of Valeant Common Stock and any Certificate with
respect thereto shall be deemed at any time after the Effective Time to
represent only the right to receive upon such surrender the Merger
Consideration which the holders of such shares were entitled to receive in
respect of such shares pursuant to Section 2.01 (and cash in lieu of
fractional shares pursuant to Section 2.02(e) and in respect of any dividends
or other distributions pursuant to Section 2.02(c)). No interest shall be paid
or shall accrue on the cash payable upon surrender of any Certificate (or
shares of Valeant Common Stock held in book-entry form).

  

  

(c) Treatment of Unexchanged Shares. No dividends or other distributions
declared or made with respect to Biovail Common Stock with a record date after
the Effective Time shall be paid to the holder of any unsurrendered
Certificate (or shares of Valeant Common Stock held in book-entry form) with
respect to the shares of Biovail Common Stock issuable upon surrender thereof,
and no cash payment in lieu of fractional shares shall be paid to any such
holder pursuant to Section 2.02(e), until the surrender of such Certificate
(or shares of Valeant Common Stock held in book-entry form) in accordance with
this Article II. Subject to escheat, Tax or other applicable Law, following
surrender of any such Certificate (or shares of Valeant Common Stock held in
book-entry form), there shall be paid to the holder of the certificate
representing whole shares of Biovail Common Stock issued in exchange therefor,
without interest, (i) at the time of such surrender, the amount of any cash
payable in lieu of a fractional share of Biovail Common Stock to which such
holder is entitled pursuant to Section 2.02(e) and the amount of dividends or
other distributions with a record date after the Effective Time theretofore
paid with respect to such whole shares of Biovail Common Stock and (ii) at the
appropriate payment date, the amount of dividends or other distributions with
a record date after the Effective Time but prior to such surrender and a
payment date subsequent to such surrender payable with respect to such whole
shares of Biovail Common Stock.

  

  

  

 

 

 

  

 

6  

  

 

 

 

  

  

  

(d) No Further Ownership Rights in Valeant Common Stock. The shares of Biovail
Common Stock issued and cash paid in accordance with the terms of this Article
II upon conversion of any shares of Valeant Common Stock (including any cash
paid pursuant to Section 2.02(e)) shall be deemed to have been issued and paid
in full satisfaction of all rights pertaining to such shares of Valeant Common
Stock. From and after the Effective Time, there shall be no further
registration of transfers on the stock transfer books of the Surviving Company
of shares of Valeant Common Stock that were outstanding immediately prior to
the Effective Time. If, after the Effective Time, any Certificates formerly
representing shares of Valeant Common Stock (or shares of Valeant Common Stock
held in book-entry form) are presented to Biovail or the Exchange Agent for
any reason, they shall be canceled and exchanged as provided in this Article
II.

  

  

(e) No Fractional Shares. No certificates or scrip representing fractional
shares of Biovail Common Stock shall be issued upon the conversion of Valeant
Common Stock pursuant to Section 2.01, and such fractional share interests
shall not entitle the owner thereof to vote or to any rights of a holder of
Biovail Common Stock. Notwithstanding any other provision of this Agreement,
each holder of shares of Valeant Common Stock converted pursuant to the Merger
who would otherwise have been entitled to receive a fraction of a share of
Biovail Common Stock (after taking into account all shares of Valeant Common
Stock exchanged by such holder) shall receive, in lieu thereof, cash (without
interest) in an amount equal to such fractional amount multiplied by the
average of the volume weighted average price per share of Biovail Common Stock
on the New York Stock Exchange ("NYSE") (as reported by Bloomberg L.P. or, if
not reported therein, in another authoritative source mutually selected by
Biovail and Valeant) on each of the 10 consecutive trading days ending with
the second complete trading day prior to the date of the Effective Time,
weighted by the total volume of trading in Biovail Common Stock on each such
trading day. The payment of cash in lieu of fractional share interests
pursuant to this Section 2.02(e) is not a separately bargained-for
consideration.

  

  

(f) Termination of Exchange Fund. Any portion of the Exchange Fund (including
any interest received with respect thereto) that remains undistributed to the
holders of Valeant Common Stock for 360 days after the Effective Time shall be
delivered to the Surviving Company, upon demand, and any holder of Valeant
Common Stock who has not theretofore complied with this Article II shall
thereafter look only to Biovail for payment of its claim for Merger
Consideration, any cash in lieu of fractional shares and any dividends and
distributions to which such holder is entitled pursuant to this Article II.

  

  

  

 

 

 

  

 

7  

  

 

 

 

  

  

  

(g) No Liability. None of Valeant, Biovail, Merger Sub or the Exchange Agent
shall be liable to any Person in respect of any portion of the Exchange Fund
delivered to a public official pursuant to any applicable abandoned property,
escheat or similar Law. Any portion of the Exchange Fund which remains
undistributed to the holders of Certificates for two years after the Effective
Time (or immediately prior to such earlier date on which the Exchange Fund
would otherwise escheat to, or become the property of, any Governmental
Entity), shall, to the extent permitted by applicable Law, become the property
of the Surviving Company, free and clear of all claims or interest of any
Person previously entitled thereto.

  

  

(h) Investment of Exchange Fund. The Exchange Agent shall invest any cash in
the Exchange Fund as mutually directed by Biovail and Valeant. Any interest
and other income resulting from such investments shall be paid to the
Surviving Company.

  

  

(i) Withholding Rights. The Exchange Agent shall be entitled to deduct and
withhold from the consideration otherwise payable to any holder of Valeant
Common Stock pursuant to this Agreement such amounts as may be required to be
deducted and withheld with respect to the making of such payment under
applicable Tax Law. Amounts so withheld and paid over to the appropriate
taxing authority shall be treated for all purposes of this Agreement as having
been paid to the holder of Valeant Common Stock in respect of which such
deduction or withholding was made.

  

  

(j) Lost Certificates. If any Certificate shall have been lost, stolen or
destroyed, upon the making of an affidavit of that fact by the Person claiming
such Certificate to be lost, stolen or destroyed and, if required by Biovail,
the posting by such Person of a bond, in such reasonable and customary amount
as Biovail may direct, as indemnity against any claim that may be made against
it with respect to such Certificate, the Exchange Agent shall issue, in
exchange for such lost, stolen or destroyed Certificate, the Merger
Consideration, any cash in lieu of fractional shares and any dividends and
distributions on the Certificate deliverable in respect thereof pursuant to
this Agreement.

  

  

  

ARTICLE III

  

  

Representations and Warranties of Biovail, BAC and Merger Sub

  

  

Biovail, BAC and Merger Sub jointly and severally represent and warrant to
Valeant that the statements contained in this Article III are true and
correct, except (i) as set forth in the Biovail Reporting Documents publicly
available and filed with the SEC following January 1, 2008 and at least two
Business Days prior to the date of this Agreement (the "Filed Biovail
Reporting Documents") (excluding any disclosures in the Filed Biovail
Reporting Documents under the heading "Risk Factors" and any other disclosures
that are predictive or forward-looking in nature) or (ii) as set forth in the
disclosure letter delivered by Biovail, BAC and Merger Sub to Valeant at or
before the execution and delivery by Biovail, BAC and Merger Sub of this
Agreement (the "Biovail Disclosure Letter"). The Biovail Disclosure Letter
shall be arranged in numbered and lettered sections corresponding to the
numbered and lettered sections contained in this Article III, and the
disclosure in any section shall be deemed to qualify other sections in this
Article III to the extent (and only to the extent) that it is reasonably
apparent from the face of such disclosure that such disclosure also qualifies
or applies to such other sections.

  

  

  

 

 

 

  

 

8  

  

 

 

 

  

  

  

SECTION 3.01. Organization, Standing and Power. Each of Biovail and each of
Biovail's Subsidiaries (the "Biovail Subsidiaries") is duly organized, validly
existing and in good standing under the laws of the jurisdiction in which it
is organized (in the case of good standing, to the extent such jurisdiction
recognizes such concept), except, in the case of the Biovail Subsidiaries,
where the failure to be so organized, existing or in good standing,
individually or in the aggregate, has not had and would not reasonably be
expected to have a Biovail Material Adverse Effect. Each of Biovail and the
Biovail Subsidiaries has all requisite power and authority and possesses all
governmental franchises, licenses, permits, authorizations, variances,
exemptions, orders, registrations, clearances and approvals (collectively,
"Permits") necessary to enable it to own, operate, lease or otherwise hold its
properties and assets and to conduct its businesses as presently conducted
(the "Biovail Permits"), except where the failure to have such power or
authority or to possess Biovail Permits, individually or in the aggregate, has
not had and would not reasonably be expected to have a Biovail Material
Adverse Effect. Each of Biovail and the Biovail Subsidiaries is duly qualified
or licensed to do business in each jurisdiction where the nature of its
business or the ownership, operation or leasing of its properties make such
qualification necessary, other than in such jurisdictions where the failure to
be so qualified or licensed, individually or in the aggregate, has not had and
would not reasonably be expected to have a Biovail Material Adverse Effect.
Biovail has delivered or made available to Valeant, prior to execution of this
Agreement, true and complete copies of (a) the Articles of Continuance of
Biovail in effect as of the date of this Agreement (the "Biovail Charter") and
the By-laws of Biovail in effect as of the date of this Agreement (the
"Biovail By-laws") and (b) the constituent documents of each of BAC and Merger
Sub.

  

  

SECTION 3.02. Biovail Subsidiaries. (a) All the outstanding shares of capital
stock or voting securities of, or other equity interests in, each Biovail
Subsidiary have been validly issued and are fully paid and nonassessable and
are owned by Biovail, by another Biovail Subsidiary or by Biovail and another
Biovail Subsidiary, free and clear of all pledges, liens, claims, charges,
mortgages, encumbrances and security interests of any kind or nature
whatsoever (collectively, "Liens"), and free of any other restriction
(including any restriction on the right to vote, sell or otherwise dispose of
such capital stock, voting securities or other equity interests), except for
restrictions imposed by applicable securities laws. Section 3.02(a) of the
Biovail Disclosure Letter sets forth, as of the date of this Agreement, a true
and complete list of the Biovail Subsidiaries.

  

  

  

 

 

 

  

 

9  

  

 

 

 

  

  

  

(b) Except for the capital stock and voting securities of, and other equity
interests in, the Biovail Subsidiaries, neither Biovail nor any Biovail
Subsidiary owns, directly or indirectly, any capital stock or voting
securities of, or other equity interests in, or any interest convertible into
or exchangeable or exercisable for, any capital stock or voting securities of,
or other equity interests in, any firm, corporation, partnership, company,
limited liability company, trust, joint venture, association or other entity.

  

  

SECTION 3.03. Capital Structure. (a) The authorized capital stock of Biovail
consists of an unlimited number of shares of Biovail Common Stock and an
unlimited number of Class A Special Shares in the capital of Biovail (the
"Biovail Class A Stock" and, together with the Biovail Common Stock, the
"Biovail Capital Stock"). At the close of business on June 14, 2010, (i)
158,573,603 shares of Biovail Common Stock were issued and outstanding, none
of which were subject to vesting or other forfeiture conditions or repurchase
by Biovail, (ii) no shares of Biovail Class A Stock were issued and
outstanding, (iii) no shares of Biovail Common Stock were reserved for
issuance upon conversion of Biovail's 5.375% Senior Convertible Notes (the
"Biovail Convertible Notes"), (iv) 11,588,915 shares of Biovail Common Stock
were reserved and available for issuance pursuant to the Biovail Stock Plans,
of which (A) 3,196,577 shares were issuable upon exercise of outstanding
Biovail Stock Options and (B) 2,049,548 shares were issuable upon vesting of
outstanding Biovail Restricted Stock Units, assuming maximum performance with
respect to performance-based Biovail Restricted Stock Units, (v) Biovail
Deferred Share Units with respect to 418,737 shares of Biovail Common Stock
were outstanding and (vi) 2,282,366 shares of Biovail Common Stock were
reserved for issuance pursuant to the Biovail Employee Stock Purchase Plan.
Except as set forth in this Section 3.03(a), at the close of business on June
14, 2010, no shares of capital stock or voting securities of, or other equity
interests in, Biovail were issued, reserved for issuance or outstanding. From
the close of business on June 14, 2010 to the date of this Agreement, there
have been no issuances by Biovail of shares of capital stock or voting
securities of, or other equity interests in, Biovail, other than (1) the
issuance of Biovail Common Stock upon the conversion of Biovail Convertible
Notes, upon the exercise of Biovail Stock Options or upon the vesting of
Biovail Restricted Stock Units, in each case outstanding at the close of
business on June 14, 2010 and in accordance with their terms in effect at such
time, and (2) the issuance of Biovail Deferred Share Units.

  

  

  

 

 

 

  

 

10  

  

 

 

 

  

  

  

(b) All outstanding shares of Biovail Capital Stock are, and all shares of
Biovail Capital Stock that may be issued upon the conversion of Biovail
Convertible Notes, upon the exercise of Biovail Stock Options or upon the
vesting of Biovail Restricted Stock Units will be, when issued, duly
authorized, validly issued, fully paid and nonassessable and not subject to,
or issued in violation of, any purchase option, call option, right of first
refusal, preemptive right, subscription right or any similar right under any
provision of the Canada Business Corporations Act (the "CBCA"), the Biovail
Charter, the Biovail By-laws or any Contract to which Biovail is a party or
otherwise bound. The shares of Biovail Common Stock constituting the Merger
Consideration will be, when issued, duly authorized, validly issued, fully
paid and nonassessable and not subject to, or issued in violation of, any
purchase option, call option, right of first refusal, preemptive right,
subscription right or any similar right under any provision of the CBCA, the
Biovail Charter, the Biovail By-laws or any Contract to which Biovail is a
party or otherwise bound. Except as set forth above in this Section 3.03 or
pursuant to the terms of this Agreement, there are not issued, reserved for
issuance or outstanding, and there are not any outstanding obligations of
Biovail or any Biovail Subsidiary to issue, deliver or sell, or cause to be
issued, delivered or sold, (x) any capital stock of Biovail or any Biovail
Subsidiary or any securities of Biovail or any Biovail Subsidiary convertible
into or exchangeable or exercisable for shares of capital stock or voting
securities of, or other equity interests in, Biovail or any Biovail
Subsidiary, (y) any warrants, calls, options or other rights to acquire from
Biovail or any Biovail Subsidiary, or any other obligation of Biovail or any
Biovail Subsidiary to issue, deliver or sell, or cause to be issued, delivered
or sold, any capital stock or voting securities of, or other equity interests
in, Biovail or any Biovail Subsidiary or (z) any rights issued by or other
obligations of Biovail or any Biovail Subsidiary that are linked in any way to
the price of any class of Biovail Capital Stock or any shares of capital stock
of any Biovail Subsidiary, the value of Biovail, any Biovail Subsidiary or any
part of Biovail or any Biovail Subsidiary or any dividends or other
distributions declared or paid on any shares of capital stock of Biovail or
any Biovail Subsidiary. Except pursuant to the Biovail Stock Plans, there are
not any outstanding obligations of Biovail or any of the Biovail Subsidiaries
to repurchase, redeem or otherwise acquire any shares of capital stock or
voting securities or other equity interests of Biovail or any Biovail
Subsidiary or any securities, interests, warrants, calls, options or other
rights referred to in clause (x), (y) or (z) of the immediately preceding
sentence. Except for the Biovail Convertible Notes, there are no debentures,
bonds, notes or other Indebtedness of Biovail having the right to vote (or
convertible into, or exchangeable for, securities having the right to vote) on
any matters on which stockholders of Biovail may vote ("Biovail Voting Debt").
Neither Biovail nor any of the Biovail Subsidiaries is a party to any voting
agreement with respect to the voting of any capital stock or voting securities
of, or other equity interests in, Biovail. Except for this Agreement, neither
Biovail nor any of the Biovail Subsidiaries is a party to any agreement
pursuant to which any Person is entitled to elect, designate or nominate any
director of Biovail or any of the Biovail Subsidiaries.

  

  

SECTION 3.04. Authority; Execution and Delivery; Enforceability. (a) Each of
Biovail, BAC and Merger Sub has all requisite corporate power and authority to
execute and deliver this Agreement, to perform its obligations hereunder and
to consummate the Merger and the other transactions contemplated by this
Agreement, subject, in the case of the Share Issuance and the Valeant Stock
Plan Assumption, to the receipt of the Biovail Stockholder Approval. The Board
of Directors of Biovail (the "Biovail Board") has adopted resolutions, by
unanimous vote at a meeting duly called at which a quorum of directors of
Biovail was present, (i) approving this Agreement, (ii) determining that
entering into this Agreement is in the best interests of Biovail and its
stockholders, (iii) declaring this Agreement advisable, (iv) recommending that
Biovail's stockholders vote in favor of (A) approval of the issuance of
Biovail Common Stock constituting the Merger Consideration, (B) the change of
Biovail's name to "Valeant Pharmaceuticals International, Inc." (the "Name
Change") and (C) the issuance of Biovail Common Stock under Valeant Stock
Plans, outstanding Valeant Stock Options and Valeant Restricted Stock Units
assumed by Biovail pursuant to the Valeant Stock Plan Assumption (the "Share
Issuance") and the Valeant Stock Plan Assumption and directing that the Share
Issuance and the Valeant Stock Plan Assumption be submitted to Biovail's
stockholders for approval at a duly held meeting of such stockholders for such
purpose (the "Biovail Stockholders Meeting") and (v) subject to the discretion
of the Board of the Combined Company, determining that the Post-Merger Special
Dividend will be in the best interests of the Combined Company and its
stockholders and that it is the intention of those directors of Biovail that
will continue as directors of the Combined Company to support the declaration
and payment of the Post-Merger Special Dividend at the applicable time. Such
resolutions have not been amended or withdrawn as of the date of this
Agreement. The Board of Directors of Merger Sub has adopted resolutions (i)
approving this Agreement, (ii) determining that entering into this Agreement
is in the best interests of Merger Sub and BAC, as its sole stockholder, (iii)
declaring this Agreement advisable and

  

  

  

 

 

 

  

 

11  

  

 

 

 

  

  

  

(iv) recommending that BAC, as sole stockholder of Merger Sub, adopt this
Agreement and directing that this Agreement be submitted to BAC, as sole
stockholder of Merger Sub, for adoption. Such resolutions have not been
amended or withdrawn as of the date of this Agreement. BAC, as sole
stockholder of Merger Sub, will, immediately following the execution and
delivery of this Agreement by each of the parties hereto, adopt this
Agreement. The Board of Directors of BAC has adopted resolutions (i) approving
this Agreement, (ii) determining that entering into this Agreement is in the
best interests of BAC and Biovail, as its sole stockholder, (iii) declaring
this Agreement advisable and (iv) recommending that Biovail, as sole
stockholder of BAC, adopt this Agreement and directing that this Agreement be
submitted to Biovail, as sole stockholder of BAC, for adoption. Such
resolutions have not been amended or withdrawn as of the date of this
Agreement. Biovail, as sole stockholder of BAC, will, immediately following
the execution and delivery of this Agreement by each of the parties hereto,
adopt this Agreement. Except (A) in the case of the Share Issuance and the
Valeant Stock Plan Assumption, for the approval of the Share Issuance and
Valeant Stock Plan Assumption, respectively, by the affirmative vote of the
holders of a majority of the shares of Biovail Common Stock represented in
person or by proxy at the Biovail Stockholders Meeting, as required by Section
312.03(c) of the NYSE Listed Company Manual and by Section 611(c) and Section
613, respectively, of the Toronto Stock Exchange ("TSX") Company Manual and
the approval of the Name Change by the affirmative vote of the holders of a
majority of not less than two-thirds of the votes cast in respect of such
resolution at the Biovail Stockholders Meeting as required by Section 173 of
the CBCA (collectively, the "Biovail Stockholder Approval") and (B) solely in
the case of the Merger, for the adoption of this Agreement (1) by Biovail as
the sole stockholder of BAC, and (2) by BAC as the sole stockholder of Merger
Sub, no other corporate proceedings on the part of Biovail, BAC or Merger Sub
are necessary to authorize, adopt or approve, as applicable, this Agreement or
to consummate the Merger and the other transactions contemplated by this
Agreement (except for the filing of the appropriate merger documents as
required by the DGCL). Each of Biovail and Merger Sub has duly executed and
delivered this Agreement and, assuming the due authorization, execution and
delivery by Valeant, this Agreement constitutes its legal, valid and binding
obligation, enforceable against it in accordance with its terms.

  

  

(b) No "fair price", "moratorium", "control share acquisition" or other
similar antitakeover statute or similar statute or regulation applies with
respect to this Agreement, the Merger or any of the other transactions
contemplated by this Agreement in respect of Biovail or Merger Sub.

  

  

  

 

 

 

  

 

12  

  

 

 

 

  

  

  

SECTION 3.05. No Conflicts; Consents. (a) The execution and delivery by each
of Biovail, BAC and Merger Sub of this Agreement does not, and the performance
by each of Biovail, BAC and Merger Sub of its obligations hereunder and the
consummation of the Merger and the other transactions contemplated by this
Agreement will not, (i) conflict with, or result in any violation of any
provision of, the Biovail Charter, the Biovail By-laws or the comparable
charter or organizational documents of any Biovail Subsidiary (assuming that
the Biovail Stockholder Approval is obtained), (ii) conflict with, or result
in any violation of or default (with or without notice or lapse of time, or
both) under, or give rise to a right of termination, cancellation or
acceleration of any obligation, any obligation to make an offer to purchase or
redeem any Indebtedness or capital stock or any loss of a material benefit
under, or result in the creation of any Lien upon any of the properties or
assets of Biovail or any Biovail Subsidiary under, any provision of, any
contract, lease, license, indenture, note, bond, agreement, concession,
franchise or other instrument (a "Contract") to which Biovail or any Biovail
Subsidiary is a party or by which any of their respective properties or assets
is bound or any Biovail Permit or (iii) conflict with, or result in any
violation of any provision of, subject to the filings and other matters
referred to in Section 3.05(b), any judgment, order or decree ("Judgment") or
statute, law (including common law), ordinance, rule or regulation, including
the rules and regulations of the NYSE and TSX ("Law"), in each case,
applicable to Biovail or any Biovail Subsidiary or their respective properties
or assets (assuming that the Biovail Stockholder Approval is obtained), other
than, in the case of clauses (ii) and (iii) above, any matters that,
individually or in the aggregate, have not had and would not reasonably be
expected to have a Biovail Material Adverse Effect (it being agreed that for
purposes of this Section 3.05(a), effects resulting from or arising in
connection with the matters set forth in clause (iv) of the definition of the
term "Material Adverse Effect" shall not be excluded in determining whether a
Biovail Material Adverse Effect has occurred or would reasonably be expected
to occur) and would not prevent or materially impede, interfere with, hinder
or delay the consummation of the Merger.

  

  

  

 

 

 

  

 

13  

  

 

 

 

  

  

(b) No consent, waiver or Permit ("Consent") of or from, or registration,
declaration, notice or filing made to or with any Federal, national, state,
provincial or local, whether domestic or foreign, government or any court of
competent jurisdiction, administrative agency or commission or other
governmental authority or instrumentality, whether domestic, foreign or
supranational (a "Governmental Entity"), is required to be obtained or made by
or with respect to Biovail or any Biovail Subsidiary in connection with the
execution and delivery of this Agreement or its performance of its obligations
hereunder or the consummation of the Merger and the other transactions
contemplated by this Agreement, other than (i) (A) the filing with the
Securities and Exchange Commission (the "SEC") and the securities commissions
or similar securities regulatory authority in each of the provinces of Canada
(the "Canadian Securities Authorities") of the Joint Proxy Statement in
definitive form, (B) the filing with the SEC, and declaration of effectiveness
under the Securities Act of 1933, as amended (the "Securities Act"), of the
registration statement on Form S-4 in connection with the issuance by Biovail
of the Merger Consideration, in which the Joint Proxy Statement will be
included as a prospectus (the "Form S-4"), and (C) the filing with the SEC and
the Canadian Securities Authorities of such reports under, and such other
compliance with, the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), the Securities Act, the Canadian provincial securities laws
("Canadian Securities Laws"), and the rules and regulations thereunder, as may
be required in connection with this Agreement, the Merger and the other
transactions contemplated by this Agreement, (ii) compliance with and filings
under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended
(the "HSR Act") and, if required, Part IX of the Competition Act (Canada) (the
"Competition Act") and such other Consents, registrations, declarations,
approvals, notices or filings as are required to be made or obtained under any
foreign antitrust, competition, foreign investment, trade regulation or
similar Laws, (iii) the filing of the Certificate of Merger with the Secretary
of State of the State of Delaware and appropriate documents with the relevant
authorities of the other jurisdictions in which Biovail and Valeant are
qualified to do business, (iv) such Consents, registrations, declarations,
notices or filings as are required to be made or obtained under the securities
or "blue sky" laws of various states in connection with the issuance of the
Merger Consideration, (v) such filings with and approvals of the NYSE and TSX
as are required to permit the consummation of the Merger and the listing of
the Merger Consideration and (vi) such other matters that, individually or in
the aggregate, have not had and would not reasonably be expected to have a
Biovail Material Adverse Effect (it being agreed that for purposes of this
Section 3.05(b), effects resulting from or arising in connection with the
matters set forth in clause (iv) of the definition of the term "Material
Adverse Effect" shall not be excluded in determining whether a Biovail
Material Adverse Effect has occurred or would reasonably be expected to occur)
and would not prevent or materially impede, interfere with, hinder or delay
the consummation of the Merger.

  

  

  

 

 

 

  

 

14  

  

 

 

 

  

  

  

SECTION 3.06. Reporting Documents; Undisclosed Liabilities. (a) Biovail has
furnished or filed all reports, schedules, forms, statements and other
documents (including exhibits and other information incorporated therein)
required to be furnished or filed by Biovail with the SEC and the Canadian
Securities Authorities since January 1, 2008 (such documents, together with
any documents filed with the SEC during such period by Biovail on a voluntary
basis on a Current Report on Form 8-K, but excluding the Joint Proxy Statement
and the Form S-4, being collectively referred to as the "Biovail Reporting
Documents"). Biovail is a reporting issuer in each of the provinces of Canada
within the meaning of the Canadian Securities Laws. Biovail is in compliance
with all its material obligations under the Canadian Securities Laws and the
rules and policies of the TSX to which it is subject.

  

  

(b) Each Biovail Reporting Document (i) at the time filed, complied in all
material respects with the requirements of the Sarbanes-Oxley Act of 2002
("SOX"), the Exchange Act, the Securities Act or the Canadian Securities Laws,
as the case may be, and the rules and regulations of the SEC or the Canadian
Securities Authorities or promulgated thereunder applicable to such Biovail
Reporting Document and (ii) did not at the time it was filed (or if amended or
superseded by a filing or amendment prior to the date of this Agreement, then
at the time of such filing or amendment) contain any untrue statement of a
material fact or omit to state a material fact required to be stated therein
or necessary in order to make the statements therein, in light of the
circumstances under which they were made, not misleading. Each of the
consolidated financial statements of Biovail included in the Biovail Reporting
Documents complied at the time it was filed as to form in all material
respects with applicable accounting requirements and the published rules and
regulations of the SEC with respect thereto, was prepared in accordance with
United States generally accepted accounting principles ("GAAP") (except, in
the case of unaudited statements, as permitted by Form 10-Q of the SEC)
applied on a consistent basis during the periods involved (except as may be
indicated in the notes thereto) and fairly presented in all material respects
the consolidated financial position of Biovail and its consolidated
Subsidiaries as of the dates thereof and the consolidated results of their
operations and cash flows for the periods shown (subject, in the case of
unaudited statements, to normal year-end audit adjustments).

  

  

(c) Neither Biovail nor any Biovail Subsidiary has any liabilities or
obligations of any nature (whether accrued, absolute, contingent or otherwise)
that, individually or in the aggregate, have had or would reasonably be
expected to have a Biovail Material Adverse Effect.

  

  

(d) Each of the chief executive officer of Biovail and the chief financial
officer of Biovail (or each former chief executive officer of Biovail and each
former chief financial officer of Biovail, as applicable) has made all
applicable certifications required by Rule 13a-14 or 15d-14 under the Exchange
Act and Sections 302 and 906 of SOX with respect to the Biovail Reporting
Documents, and the statements contained in such certifications are true and
accurate. For purposes of this Agreement, "chief executive officer" and "chief
financial officer" shall have the meanings given to such terms in SOX. None of
Biovail or any of the Biovail Subsidiaries has outstanding, or has arranged
any outstanding, "extensions of credit" to directors or executive officers
within the meaning of Section 402 of SOX.

  

  

  

 

 

 

  

 

15  

  

 

 

 

  

  

  

(e) Biovail maintains a system of "internal control over financial reporting"
(as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) sufficient
to provide reasonable assurance (A) that transactions are recorded as
necessary to permit preparation of financial statements in conformity with
GAAP, consistently applied, (B) that transactions are executed only in
accordance with the authorization of management and (C) regarding prevention
or timely detection of the unauthorized acquisition, use or disposition of
Biovail's properties or assets.

  

  

(f) The "disclosure controls and procedures" (as defined in Rules 13a-15(e)
and 15d-15(e) of the Exchange Act) utilized by Biovail are reasonably designed
to ensure that all information (both financial and non-financial) required to
be disclosed by Biovail in the reports that it files or submits under the
Exchange Act is recorded, processed, summarized and reported within the time
periods specified in the rules and forms of the SEC and that all such
information required to be disclosed is accumulated and communicated to the
management of Biovail, as appropriate, to allow timely decisions regarding
required disclosure and to enable the chief executive officer and chief
financial officer of Biovail to make the certifications required under the
Exchange Act with respect to such reports.

  

  

(g) Neither Biovail nor any of the Biovail Subsidiaries is a party to, or has
any commitment to become a party to, any joint venture, off-balance sheet
partnership or any similar Contract (including any Contract or arrangement
relating to any transaction or relationship between or among Biovail and any
of the Biovail Subsidiaries, on the one hand, and any unconsolidated
Affiliate, including any structured finance, special purpose or limited
purpose entity or Person, on the other hand, or any "off-balance-sheet
arrangements" (as defined in Item 303(a) of Regulation S-K under the Exchange
Act)), where the result, purpose or intended effect of such Contract is to
avoid disclosure of any material transaction involving, or material
liabilities of, Biovail or any of the Biovail Subsidiaries in Biovail's or
such Biovail Subsidiary's published financial statements or other Biovail
Reporting Documents.

  

  

(h) Since January 1, 2009, none of Biovail, Biovail's independent accountants,
the Biovail Board or the audit committee of the Biovail Board has received any
oral or written notification of any (x) "significant deficiency" in the
internal controls over financial reporting of Biovail, (y) "material weakness"
in the internal controls over financial reporting of Biovail or (z) fraud,
whether or not material, that involves management or other employees of
Biovail who have a significant role in the internal controls over financial
reporting of Biovail. For purposes of this Agreement, the terms "significant
deficiency" and "material weakness" shall have the meanings assigned to them
in Auditing Standard No. 5 of the Public Company Accounting Oversight Board,
as in effect on the date of this Agreement.

  

  

  

 

 

 

  

 

16  

  

 

 

 

  

  

  

(i) None of the Biovail Subsidiaries is, or has at any time since January 1,
2009 been, subject to the reporting requirements of Section 13(a) or 15(d) of
the Exchange Act or a reporting issuer in any of the provinces of Canada
within the meaning of the Canadian Securities Laws.

  

  

SECTION 3.07. Information Supplied. None of the information supplied or to be
supplied by Biovail or Merger Sub for inclusion or incorporation by reference
in (i) the Form S-4 will, at the time the Form S-4 is filed with the SEC, at
any time it is amended or supplemented or at the time it is declared effective
under the Securities Act, contain any untrue statement of a material fact or
omit to state any material fact required to be stated therein or necessary to
make the statements therein not misleading or (ii) the Joint Proxy Statement
will, at the date it is first mailed to each of Biovail's stockholders and
Valeant's stockholders or at the time of each of the Biovail Stockholders
Meeting and the Valeant Stockholders Meeting, contain any untrue statement of
a material fact or omit to state any material fact required to be stated
therein or necessary in order to make the statements therein, in light of the
circumstances under which they are made, not misleading. The Form S-4 will
comply as to form in all material respects with the requirements of the
Securities Act and the rules and regulations thereunder, except that no
representation is made by Biovail or Merger Sub with respect to statements
made or incorporated by reference therein based on information supplied by
Valeant for inclusion or incorporation by reference therein. The Joint Proxy
Statement will comply as to form in all material respects with the
requirements of the Exchange Act and the rules and regulations thereunder and
the requirements of the CBCA and applicable Canadian Securities Laws, except
that no representation is made by Biovail with respect to statements made or
incorporated by reference therein based on information supplied by Valeant for
inclusion or incorporation by reference therein.

  

  

SECTION 3.08. Absence of Certain Changes or Events. From January 1, 2010 to
the date of this Agreement, each of Biovail and the Biovail Subsidiaries has
conducted its respective business in the ordinary course in all material
respects, and during such period there has not occurred:

  

  

(a) any fact, circumstance, effect, change, event or development that,
individually or in the aggregate, has had or would reasonably be expected to
have a Biovail Material Adverse Effect;

  

  

(b) any declaration, setting aside or payment of any dividend or other
distribution (whether in cash, stock or property or any combination thereof)
in respect of any capital stock or voting securities of, or other equity
interests in, Biovail or the capital stock or voting securities of, or other
equity interests in, any of the Biovail Subsidiaries (other than (x) regular
quarterly cash dividends in an amount not exceeding $0.095 per share of
Biovail Common Stock and (y) dividends or other distributions by a direct or
indirect wholly owned Biovail Subsidiary to its parent) or any repurchase for
value by Biovail of any capital stock or voting securities of, or other equity
interests in, Biovail or the capital stock or voting securities of, or other
equity interests in, any of the Biovail Subsidiaries;

  

  

  

 

 

 

  

 

17  

  

 

 

 

  

  

  

(c) any split, reverse split, combination, subdivision or reclassification of
any capital stock or voting securities of, or other equity interests in,
Biovail, securities convertible into or exercisable or exchangeable for
capital stock or voting securities of, or other equity interests in, Biovail
or any issuance or the authorization of any issuance of any other securities
in respect of, in lieu of or in substitution for shares of capital stock or
voting securities of, or other equity interests in, Biovail;

  

  

(d) any incurrence of material Indebtedness for borrowed money or any
guarantee of such Indebtedness for another Person, or any issue or sale of
debt securities, warrants or other rights to acquire any debt security of
Biovail or any Biovail Subsidiary other than draws on existing revolving
credit facilities in the ordinary course of business;

  

  

(e) (i) any transfer, lease, license, sale, mortgage, pledge or other disposal
or encumbrance of any of Biovail's or Biovail's Subsidiaries' property or
assets outside of the ordinary course of business consistent with past
practice with a fair market value in excess of $5,000,000 or (ii) any
acquisitions of businesses, whether by merger, consolidation, purchase of
property or assets or otherwise;

  

  

(f) (i) any granting by Biovail to any director or executive officer of
Biovail of any material increase in compensation, (ii) any granting by Biovail
to any director or executive officer of Biovail of any material increase in
change in control, severance or termination pay, (iii) any establishment,
adoption, entry into or amendment in any material respect of any collective
bargaining agreement or material Biovail Benefit Plan or (iv) the taking of
any action to accelerate the time of vesting or payment of any material
compensation or benefits under any Biovail Benefit Plan;

  

  

(g) any change in accounting methods, principles or practices by Biovail or
any Biovail Subsidiary, except insofar as may have been required by a change
in GAAP; or

  

  

(h) any material elections or changes thereto with respect to Taxes by Biovail
or any Biovail Subsidiary or any settlement or compromise by Biovail or any
Biovail Subsidiary of any material Tax liability or refund, other than in the
ordinary course of business.

  

  

  

 

 

 

  

 

18  

  

 

 

 

  

  

  

SECTION 3.09. Taxes. (a) (i) Each of Biovail and each Biovail Subsidiary has
timely filed, taking into account any extensions, all material Tax Returns
required to have been filed and such Tax Returns are accurate and complete in
all material respects; (ii) each of Biovail and each Biovail Subsidiary has
paid all material Taxes required to have been paid by it other than Taxes that
are not yet due or that are being contested in good faith in appropriate
proceedings; and (iii) no deficiency for any Tax has been asserted or assessed
by a taxing authority against Biovail or any Biovail Subsidiary which
deficiency has not been paid or is not being contested in good faith in
appropriate proceedings.

  

  

(b) No Tax Return of Biovail or any Biovail Subsidiary is under audit or
examination by any taxing authority, and no written (or, to the Knowledge of
Biovail, oral) notice of such an audit or examination has been received by
Biovail or any Biovail Subsidiary. No deficiencies for any Taxes have been
proposed, asserted or assessed against Biovail or any Biovail Subsidiary, and
no requests for waivers of the time to assess any such Taxes are pending.
There are no outstanding waivers of any limitation periods or agreements
providing for an extension of time for the filing of any Tax Return, the
assessment or collection thereof by any relevant taxing authority or the
payment of any Tax by Biovail or any Biovail Subsidiary. No other procedure,
proceeding or contest of any refund or deficiency in respect of Taxes is
pending in or on appeal from any Governmental Entity.

  

  

(c) Each of Biovail and each Biovail Subsidiary has complied in all material
respects with all applicable Laws relating to the withholding, collection and
remittance of Taxes and other deductions required to be withheld

  

  

(d) Other than for Taxes not yet due and delinquent or that are being
contested in good faith in appropriate proceedings, there are no Liens with
respect to Taxes against any of the assets of Biovail or any Biovail
Subsidiary. No written or, to the Knowledge of Biovail, other claim has been
received by Biovail or any Biovail Subsidiary from an authority in a
jurisdiction where such corporation does not file Tax Returns that it is or
may be subject to material taxation by such jurisdiction. Neither Biovail nor
any Biovail Subsidiary has a permanent establishment or is resident for Tax
purposes outside of its jurisdiction or territory of incorporation or
formation.

  

  

(e) Each of Biovail and the Biovail Subsidiaries has not and has not been
deemed to have for purposes of the Income Tax Act (or any other applicable
Law), acquired property from a non-arm's length Person, within the meaning of
the Income Tax Act (or such other applicable Law), for consideration, the
value of which is less than the fair market value of the property in
circumstances which could subject it to a liability under section 160 of the
Income Tax Act (or the analogous provision of such other applicable Law).

  

  

(f) With respect to any transaction with any non-arm's length Person that is
not a resident of Canada within the meaning of the Income Tax Act, neither
Biovail nor any Biovail Subsidiary resident in Canada has (i) paid any
consideration for any property (including for the use of property) or services
that is in excess of the fair market value thereof, nor (ii) received any
consideration for any property (including for the use of property) or services
that is less than the fair market value thereof. For all such transactions,
Biovail and any Biovail Subsidiary resident in Canada, as the case may be, has
made or obtained records or documents that meet the requirements of paragraphs
247(4)(a) to (c) of the Income Tax Act.

  

  

  

 

 

 

  

 

19  

  

 

 

 

  

  

  

(g) None of sections 78, 80, 80.01, 80.02, 80.03 and 80.04 of the Income Tax
Act, or any equivalent provision of the Laws of any other jurisdiction, has
applied in any material manner or shall apply in any material manner to any of
Biovail or the Biovail Subsidiaries as of the Closing Date.

  

  

(h) Neither Biovail nor any Biovail Subsidiary has received any material
requirement pursuant to section 224 of the Income Tax Act which remains
unsatisfied in any respect.

  

  

(i) Neither Biovail nor any Biovail Subsidiary is a party to or is otherwise
bound by any material Tax sharing, allocation or indemnification agreement or
arrangement (other than such an agreement or arrangement exclusively between
or among Biovail and wholly owned Biovail Subsidiaries).

  

  

(j) Within the past three years, neither Biovail nor any Biovail Subsidiary
has been a "distributing corporation" or a "controlled corporation" in a
distribution intended to qualify for tax-free treatment under Section 355 of
the Code.

  

  

(k) Neither Biovail nor any Biovail Subsidiary has participated in or been a
party to a transaction that, as of the date of this Agreement, constitutes a
"listed transaction" within the meaning of Section 6011 of the Code and
applicable Treasury Regulations thereunder (or a similar provision of state or
foreign Law).

  

  

(l) This Agreement (including any exhibits hereto) sets forth the complete
terms of the Merger. Neither Biovail nor any Biovail Subsidiary has taken any
other action or knows of any other fact relating to the Merger that would
reasonably be expected to prevent the Merger from qualifying for the Intended
Tax Treatment.

  

  

(m) No amounts paid or payable by Biovail or any Biovail Subsidiary as
employee compensation, whether under any contract, plan, program or
arrangement, understanding or otherwise (including any Biovail Benefit Plan or
Biovail Benefit Arrangement), individually or in the aggregate, is or would
reasonably be expected to be non-deductible for federal income tax purposes by
virtue of Section 162(m) or 280G of the Code.

  

  

  

 

 

 

  

 

20  

  

 

 

 

  

  

  

SECTION 3.10. Employee Benefits. (a) Section 3.10(a) of the Biovail Disclosure
Letter sets forth a complete and accurate list of each material Biovail
Benefit Plan and each material Biovail Benefit Agreement.

  

  

(b) With respect to each material Biovail Benefit Plan and material Biovail
Benefit Agreement, Biovail has made available to Valeant complete and accurate
copies of (A) such Biovail Benefit Plan or Biovail Benefit Agreement,
including any material amendment thereto, and, to the extent applicable,
summary plan description thereof, (B) each trust, insurance, annuity or other
funding Contract related thereto, (C) the most recent audited financial
statements and actuarial or other valuation reports prepared with respect
thereto, (D) the two most recent annual reports on Form 5500 required to be
filed with the Internal Revenue Service with respect thereto and the two most
recent annual information returns required to be filed with any Governmental
Entity and (E) the most recently received IRS determination letter.

  

  

(c) Each Biovail Benefit Plan and Biovail Benefit Agreement (and any related
trust or other funding vehicle) has been administered in accordance with its
terms and is in compliance with ERISA, the Code and all other applicable Laws,
other than instances of non-compliance that, individually or in the aggregate,
have not had and would not reasonably be expected to have a Biovail Material
Adverse Effect.

  

  

(d) Except for matters that, individually or in the aggregate, have not had
and would not reasonably be expected to have a Biovail Material Adverse
Effect, neither Biovail nor any Biovail Subsidiary nor any Biovail Commonly
Controlled Entity currently sponsors, maintains or contributes to, or has
sponsored, maintained, contributed to or been required to maintain or
contribute to, or has any actual or contingent liability under, any Benefit
Plan that is subject to Section 302 or Title IV of ERISA or Section 412 of the
Code or is otherwise a defined benefit plan (including any such plan
maintained outside the United States).

  

  

(e) None of the Biovail Benefit Plans is a "registered pension plan" within
the meaning of Section 248(1) of the Income Tax Act (Canada) R.S.C. 1985, as
amended (the "Income Tax Act").

  

  

(f) Neither Biovail nor any Biovail Subsidiary has any liability for providing
health, medical or other welfare benefits after retirement or other
termination of employment (other than for continuation coverage required under
Section 4980(B)(f) of the Code or applicable Law), except for any liabilities
that, individually and in the aggregate, have not had and would not reasonably
be expected to have a Biovail Material Adverse Effect.

  

  

(g) None of the execution and delivery of this Agreement, the performance by
either party of its obligations hereunder or the consummation of the Merger
and the other transactions contemplated by this Agreement (alone or in
conjunction with any other event, including any termination of employment on
or following the Effective Time) will (i) entitle any Biovail Personnel to any
material compensation or benefit, (ii) accelerate the time of payment or
vesting, or trigger any payment or funding, of any material compensation or
benefit or trigger any other material obligation under any Biovail Benefit
Plan or Biovail Benefit Agreement or (iii) result in any breach or violation
of, or default under, or limit Biovail's right to amend, modify or terminate,
any Biovail Benefit Plan or Biovail Benefit Agreement.

  

  

  

 

 

 

  

 

21  

  

 

 

 

  

  

  

SECTION 3.11. Litigation. There is no, and since January 1, 2008, there has
been no, suit, action or other proceeding pending or, to the Knowledge of
Biovail, threatened against or affecting Biovail or any Biovail Subsidiary (i)
that, individually or in the aggregate, has had or would reasonably be
expected to have a Biovail Material Adverse Effect or (ii) that, as of the
date of this Agreement, challenges or seeks to prevent, enjoin, alter in any
material respect or materially delay the Merger or any of the other
transactions contemplated hereby. There is no, and since January 1, 2008,
there has been no, Judgment outstanding against or, to the Knowledge of
Biovail, investigation by any Governmental Entity involving, Biovail or any
Biovail Subsidiary or any of their respective properties or assets that,
individually or in the aggregate, has had or would reasonably be expected to
have a Biovail Material Adverse Effect.

  

  

SECTION 3.12. Compliance with Applicable Laws. Except for matters that,
individually or in the aggregate, have not had and would not reasonably be
expected to have a Biovail Material Adverse Effect, Biovail and the Biovail
Subsidiaries are, and since January 1, 2008, have been, in compliance with all
applicable Laws and Biovail Permits. Except for matters that, individually or
in the aggregate, have not had and would not reasonably be expected to have a
Biovail Material Adverse Effect, there is no, and since January 1, 2008, there
has been no, material action, demand or investigation by or before any
Governmental Entity pending or, to the Knowledge of Biovail, threatened
alleging that Biovail or a Biovail Subsidiary is not in compliance with any
applicable Law or Biovail Permit or which challenges or questions the validity
of any rights of the holder of any Biovail Permit. To the Knowledge of
Biovail, Biovail is, and since January 1, 2008, has been, in material
compliance with the Foreign Corrupt Practices Act of 1977, as amended (the
"FCPA") and any rules and regulations thereunder. This Section 3.12 does not
relate to Tax matters, employee benefits matters, environmental matters or
Intellectual Property matters, which are the subjects of Sections 3.09, 3.10,
3.13 and 3.16, respectively.

  

  

SECTION 3.13. Environmental Matters. (a) Except for matters that, individually
or in the aggregate, have not had and would not reasonably be expected to have
a Biovail Material Adverse Effect:

  

  

(i) Biovail and the Biovail Subsidiaries are in compliance with all
Environmental Laws (which compliance includes the possession by Biovail and
the Biovail Subsidiaries of all Permits required under applicable
Environmental Laws necessary for their operations as currently conducted, and
compliance with the terms and conditions thereof), and neither Biovail nor any
Biovail Subsidiary has received any written communication, whether from a
Governmental Entity, citizens group, employee or otherwise, alleging that
Biovail or any Biovail Subsidiary is not in such compliance, and, to the
Knowledge of Biovail, there are no past or present circumstances, conditions,
events or incidents that would reasonably be expected to prevent or interfere
with such compliance in the future;

  

  

  

 

 

 

  

 

22  

  

 

 

 

  

  

  

(ii) there are no Environmental Claims pending or, to the Knowledge of
Biovail, threatened against Biovail or any of the Biovail Subsidiaries or, to
the Knowledge of Biovail, against any Person whose liability for any
Environmental Claim Biovail or any of the Biovail Subsidiaries has or may have
retained or assumed, either contractually or by operation of law;

  

  

(iii) there have been no Releases of any Hazardous Material that would
reasonably be expected to form the basis of any Environmental Claim against
Biovail or any of the Biovail Subsidiaries or, to the Knowledge of Biovail,
against any Person whose liabilities for such Environmental Claims Biovail or
any of the Biovail Subsidiaries has, or may have, retained or assumed, either
contractually or by operation of Law; and

  

  

(iv) neither Biovail nor any of the Biovail Subsidiaries has retained or
assumed, either contractually or by operation of law, any liabilities or
obligations that would reasonably be expected to form the basis of any
Environmental Claim against Biovail or any of the Biovail Subsidiaries.

  

  

(b) As used herein:

  

  

(i) "Environmental Claim" means any administrative, regulatory or judicial
actions, suits, orders, demands, directives, claims, liens, cause of action,
investigations, proceedings or written or oral notices of noncompliance or
violation by or from any Person alleging liability of whatever kind or nature
(including potential liability for investigatory costs, cleanup costs,
governmental response costs, natural resources damages, property damages,
personal injuries, or penalties) arising out of, based on or resulting from
(y) the presence or Release of, or exposure to, any Hazardous Materials at any
location; or (z) circumstances forming the basis of any violation, or alleged
violation, of any Environmental Law.

  

  

(ii) "Environmental Laws" means all applicable Federal, national, state,
provincial or local, foreign and common Laws, Judgments, or Contracts issued,
promulgated or entered into by or with any Governmental Entity, relating to
pollution, natural resources or protection of endangered or threatened
species, human health (as it relates to environmental conditions or exposure
to Hazardous Materials) or the environment (including ambient air, surface
water, groundwater, land surface or subsurface strata), including those
relating to the exposure to, or Releases or threatened Releases of, Hazardous
Materials.

  

  

  

 

 

 

  

 

23  

  

 

 

 

  

  

  

(iii) "Hazardous Materials" means (y) any petroleum or petroleum products,
explosive or radioactive materials or wastes, asbestos in any form, toxic
mold, and polychlorinated biphenyls; and (z) any other chemical, material,
substance or waste that in relevant form or concentration is prohibited,
limited or regulated under any Environmental Law.

  

  

(iv) "Release" means any actual or threatened release, spill, emission,
leaking, dumping, injection, pouring, deposit, disposal, discharge, dispersal,
leaching or migration into or through the indoor or outdoor environment
(including ambient air, surface water, groundwater, land surface or subsurface
strata) or within any building, structure, facility or fixture, including the
movement of Hazardous Materials through or in the air, soil, surface water,
groundwater or property.

  

  

SECTION 3.14. Contracts. (a) As of the date of this Agreement, neither Biovail
nor any Biovail Subsidiary is a party to any Contract required to be filed by
Biovail as a "material contract" pursuant to Item 601(b)(10) of Regulation S-K
under the Securities Act (a "Filed Biovail Contract") that has not been so
filed.

  

  

(b) Section 3.14(b) of the Biovail Disclosure Letter sets forth, as of the
date of this Agreement, a true and complete list of (i) non-competition
Contracts or any other Contract containing terms that expressly (A) limit or
otherwise restrict Biovail or the Biovail Subsidiaries or (B) to the Knowledge
of Biovail, would, after the Effective Time, by its terms expressly limit or
otherwise restrict the Combined Company from, in the case of either (A) or
(B), engaging or competing in any line of business or in any geographic area
or from developing or commercializing any compounds, any therapeutic area,
class of drugs or mechanism of action, in a manner that would be reasonably
likely to be material, in the case of (A), to Biovail and the Biovail
Subsidiaries, taken as a whole, or in the case of (B), to the Combined
Company, taken as a whole, (ii) each loan and credit agreement, note,
debenture, bond, indenture or other similar agreement pursuant to which any
Indebtedness of Biovail or any of the Biovail Subsidiaries is outstanding or
may be incurred, other than any such agreement between or among Biovail and
the wholly owned Biovail Subsidiaries, and (iii) each partnership, joint
venture or similar agreement or understanding to which Biovail or any of the
Biovail Subsidiaries is a party relating to the formation, creation,
operation, management or control of any partnership or joint venture material
to Biovail and the Biovail Subsidiaries, taken as a whole. Each agreement,
understanding or undertaking of the type described in this Section 3.14(b) and
each Filed Biovail Contract is referred to herein as a "Biovail Material
Contract".

  

  

(c) Except for matters which, individually or in the aggregate, have not had
and would not reasonably be expected to have a Biovail Material Adverse
Effect, (i) each Biovail Material Contract (including, for purposes of this
Section 3.14(c), any Contract entered into after the date of this Agreement
that would have been a Biovail Material Contract if such Contract existed on
the date of this Agreement) is a valid, binding and legally enforceable
obligation of Biovail or one of the Biovail Subsidiaries, as the case may be,
and, to the Knowledge of Biovail, of the other parties thereto, except, in
each case, as enforcement may be limited by bankruptcy, insolvency,
reorganization or similar Laws affecting creditors' rights generally and by
general principles of equity, (ii) each such Biovail Material Contract is in
full force and effect and (iii) none of Biovail or any of the Biovail
Subsidiaries is (with or without notice or lapse of time, or both) in breach
or default under any such Biovail Material Contract and, to the Knowledge of
Biovail, no other party to any such Biovail Material Contract is (with or
without notice or lapse of time, or both) in breach or default thereunder.

  

  

  

 

 

 

  

 

24  

  

 

 

 

  

  

  

SECTION 3.15. Properties. (a) Biovail and each Biovail Subsidiary has good and
valid title to, and with respect to real property owned by Biovail or any
Biovail Subsidiary, marketable and insurable fee simple interest in, or valid
license or leasehold interests in, all their respective properties and assets,
except in respects that, individually or in the aggregate, have not had and
would not reasonably be expected to have a Biovail Material Adverse Effect.
All such properties and assets, other than properties and assets in which
Biovail or any of the Biovail Subsidiaries has a license or leasehold
interest, are free and clear of all conditions, encroachments, easements,
rights of way, restrictions and Liens, except for such conditions,
encroachments, easements, rights of way, restrictions and Liens that,
individually or in the aggregate, have not had and would not reasonably be
expected to have a Biovail Material Adverse Effect. This Section 3.15 does not
relate to Intellectual Property matters, which are the subject of Section
3.16.

  

  

(b) Biovail and each of the Biovail Subsidiaries has complied with the terms
of all leases to which it is a party, and all leases to which Biovail or any
Biovail Subsidiary is a party are in full force and effect, except for such
noncompliance or failure to be in full force and effect that, individually or
in the aggregate, has not had and would not reasonably be expected to have a
Biovail Material Adverse Effect. Biovail and each Biovail Subsidiary is in
possession of the properties or assets purported to be leased under all its
leases, except for such failures to have such possession as, individually or
in the aggregate, have not had and would not reasonably be expected to have a
Biovail Material Adverse Effect.

  

  

SECTION 3.16. Intellectual Property. (a) Except for matters that, individually
or in the aggregate, have not had and would not reasonably be expected to have
a Biovail Material Adverse Effect, (i) to the Knowledge of Biovail, Biovail
and each of the Biovail Subsidiaries owns, or is licensed to use (in each
case, free and clear of any Liens), all Intellectual Property used in or
necessary for the conduct of its business as currently conducted, and to its
Knowledge, all such Intellectual Property, is valid, enforceable and
subsisting; (ii) to the Knowledge of Biovail, the use of any Intellectual
Property by Biovail and the Biovail Subsidiaries does not infringe on or
otherwise violate the rights of any Person and is in accordance with any
applicable license pursuant to which Biovail or any Biovail Subsidiary
acquired the right to use any Intellectual Property; (iii) to the Knowledge of
Biovail, no Person is challenging, infringing on or otherwise violating any
right of Biovail or any of the Biovail Subsidiaries with respect to any
Intellectual Property owned by or licensed to Biovail or any of the Biovail
Subsidiaries; and (iv) to the Knowledge of Biovail, neither Biovail nor any of
the Biovail Subsidiaries has received any written notice or otherwise has
Knowledge of any pending claim, order or proceeding with respect to any
Intellectual Property used by Biovail and the Biovail Subsidiaries and to its
Knowledge no Intellectual Property owned or licensed by Biovail or the Biovail
Subsidiaries is being used or enforced in a manner that would reasonably be
expected to result in the abandonment, cancellation or unenforceability of
such Intellectual Property. This Section 3.16(a) constitutes the only
representation and warranty of Biovail with respect to any actual or alleged
infringement or other violation of any Intellectual Property of any other
Person. For purposes of this Agreement, "Intellectual Property" shall mean (A)
trademarks, service marks, certification marks, names, corporate names, trade
names, domain names, logos, slogans, trade dress, design rights, and other
similar designations of sources of origin, the goodwill associated with the
foregoing and registrations of, and applications to register, the foregoing,
including any extension, modification or renewal of any such registration or
application, (B) inventions, discoveries and ideas, whether patentable or not,
(C) patents, applications for patents (including any division, continuation,
continuation in part or renewal application) and any renewals, extensions,
substitutions, or reissues thereof, (D) trade secrets and confidential
information and rights to limit the use or disclosure thereof by any person,
(E) writings and other works, whether copyrightable or not, (F) registrations
and applications for registration of copyrights and any renewals or extensions
thereof, (G) moral rights and rights of attribution and integrity, (H) all
rights in the foregoing, in any similar intangible assets, and in any similar
intellectual property or proprietary rights, in each case in any domestic or
foreign jurisdiction.

  

  

  

 

 

 

  

 

25  

  

 

 

 

  

  

  

(b) Biovail and the Biovail Subsidiaries have taken reasonable steps to
protect the confidentiality and value of all trade secrets and any other
confidential information that are owned, used or held by Biovail and the
Biovail Subsidiaries in confidence, including entering into licenses and
Contracts that require employees, licensees, contractors and other Persons
with access to trade secrets or other confidential information to safeguard
and maintain the secrecy and confidentiality of such trade secrets and
confidential information. To the Knowledge of Biovail, such trade secrets and
confidential information have not been used, disclosed to or discovered by any
Person except pursuant to a valid non-disclosure, license or other appropriate
Contract which has not been breached.

  

  

(c) To the Knowledge of Biovail, Biovail and the Biovail Subsidiaries are in
compliance with all applicable Law, as well as their own policies, relating to
privacy, data protection, and the collection and use of personal information
collected, used, or held for use by Biovail or the Biovail Subsidiaries, and
as of the date hereof no claims are pending or threatened in writing against
Biovail or the Biovail Subsidiaries alleging a violation of any Person's
privacy or personal information.

  

  

  

 

 

 

  

 

26  

  

 

 

 

  

  

  

(d) Except for matters that, individually or in the aggregate, have not had
and would not reasonably be expected to have a Biovail Material Adverse Effect
(it being agreed that for purposes of this Section 3.16(d), effects resulting
from or arising in connection with the matters set forth in clause (iv) of the
definition of the term "Material Adverse Effect" shall not be excluded in
determining whether a Biovail Material Adverse Effect has occurred or would
reasonably be expected to occur) and except as set forth in Section 3.16(d) of
the Biovail Disclosure Letter, to the Knowledge of Biovail, the consummation
of the transactions contemplated by this Agreement will not (i) result in the
loss of, or otherwise adversely affect, any rights of Biovail or the Biovail
Subsidiaries in any Intellectual Property, (ii) grant or require Biovail or
the Biovail Subsidiaries to grant to any Person any rights with respect to any
Intellectual Property of Biovail or the Biovail Subsidiaries, (iii) subject
Biovail or any of the Biovail Subsidiaries to any increase in royalties or
other payments in respect of any Intellectual Property, (iv) by the terms of
any Contract to which Biovail or a Subsidiary of Biovail is a party, diminish
any royalties or other payments Biovail or a Subsidiary of Biovail would
otherwise be entitled to in respect of any Intellectual Property or (v) result
in the breach or, by the terms of such Contract, termination of any agreement
relating to the Intellectual Property of Biovail.

  

  

SECTION 3.17. Regulatory Matters. (a) Except as has not had and would not
reasonably be expected to have, individually or in the aggregate, a Biovail
Material Adverse Effect, (i) each of Biovail and the Biovail Subsidiaries
holds all Biovail Permits, including all authorizations under the Federal
Food, Drug and Cosmetic Act of 1938, as amended (the "FDCA"), the Public
Health Service Act of 1944, as amended (the "PHSA"), and the regulations of
the United States Food and Drug Administration (the "FDA") promulgated
thereunder, the Food and Drugs Act, as amended (the "Food and Drugs Act"), the
Controlled Drugs and Substances Act, as amended (the "CDSA"), and the
regulations of Health Canada promulgated thereunder, and any other
Governmental Entity that is concerned with the quality, identity, strength,
purity, safety, efficacy, manufacturing, distribution, sale, import or export
of the Biovail Products (any such Governmental Entity, a "Biovail Regulatory
Agency") necessary for the lawful operating of the businesses of Biovail or
any of the Biovail Subsidiaries and the testing, manufacturing, sale or
distribution, as applicable, of each of the Biovail Products (the "Biovail
Regulatory Permits") and (ii) all such Biovail Regulatory Permits are valid
and in full force and effect. Since January 1, 2009, there has not occurred
any violation of, default (with or without notice or lapse of time or both)
under, or event giving to others any right of termination, amendment or
cancellation of, with or without notice or lapse of time or both, any Biovail
Regulatory Permit, except as has not had and would not reasonably be expected
to have, individually or in the aggregate, a Biovail Material Adverse Effect.
Biovail and each of the Biovail Subsidiaries are in compliance in all material
respects with the terms of all Biovail Regulatory Permits, and no event has
occurred that, to the Knowledge of Biovail, would reasonably be expected to
result in a penalty under or the revocation, cancellation, non-renewal or
adverse modification of any Biovail Regulatory Permit, except as has not had
and would not reasonably be expected to have, individually or in the
aggregate, a Biovail Material Adverse Effect.

  

  

  

 

 

 

  

 

27  

  

 

 

 

  

  

  

(b) Except as would not, individually or in the aggregate, reasonably be
expected to have a Biovail Material Adverse Effect, the businesses of each of
Biovail and the Biovail Subsidiaries are being conducted in compliance with
all applicable Laws, including (i) the FDCA, including the rules and
regulations promulgated thereunder; (ii) federal Medicare and Medicaid
statutes and related state or local statutes or regulations; (iii) the Food
and Drugs Act and the CDSA, including the rules and regulations promulgated
thereunder; (iv) provincial formulary and drug pricing statutes, including the
rules and regulations promulgated thereunder, (v) any comparable foreign Laws
for any of the foregoing; (vi) federal, state or provincial criminal or civil
Laws (including the federal Anti-Kickback Statute (42 U.S.C. 1320a-7(b)),
Stark Law (42 U.S.C. 1395nn), False Claims Act (42 U.S.C. 1320a-7b(a)),
Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. 1320d
et. seq., and any comparable state, provincial or local Laws) and (vii) state
or provincial licensing, disclosure and reporting requirements.

  

  

(c) Each of Biovail and the Biovail Subsidiaries are in compliance in all
material respects with the terms of the Corporate Integrity Agreement, dated
September 11, 2009, between the Office of Inspector General of the Department
of Health and Human Services and Biovail.

  

  

(d) All pre-clinical and clinical investigations conducted or sponsored by
each of Biovail and the Biovail Subsidiaries are being conducted in compliance
in all material respects with all applicable Laws administered or issued by
the applicable Regulatory Authorities, including (i) FDA standards for
conducting non-clinical laboratory studies contained in Title 21 part 58 of
the Code of Federal Regulations, (ii) FDA standards for the design, conduct,
performance, monitoring, auditing, recording, analysis and reporting of
clinical trials contained in Title 21 parts 50, 54, 56, 312, 314 and 320 of
the Code of Federal Regulations, (iii) Division 5 of the Food and Drug
Regulations regarding Drugs for Clinical Trials Involving Human Subjects, and
(iv) federal, state and provincial Laws restricting the collection, use and
disclosure of individually identifiable health information and personal
information.

  

  

(e) Neither Biovail nor any of the Biovail Subsidiaries has received any
written information from the FDA, the European Medicines Agency ("EMEA") or
Health Canada or any foreign agency with jurisdiction over the marketing,
sale, use handling and control, safety, efficacy, reliability, or
manufacturing of drugs which would reasonably be expected to lead to the
denial of any application for marketing approval currently pending before the
FDA, Health Canada or such other Biovail Regulatory Agency.

  

  

  

 

 

 

  

 

28  

  

 

 

 

  

  

(f) All material reports, documents, claims, permits and notices required to
be filed, maintained or furnished to the FDA, Health Canada or any other
Biovail Regulatory Agency by Biovail and the Biovail Subsidiaries have been so
filed, maintained or furnished. All such reports, documents, claims, permits
and notices were complete and accurate in all material respects on the date
filed (or were corrected in or supplemented by a subsequent filing) such that
no liability exists with respect to such filing. Neither Biovail nor any of
the Biovail Subsidiaries, nor, to the Knowledge of Biovail, any officer,
employee, agent or distributor of Biovail or any of the Biovail Subsidiaries,
has made an untrue statement of a material fact or a fraudulent statement to
the FDA, Health Canada or any other Biovail Regulatory Agency, failed to
disclose a material fact required to be disclosed to the FDA, Health Canada or
any other Biovail Regulatory Agency, or committed an act, made a statement, or
failed to make a statement that, at the time such disclosure was made, would
reasonably be expected to provide a basis for the FDA, Health Canada or any
other Biovail Regulatory Agency to invoke its policy respecting "Fraud, Untrue
Statements of Material Facts, Bribery, and Illegal Gratuities", set forth in
56 Fed. Reg. 46191 (September 10, 1991) or any similar policy. Neither Biovail
nor any of the Biovail Subsidiaries, nor, to the Knowledge of Biovail, any
officer, employee, agent or distributor of Biovail or any of the Biovail
Subsidiaries, has been convicted of any crime or engaged in any conduct for
which debarment is mandated by 21 U.S.C.  335a(a) or any similar Law or
authorized by 21 U.S.C.  335a(b) or any similar Law. Neither Biovail nor any
of the Biovail Subsidiaries, nor, to the Knowledge of Biovail, any officer,
employee, agent or distributor of Biovail or any of the Biovail Subsidiaries,
has been convicted of any crime or engaged in any conduct for which such
Person could be excluded from participating in the federal health care
programs under Section 1128 of the Social Security Act of 1935, as amended, or
any similar Law or program.

  

  

(g) As to each Biovail Product or Biovail Product candidate subject to the
FDCA and the regulations of the FDA promulgated thereunder, the Food and Drugs
Act, the CDSA and the regulations of Health Canada promulgated thereunder, or
similar Law in any foreign jurisdiction that is or has been developed,
manufactured, tested, distributed or marketed by or on behalf of Biovail or
any of the Biovail Subsidiaries, each such Biovail Product or Biovail Product
candidate is being or has been developed, manufactured, tested, distributed or
marketed in compliance in all material respects with all applicable
requirements under the FDCA and the regulations of the FDA promulgated
thereunder, the Food and Drugs Act, the CDSA and the regulations of Health
Canada promulgated thereunder, and similar Laws in any foreign jurisdiction,
including those relating to investigational use, premarket clearance or
marketing approval, good manufacturing practices, good clinical practices,
good laboratory practices, labeling, advertising, record keeping, filing of
reports, and security. There is no action or proceeding pending or threatened,
including any prosecution, injunction, seizure, civil fine, debarment,
suspension or recall, in each case alleging any violation applicable to any
Biovail Product or Biovail Product candidate by Biovail or any of the Biovail
Subsidiaries of any Law, except as would not, individually or in the
aggregate, reasonably be expected to have a Biovail Material Adverse Effect.

  

  

 

 

 

  

 

29  

  

 

 

 

  

  

(h) Since January 1, 2009, each of Biovail and the Biovail Subsidiaries have
neither voluntarily nor involuntarily initiated, conducted or issued, or
caused to be initiated, conducted or issued, any recall, field notifications,
field corrections, market withdrawal or replacement, safety alert, warning,
"dear doctor" letter, investigator notice, safety alert or other notice or
action relating to an alleged lack of safety, efficacy or regulatory
compliance of any Biovail Product. Each of Biovail and the Biovail
Subsidiaries are not aware of any facts which are reasonably likely to cause
(i) the recall, market withdrawal or replacement of any Biovail Product sold
or intended to be sold by Biovail or the Biovail Subsidiaries, (ii) a change
in the marketing classification or a material change in the labeling of any
such Biovail Products, or (iii) a termination or suspension of the marketing
of such Biovail Products.

  

  

(i) To Biovail's Knowledge, no data generated by Biovail or any of the Biovail
Subsidiaries with respect to the Biovail Products that has been provided to
its customers or otherwise made public or filed with a Biovail Regulatory
Agency is the subject of any regulatory or other action, either pending or
threatened, by any Biovail Regulatory Agency relating to the truthfulness or
scientific adequacy of such data.

  

  

(j) Since January 1, 2009, neither Biovail nor any of the Biovail Subsidiaries
has received any written notice that the FDA, Health Canada or any other
Biovail Regulatory Agency has (i) commenced, or threatened to initiate, any
action to request the recall of any product sold or intended to be sold by
Biovail or the Biovail Subsidiaries, or (ii) commenced, or threatened to
initiate, any action to enjoin manufacture or distribution of any product sold
or intended to be sold by Biovail or the Biovail Subsidiaries.

  

  

(k) Since January 1, 2009, neither Biovail nor any of the Biovail Subsidiaries
has received any written notice from the FDA, Health Canada or any other
Biovail Regulatory Agency regarding inappropriate advertising or marketing of
a Biovail Product or a negative change in reimbursement status of a Biovail
Product.

  

  

(l) Except as would not, individually or in the aggregate, reasonably be
expected to have a Biovail Material Adverse Effect, no Biovail Product
manufactured or distributed by Biovail or any of the Biovail Subsidiaries is
(i) adulterated within the meaning of 21 U.S.C.  351 (or any similar Law),
(ii) misbranded within the meaning of 21 U.S.C.  352 (or any similar Law).

  

  

(m) To the Knowledge of Biovail, all of its vendors are in compliance in all
material respects with good manufacturing practice and similar regulations
promulgated by regulatory agencies with jurisdiction over Biovail's vendors.

  

  

  

 

 

 

  

 

30  

  

 

 

 

  

  

  

(n) This Section 3.17 does not apply to environmental matters, which are the
subject of Section 3.13.

  

  

SECTION 3.18. Insurance. Since January 1, 2009, Biovail and the Biovail
Subsidiaries have maintained continuous insurance coverage, in each case, in
those amounts and covering those risks as are in accordance, in all material
respects, with normal industry practice for companies of the size and
financial condition of Biovail engaged in businesses similar to those of
Biovail and the Biovail Subsidiaries.

  

  

SECTION 3.19. Labor and Employment Matters. Neither Biovail nor any Biovail
Subsidiary is a party to any collective bargaining agreement and, as of the
date of this Agreement, there are not, to the Knowledge of Biovail, any union
organizing activities concerning any employees of Biovail or any of the
Biovail Subsidiaries, other than any such activities that, individually or in
the aggregate, have not had and would not reasonably be expected to have a
Biovail Material Adverse Effect. As of the date of this Agreement, there are
no labor strikes, slowdowns, work stoppages or lockouts pending or, to the
Knowledge of Biovail, threatened in writing against Biovail or any Biovail
Subsidiary, other than any such matters that, individually or in the
aggregate, have not had and would not reasonably be expected to have a Biovail
Material Adverse Effect.

  

  

SECTION 3.20. Brokers' Fees and Expenses. No broker, investment banker,
financial advisor or other Person, other than Morgan Stanley and Co.
Incorporated (the "Biovail Financial Advisor"), the fees and expenses of which
will be paid by Biovail, is entitled to any broker's, finder's, financial
advisor's or other similar fee or commission in connection with the Merger or
any of the other transactions contemplated by this Agreement based upon
arrangements made by or on behalf of Biovail or Merger Sub. Biovail has
furnished to Valeant true and complete copies of all agreements between
Biovail and the Biovail Financial Advisor relating to the Merger or any of the
other transactions contemplated by this Agreement.

  

  

SECTION 3.21. Opinion of Financial Advisor. Biovail has received an opinion
from the Biovail Financial Advisor, dated the date of this Agreement, to the
effect that, as of such date, subject to the assumptions and qualifications
set forth therein, the Exchange Ratio is fair to Biovail from a financial
point of view.

  

  

SECTION 3.22. BAC; Merger Sub. Biovail is the sole stockholder of BAC. BAC is
the sole stockholder of Merger Sub. Since its date of incorporation, Merger
Sub has not carried on any business nor conducted any operations other than
the execution of this Agreement, the performance of its obligations hereunder
and matters ancillary thereto.

  

  

SECTION 3.23. Affiliate Transactions. Except for (i) Contracts filed or
incorporated by reference as an exhibit to the Filed Biovail Reporting
Documents, (ii) Biovail Benefits Plans, (iii) indemnification agreements
between Biovail or any Biovail Subisidiary, on the one hand, and, on the other
hand, any current or former executive officer or director of Biovail or any
Biovail Subisidiary, or (iv) Contracts or arrangements entered into in the
ordinary course of business with customers, suppliers or service providers,
Section 3.23 of the Biovail Disclosure Letter sets forth a correct and
complete list of the contracts or arrangements that are in existence as of the
date of this Agreement between Biovail or any of its Subsidiaries, on the one
hand, and, on the other hand, any (x) present executive officer or director of
either Biovail or any of the Biovail Subsidiaries or any person that has
served as such an executive officer or director within the last five years or
any of such officer's or director's immediate family members, (y) record or
beneficial owner of more than 5% of the shares of Biovail Common Stock as of
the date hereof or (z) to the Knowledge of Biovail, any affiliate of any such
officer, director or owner (other than Biovail or any of the Biovail
Subsidiaries).

  

  

  

 

 

 

  

 

31  

  

 

 

 

  

  

SECTION 3.24. No Other Representations or Warranties. Except for the
representations and warranties contained in this Article III, Valeant
acknowledges that none of Biovail, the Biovail Subsidiaries or any other
Person on behalf of Biovail makes any other express or implied representation
or warranty in connection with the transactions contemplated by this
Agreement.

  

  

  

ARTICLE IV

  

  

Representations and Warranties of Valeant

  

  

Valeant represents and warrants to Biovail and Merger Sub that the statements
contained in this Article IV are true and correct, except (i) as set forth in
the Valeant Reporting Documents publicly available and filed with the SEC
following January 1, 2008 and at least two Business Days prior to the date of
this Agreement (the "Filed Valeant Reporting Documents") (excluding any
disclosures in the Filed Valeant Reporting Documents under the heading "Risk
Factors" and any other disclosures that are predictive or forward-looking in
nature) or (ii) as set forth in the disclosure letter delivered by Valeant to
Biovail at or before the execution and delivery by Valeant of this Agreement
(the "Valeant Disclosure Letter"). The Valeant Disclosure Letter shall be
arranged in numbered and lettered sections corresponding to the numbered and
lettered sections contained in this Article IV, and the disclosure in any
section shall be deemed to qualify other sections in this Article IV to the
extent (and only to the extent) that it is reasonably apparent from the face
of such disclosure that such disclosure also qualifies or applies to such
other sections.

  

  

SECTION 4.01. Organization, Standing and Power. Each of Valeant and each of
Valeant's Subsidiaries (the "Valeant Subsidiaries") is duly organized, validly
existing and in good standing under the laws of the jurisdiction in which it
is organized (in the case of good standing, to the extent such jurisdiction
recognizes such concept), except, in the case of the Valeant Subsidiaries,
where the failure to be so organized, existing or in good standing,
individually or in the aggregate, has not had and would not reasonably be
expected to have a Valeant Material Adverse Effect. Each of Valeant and the
Valeant Subsidiaries has all requisite power and authority and possesses all
Permits necessary to enable it to own, operate, lease or otherwise hold its
properties and assets and to conduct its businesses as presently conducted
(the "Valeant Permits"), except where the failure to have such power or
authority or to possess Valeant Permits, individually or in the aggregate, has
not had and would not reasonably be expected to have a Valeant Material
Adverse Effect. Each of Valeant and the Valeant Subsidiaries is duly qualified
or licensed to do business in each jurisdiction where the nature of its
business or the ownership, operation or leasing of its properties make such
qualification necessary, other than in such jurisdictions where the failure to
be so qualified or licensed, individually or in the aggregate, has not had and
would not reasonably be expected to have a Valeant Material Adverse Effect.
Valeant has delivered or made available to Biovail, prior to execution of this
Agreement, true and complete copies of the Certificate of Incorporation of
Valeant in effect as of the date of this Agreement (the "Valeant Charter") and
the By-laws of Valeant in effect as of the date of this Agreement (the
"Valeant By-laws").

  

  

  

 

 

 

  

 

32  

  

 

 

 

  

  

  

SECTION 4.02. Valeant Subsidiaries. (a) All the outstanding shares of capital
stock or voting securities of, or other equity interests in, each Valeant
Subsidiary have been validly issued and are fully paid and nonassessable and
are owned by Valeant, by another Valeant Subsidiary or by Valeant and another
Valeant Subsidiary, free and clear of all Liens, and free of any other
restriction (including any restriction on the right to vote, sell or otherwise
dispose of such capital stock, voting securities or other equity interests),
except for restrictions imposed by applicable securities laws. Section 4.02(a)
of the Valeant Disclosure Letter sets forth, as of the date of this Agreement,
a true and complete list of the Valeant Subsidiaries.

  

  

(b) Except for the capital stock and voting securities of, and other equity
interests in, the Valeant Subsidiaries, neither Valeant nor any Valeant
Subsidiary owns, directly or indirectly, any capital stock or voting
securities of, or other equity interests in, or any interest convertible into
or exchangeable or exercisable for, any capital stock or voting securities of,
or other equity interests in, any firm, corporation, partnership, company,
limited liability company, trust, joint venture, association or other entity.

  

  

SECTION 4.03. Capital Structure. (a) The authorized capital stock of Valeant
consists of 200,000,000 shares of Valeant Common Stock and 10,000,000 shares
of preferred stock, par value $0.01 per share (the "Valeant Preferred Stock"
and, together with the Valeant Common Stock, the "Valeant Capital Stock"). At
the close of business on June 14, 2010, (i) 75,786,925 shares of Valeant
Common Stock were issued and outstanding, none of which were subject to
vesting or other forfeiture conditions or repurchase by Valeant, (ii) no
shares of Valeant Preferred Stock were issued and outstanding, (iii)
28,086,863 shares of Valeant Common Stock were held by Valeant in its
treasury, (iv) 8,662,102 shares of Valeant Common Stock were issuable upon
conversion of (A) Valeant's 3.0% Convertible Subordinated Notes due 2010 (the
"Valeant 3.0% Convertible Notes") and (B) Valeant's 4.0% Convertible
Subordinated Notes due 2013 (together with the Valeant 3.0% Convertible Notes,
the "Valeant Convertible Notes"), (v) 1,710,585 shares of Valeant Common Stock
were underlying warrants issued pursuant to the Exchange Agreement, dated
August 13, 2009, among Valeant and certain holders of the Valeant 3.0%
Convertible Notes (the "Valeant Warrants"), (vi) 14,808,875 shares of Valeant
Common Stock were reserved and available for issuance pursuant to the Valeant
Stock Plans, of which (A) 4,920,081 shares were issuable upon exercise of
outstanding Valeant Stock Options and (B) 5,376,442 shares were issuable upon
settlement of outstanding Valeant Restricted Stock Units, assuming maximum
performance with respect to performance-based Valeant Restricted Stock Units
and (vii) 1,189,437 shares of Valeant Common Stock were reserved for issuance
pursuant to the Valeant ESPP. Except as set forth in this Section 4.03(a), at
the close of business on June 14, 2010, no shares of capital stock or voting
securities of, or other equity interests in, Valeant were issued, reserved for
issuance or outstanding. From the close of business on June 14, 2010 to the
date of this Agreement, there have been no issuances by Valeant of shares of
capital stock or voting securities of, or other equity interests in, Valeant,
other than the issuance of Valeant Common Stock upon the conversion of Valeant
Convertible Notes, upon the exercise of Valeant Warrants, Valeant Stock
Options or rights under the Valeant ESPP or upon the vesting of Valeant
Restricted Stock Units, in each case outstanding at the close of business on
June 14, 2010 and in accordance with their terms in effect at such time.

  

  

  

 

 

 

  

 

33  

  

 

 

 

  

  

  

(b) At the close of business on June 14, 2010, assuming the Pre-Merger Special
Dividend was paid on June 14, 2010, (i) 75,786,925 shares of Valeant Common
Stock would have been issued and outstanding, none of which would have been
subject to vesting or other forfeiture conditions or repurchase by Valeant,
(ii) no shares of Valeant Preferred Stock would have been issued and
outstanding, (iii) 28,086,863 shares of Valeant Common Stock would have been
held by Valeant in its treasury, (iv) assuming that the "Current Market Price"
(as defined in the the Indenture, dated as of November 19, 2003, among
Valeant, Ribapharm Inc. and The Bank of New York, as trustee (the "Valeant
Convertible Notes Indenture")) was $46.14, 13,607,296 shares of Valeant Common
Stock would have been issuable upon conversion of the Valeant Convertible
Notes, (v) 1,710,585 shares of Valeant Common Stock would be underlying the
Valeant Warrants (of which a total of 785,569 shares of Valeant Common Stock
would have been issuable upon net share settlement of the Valeant Warrants on
June 14, 2010 based on a share price of $46.14), (vi) 23,263,262 shares of
Valeant Common Stock would have been reserved and available for issuance
pursuant to the Valeant Stock Plans, of which (A) 7,728,955 shares would have
been issuable upon exercise of outstanding Valeant Stock Options and (B)
5,642,372 shares would have been issuable upon settlement of outstanding
Valeant Restricted Stock Units, assuming (1) a price of $46.14 per share of
Valeant Common Stock, and (2) the treatment of Valeant Restricted Stock Units
in accordance with Section 6.04, and (vii) 1,868,487 shares of Valeant Common
Stock would have been reserved for issuance pursuant to the Valeant ESPP.

  

  

  

 

 

 

  

 

34  

  

 

 

 

  

  

  

(c) All outstanding shares of Valeant Capital Stock are, and all such shares
that may be issued upon the conversion of Valeant Convertible Notes, upon the
exercise of Valeant Warrants, Valeant Stock Options or rights under the
Valeant ESPP or upon the vesting of Valeant Restricted Stock Units will be,
when issued, duly authorized, validly issued, fully paid and nonassessable and
not subject to, or issued in violation of, any purchase option, call option,
right of first refusal, preemptive right, subscription right or any similar
right under any provision of the DGCL, the Valeant Charter, the Valeant By-
laws or any Contract to which Valeant is a party or otherwise bound. Except as
set forth above in this Section 4.03, there are not issued, reserved for
issuance or outstanding, and there are not any outstanding obligations of
Valeant or any Valeant Subsidiary to issue, deliver or sell, or cause to be
issued, delivered or sold, (x) any capital stock of Valeant or any Valeant
Subsidiary or any securities of Valeant or any Valeant Subsidiary convertible
into or exchangeable or exercisable for shares of capital stock or voting
securities of, or other equity interests in, Valeant or any Valeant
Subsidiary, (y) any warrants, calls, options or other rights to acquire from
Valeant or any Valeant Subsidiary, or any other obligation of Valeant or any
Valeant Subsidiary to issue, deliver or sell, or cause to be issued, delivered
or sold, any capital stock or voting securities of, or other equity interests
in, Valeant or any Valeant Subsidiary or (z) any rights issued by or other
obligations of Valeant or any Valeant Subsidiary that are linked in any way to
the price of any class of Valeant Capital Stock or any shares of capital stock
of any Valeant Subsidiary, the value of Valeant, any Valeant Subsidiary or any
part of Valeant or any Valeant Subsidiary or any dividends or other
distributions declared or paid on any shares of capital stock of Valeant or
any Valeant Subsidiary. Except pursuant to the Valeant Stock Plans, there are
not any outstanding obligations of Valeant or any of the Valeant Subsidiaries
to repurchase, redeem or otherwise acquire any shares of capital stock or
voting securities or other equity interests of Valeant or any Valeant
Subsidiary or any securities, interests, warrants, calls, options or other
rights referred to in clause (x), (y) or (z) of the immediately preceding
sentence. Except for the Valeant Convertible Notes, there are no debentures,
bonds, notes or other Indebtedness of Valeant having the right to vote (or
convertible into, or exchangeable for, securities having the right to vote) on
any matters on which stockholders of Valeant may vote ("Valeant Voting Debt").
Neither Valeant nor any of the Valeant Subsidiaries is a party to any voting
agreement with respect to the voting of any capital stock or voting securities
of, or other equity interests in, Valeant. Except for this Agreement and the
Standstill and Board Nomination Agreement, dated as of December 17, 2009,
among Valeant, ValueAct Capital Master Fund, L.P., VA Partners I, LLC,
ValueAct Capital Management, L.P., ValueAct Capital Management, LLC, ValueAct
Holdings, L.P. and ValueAct Holdings GP, LLC (the "Valeant Board Nomination
Agreement"), neither Valeant nor any of the Valeant Subsidiaries is a party to
any agreement pursuant to which any Person is entitled to elect, designate or
nominate any director of Valeant or any of the Valeant Subsidiaries.

  

  

SECTION 4.04. Authority; Execution and Delivery; Enforceability. (a) Valeant
has all requisite corporate power and authority to execute and deliver this
Agreement, to perform its obligations hereunder and to consummate the Merger
and the other transactions contemplated by this Agreement, subject, in the
case of the Merger, to the receipt of the Valeant Stockholder Approval. The
Board of Directors of Valeant (the "Valeant Board") has adopted resolutions,
by unanimous vote at a meeting duly called at which a quorum of directors of
Valeant was present, (i) approving this Agreement, (ii) determining that
entering into this Agreement is in the best interests of Valeant and its
stockholders, (iii) declaring this Agreement advisable, (iv) recommending that
Valeant's stockholders adopt this Agreement and directing that this Agreement
be submitted to Valeant's stockholders for adoption at a duly held meeting of
such stockholders for such purpose (the "Valeant Stockholders Meeting") and
(v) subject to the discretion of the Board of the Combined Company,
determining that the Post-Merger Special Dividend will be in the best
interests of the Combined Company and its stockholders and that it is the
intention of those directors of Valeant that will become directors of the
Combined Company to support the declaration and payment of the Post-Merger
Special Dividend at the applicable time. Such resolutions have not been
amended or withdrawn as of the date of this Agreement. Except for the adoption
of this Agreement by the affirmative vote of a majority of the outstanding
shares of Valeant Common Stock entitled to vote at the Valeant Stockholders
Meeting (the "Valeant Stockholder Approval"), no other corporate proceedings
on the part of Valeant are necessary to authorize, adopt or approve this
Agreement or to consummate the Merger and the other transactions contemplated
by this Agreement (except for the filing of the appropriate merger documents
as required by the DGCL). Valeant has duly executed and delivered this
Agreement and, assuming the due authorization, execution and delivery by
Biovail and Merger Sub, this Agreement constitutes its legal, valid and
binding obligation, enforceable against it in accordance with its terms.

  

  

  

 

 

 

  

 

35  

  

 

 

 

  

  

  

(b) The Valeant Board has adopted such resolutions as are necessary to render
inapplicable to this Agreement, the Merger and the other transactions
contemplated by this Agreement the restrictions on (i) "business combinations"
(as defined in Section 203 of the DGCL) as set forth in Section 203 of the
DGCL and (ii) "Business Combinations" (as defined in Article Fourteenth of the
Valeant Charter) as set forth in Article Fourteenth of the Valeant Charter. No
"fair price", "moratorium", "control share acquisition" or other similar
antitakeover statute or similar statute or regulation applies with respect to
this Agreement, the Merger or any of the other transactions contemplated by
this Agreement in respect of Valeant.

  

  

SECTION 4.05. No Conflicts; Consents. (a) The execution and delivery by
Valeant of this Agreement does not, and the performance by Valeant of its
obligations hereunder and the consummation of the Merger and the other
transactions contemplated by this Agreement will not, (i) conflict with, or
result in any violation of any provision of, the Valeant Charter, the Valeant
By-laws or the comparable charter or organizational documents of any Valeant
Subsidiary (assuming that the Valeant Stockholder Approval is obtained), (ii)
conflict with, or result in any violation of or default (with or without
notice or lapse of time, or both) under, or give rise to a right of
termination, cancellation or acceleration of any obligation, any obligation to
make an offer to purchase or redeem any Indebtedness or capital stock or any
loss of a material benefit under, or result in the creation of any Lien upon
any of the properties or assets of Valeant or any Valeant Subsidiary under,
any provision of, any Contract to which Valeant or any Valeant Subsidiary is a
party or by which any of their respective properties or assets is bound or any
Valeant Permit or (iii) conflict with, or result in any violation of any
provision of, subject to the filings and other matters referred to in Section
4.05(b), any Judgment or Law, in each case, applicable to Valeant or any
Valeant Subsidiary or their respective properties or assets (assuming that the
Valeant Stockholder Approval is obtained), other than, in the case of clauses
(ii) and (iii) above, any matters that, individually or in the aggregate, have
not had and would not reasonably be expected to have a Valeant Material
Adverse Effect (it being agreed that for purposes of this Section 4.05(a),
effects resulting from or arising in connection with the matters set forth in
clause (iv) of the definition of the term "Material Adverse Effect" shall not
be excluded in determining whether a Valeant Material Adverse Effect has
occurred or would reasonably be expected to occur) and would not prevent or
materially impede, interfere with, hinder or delay the consummation of the
Merger.

  

  

  

 

 

 

  

 

36  

  

 

 

 

  

  

  

(b) No Consent of or from, or registration, declaration, notice or filing made
to or with any Governmental Entity is required to be obtained or made by or
with respect to Valeant or any Valeant Subsidiary in connection with the
execution and delivery of this Agreement or its performance of its obligations
hereunder or the consummation of the Merger and the other transactions
contemplated by this Agreement, other than (i) (A) the filing with the SEC of
the Joint Proxy Statement in definitive form, (B) the filing with the SEC, and
declaration of effectiveness under the Securities Act, of the Form S-4, and
(C) the filing with the SEC of such reports under, and such other compliance
with, the Exchange Act and the Securities Act, and the rules and regulations
thereunder, as may be required in connection with this Agreement, the Merger
and the other transactions contemplated by this Agreement, (ii) compliance
with and filings under the HSR Act and, if required, Part IX of the
Competition Act and such other Consents, registrations, declarations,
approvals, notices or filings as are required to be made or obtained under any
foreign antitrust, competition, foreign investment, trade regulation or
similar Laws, (iii) the filing of the Certificate of Merger with the Secretary
of State of the State of Delaware and appropriate documents with the relevant
authorities of the other jurisdictions in which Biovail and Valeant are
qualified to do business, (iv) such filings with and approvals of the NYSE and
TSX as are required to permit the consummation of the Merger and (v) such
other matters that, individually or in the aggregate, have not had and would
not reasonably be expected to have a Valeant Material Adverse Effect (it being
agreed that for purposes of this Section 4.05(b), effects resulting from or
arising in connection with the matters set forth in clause (iv) of the
definition of the term "Material Adverse Effect" shall not be excluded in
determining whether a Valeant Material Adverse Effect has occurred or would
reasonably be expected to occur) and would not prevent or materially impede,
interfere with, hinder or delay the consummation of the Merger.

  

  

  

 

 

 

  

 

37  

  

 

 

 

  

  

  

SECTION 4.06. Reporting Documents; Undisclosed Liabilities. (a) Valeant has
furnished or filed all reports, schedules, forms, statements and other
documents (including exhibits and other information incorporated therein)
required to be furnished or filed by Valeant with the SEC since January 1,
2008 (such documents, together with any documents filed with the SEC during
such period by Valeant on a voluntary basis on a Current Report on Form 8-K,
but excluding the Joint Proxy Statement and the Form S-4, being collectively
referred to as the "Valeant Reporting Documents").

  

  

(b) Each Valeant Reporting Document (i) at the time filed, complied in all
material respects with the requirements of SOX and the Exchange Act or the
Securities Act, as the case may be, and the rules and regulations of the SEC
promulgated thereunder applicable to such Valeant Reporting Document and (ii)
did not at the time it was filed (or if amended or superseded by a filing or
amendment prior to the date of this Agreement, then at the time of such filing
or amendment) contain any untrue statement of a material fact or omit to state
a material fact required to be stated therein or necessary in order to make
the statements therein, in light of the circumstances under which they were
made, not misleading. Each of the consolidated financial statements of Valeant
included in the Valeant Reporting Documents complied at the time it was filed
as to form in all material respects with applicable accounting requirements
and the published rules and regulations of the SEC with respect thereto, was
prepared in accordance with GAAP (except, in the case of unaudited statements,
as permitted by Form 10-Q of the SEC) applied on a consistent basis during the
periods involved (except as may be indicated in the notes thereto) and fairly
presented in all material respects the consolidated financial position of
Valeant and its consolidated Subsidiaries as of the dates thereof and the
consolidated results of their operations and cash flows for the periods shown
(subject, in the case of unaudited statements, to normal year-end audit
adjustments).

  

  

(c) Neither Valeant nor any Valeant Subsidiary has any liabilities or
obligations of any nature (whether accrued, absolute, contingent or otherwise)
that, individually or in the aggregate, have had or would reasonably be
expected to have a Valeant Material Adverse Effect.

  

  

(d) Each of the chief executive officer of Valeant and the chief financial
officer of Valeant (or each former chief executive officer of Valeant and each
former chief financial officer of Valeant, as applicable) has made all
applicable certifications required by Rule 13a-14 or 15d-14 under the Exchange
Act and Sections 302 and 906 of SOX with respect to the Valeant Reporting
Documents, and the statements contained in such certifications are true and
accurate. None of Valeant or any of the Valeant Subsidiaries has outstanding,
or has arranged any outstanding, "extensions of credit" to directors or
executive officers within the meaning of Section 402 of SOX.

  

  

(e) Valeant maintains a system of "internal control over financial reporting"
(as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) sufficient
to provide reasonable assurance (A) that transactions are recorded as
necessary to permit preparation of financial statements in conformity with
GAAP, consistently applied, (B) that transactions are executed only in
accordance with the authorization of management and (C) regarding prevention
or timely detection of the unauthorized acquisition, use or disposition of
Valeant's properties or assets.

  

  

  

 

 

 

  

 

38  

  

 

 

 

  

  

  

(f) The "disclosure controls and procedures" (as defined in Rules 13a-15(e)
and 15d-15(e) of the Exchange Act) utilized by Valeant are reasonably designed
to ensure that all information (both financial and non-financial) required to
be disclosed by Valeant in the reports that it files or submits under the
Exchange Act is recorded, processed, summarized and reported within the time
periods specified in the rules and forms of the SEC and that all such
information required to be disclosed is accumulated and communicated to the
management of Valeant, as appropriate, to allow timely decisions regarding
required disclosure and to enable the chief executive officer and chief
financial officer of Valeant to make the certifications required under the
Exchange Act with respect to such reports.

  

  

(g) Neither Valeant nor any of the Valeant Subsidiaries is a party to, or has
any commitment to become a party to, any joint venture, off-balance sheet
partnership or any similar Contract (including any Contract or arrangement
relating to any transaction or relationship between or among Valeant and any
of the Valeant Subsidiaries, on the one hand, and any unconsolidated
Affiliate, including any structured finance, special purpose or limited
purpose entity or Person, on the other hand, or any "off-balance sheet
arrangements" (as defined in Item 303(a) of Regulation S-K under the Exchange
Act)), where the result, purpose or intended effect of such Contract is to
avoid disclosure of any material transaction involving, or material
liabilities of, Valeant or any of the Valeant Subsidiaries in Valeant's or
such Valeant Subsidiary's published financial statements or other Valeant
Reporting Documents.

  

  

(h) Since January 1, 2009, none of Valeant, Valeant's independent accountants,
the Valeant Board or the audit committee of the Valeant Board has received any
oral or written notification of any (x) "significant deficiency" in the
internal controls over financial reporting of Valeant, (y) "material weakness"
in the internal controls over financial reporting of Valeant or (z) fraud,
whether or not material, that involves management or other employees of
Valeant who have a significant role in the internal controls over financial
reporting of Valeant.

  

  

(i) None of the Valeant Subsidiaries is, or has at any time since January 1,
2009 been, subject to the reporting requirements of Section 13(a) or 15(d) of
the Exchange Act or a reporting issuer in any of the provinces of Canada
within the meaning of the Canadian Securities Laws.

  

  

SECTION 4.07. Information Supplied. None of the information supplied or to be
supplied by Valeant for inclusion or incorporation by reference in (i) the
Form S-4 will, at the time the Form S-4 is filed with the SEC, at any time it
is amended or supplemented or at the time it is declared effective under the
Securities Act, contain any untrue statement of a material fact or omit to
state any material fact required to be stated therein or necessary to make the
statements therein not misleading or (ii) the Joint Proxy Statement will, at
the date it is first mailed to each of Biovail's stockholders and Valeant's
stockholders or at the time of each of the Biovail Stockholders Meeting and
the Valeant Stockholders Meeting, contain any untrue statement of a material
fact or omit to state any material fact required to be stated therein or
necessary in order to make the statements therein, in light of the
circumstances under which they are made, not misleading. The Joint Proxy
Statement will comply as to form in all material respects with the
requirements of the Exchange Act and the rules and regulations thereunder,
except that no representation is made by Valeant with respect to statements
made or incorporated by reference therein based on information supplied by
Biovail or Merger Sub for inclusion or incorporation by reference therein.

  

  

  

 

 

 

  

 

39  

  

 

 

 

  

  

  

SECTION 4.08. Absence of Certain Changes or Events. From January 1, 2010 to
the date of this Agreement, each of Valeant and the Valeant Subsidiaries has
conducted its respective business in the ordinary course in all material
respects, and during such period there has not occurred:

  

  

(a) any fact, circumstance, effect, change, event or development that,
individually or in the aggregate, has had or would reasonably be expected to
have a Valeant Material Adverse Effect;

  

  

(b) any declaration, setting aside or payment of any dividend or other
distribution (whether in cash, stock or property or any combination thereof)
in respect of any capital stock or voting securities of, or other equity
interests in, Valeant or the capital stock or voting securities of, or other
equity interests in, any of the Valeant Subsidiaries (other than dividends or
other distributions by a direct or indirect wholly owned Valeant Subsidiary to
its parent) or any repurchase for value by Valeant of any capital stock or
voting securities of, or other equity interests in, Valeant or the capital
stock or voting securities of, or other equity interests in, any of the
Valeant Subsidiaries;

  

  

(c) any split, reverse split, combination, subdivision or reclassification of
any capital stock or voting securities of, or other equity interests in,
Valeant, securities convertible into or exercisable or exchangeable for
capital stock or voting securities of, or other equity interests in, Valeant
or any issuance or the authorization of any issuance of any other securities
in respect of, in lieu of or in substitution for shares of capital stock or
voting securities of, or other equity interests in, Valeant;

  

  

(d) any incurrence of material Indebtedness for borrowed money or any
guarantee of such Indebtedness for another Person, or any issue or sale of
debt securities, warrants or other rights to acquire any debt security of
Valeant or any Valeant Subsidiary other than the issuance of commercial paper
in the ordinary course of business;

  

  

  

 

 

 

  

 

40  

  

 

 

 

  

  

  

(e) (i) any transfer, lease, license, sale, mortgage, pledge or other disposal
or encumbrance of any of Valeant's or Valeant's Subsidiaries' property or
assets outside of the ordinary course of business consistent with past
practice with a fair market value in excess of $5,000,000 or (ii) any
acquisitions of businesses, whether by merger, consolidation, purchase of
property or assets or otherwise;

  

  

(f) (i) any granting by Valeant to any director or executive officer of
Valeant of any material increase in compensation, (ii) any granting by Valeant
to any director or executive officer of Valeant of any material increase in
change in control, severance or termination pay, (iii) any establishment,
adoption, entry into or amendment in any material respect of any collective
bargaining agreement or material Valeant Benefit Plan or (iv) the taking of
any action to accelerate the time of vesting or payment of any material
compensation or benefits under any Valeant Benefit Plan;

  

  

(g) any change in accounting methods, principles or practices by Valeant or
any Valeant Subsidiary, except insofar as may have been required by a change
in GAAP; or

  

  

(h) any material elections or changes thereto with respect to Taxes by Valeant
or any Valeant Subsidiary or any settlement or compromise by Valeant or any
Valeant Subsidiary of any material Tax liability or refund, other than in the
ordinary course of business.

  

  

SECTION 4.09. Taxes. (a) (i) Each of Valeant and each Valeant Subsidiary has
timely filed, taking into account any extensions, all material Tax Returns
required to have been filed and such Tax Returns are accurate and complete in
all material respects; (ii) each of Valeant and each Valeant Subsidiary has
paid all material Taxes required to have been paid by it other than Taxes that
are not yet due or that are being contested in good faith in appropriate
proceedings; and (iii) no deficiency for any Tax has been asserted or assessed
by a taxing authority against Valeant or any Valeant Subsidiary which
deficiency has not been paid or is not being contested in good faith in
appropriate proceedings.

  

  

(b) No Tax Return of Valeant or any Valeant Subsidiary is under audit or
examination by any taxing authority, and no written (or, to the Knowledge of
Valeant, oral) notice of such an audit or examination has been received by
Valeant or any Valeant Subsidiary. No deficiencies for any Taxes have been
proposed, asserted or assessed against Valeant or any Valeant Subsidiary, and
no requests for waivers of the time to assess any such Taxes are pending.
There are no outstanding waivers of any limitation periods or agreements
providing for an extension of time for the filing of any Tax Return, the
assessment or collection thereof by any relevant taxing authority or the
payment of any Tax by Valeant or any Valeant Subsidiary. No other procedure,
proceeding or contest of any refund or deficiency in respect of Taxes is
pending in or on appeal from any Governmental Entity.

  

  

  

 

 

 

  

 

41  

  

 

 

 

  

  

  

(c) Each of Valeant and each Valeant Subsidiary has complied in all material
respects with all applicable Laws relating to the withholding, collection and
remittance of Taxes and other deductions required to be withheld.

  

  

(d) Other than for Taxes not yet due and delinquent or that are being
contested in good faith in appropriate proceedings, there are no Liens with
respect to Taxes against any of the assets of Valeant or any Valeant
Subsidiary. No written or, to the Knowledge of Valeant, other claim has been
received by Valeant or any Valeant Subsidiary from an authority in a
jurisdiction where such corporation does not file Tax Returns that it is or
may be subject to material taxation by such jurisdiction. Neither Valeant nor
any Valeant Subsidiary has a permanent establishment or is resident for Tax
purposes outside of its jurisdiction or territory of incorporation or
formation.

  

  

(e) Each of Valeant and the Valeant Subsidiaries has not and has not been
deemed to have for purposes of the Income Tax Act (or any other applicable
Law), acquired property from a non-arm's length Person, within the meaning of
the Income Tax Act (or such other applicable Law), for consideration, the
value of which is less than the fair market value of the property in
circumstances which could subject it to a liability under section 160 of the
Income Tax Act (or the analogous provision of such other applicable Law).

  

  

(f) With respect to any transaction with any non-arm's length Person that is
not a resident of Canada within the meaning of the Income Tax Act, no Valeant
Subsidiary resident in Canada has (i) paid any consideration for any property
(including for the use of property) or services that is in excess of the fair
market value thereof, nor (ii) received any consideration for any property
(including for the use of property) or services that is less than the fair
market value thereof. For all such transactions, each Valeant Subsidiary
resident in Canada has made or obtained records or documents that meet the
requirements of paragraphs 247(4)(a) to (c) of the Income Tax Act.

  

  

(g) None of sections 78, 80, 80.01, 80.02, 80.03 and 80.04 of the Income Tax
Act, or any equivalent provision of the Laws of any other jurisdiction, has
applied in any material manner or shall apply in any material manner to any of
Valeant or the Valeant Subsidiaries as of the Closing Date.

  

  

(h) Neither Valeant nor any Valeant Subsidiary has received any material
requirement pursuant to section 224 of the Income Tax Act which remains
unsatisfied in any respect.

  

  

  

 

 

 

  

 

42  

  

 

 

 

  

  

  

(i) Neither Valeant nor any Valeant Subsidiary is a party to or is otherwise
bound by any material Tax sharing, allocation or indemnification agreement or
arrangement (other than such an agreement or arrangement exclusively between
or among Valeant and wholly owned Valeant Subsidiaries).

  

  

(j) Within the past three years, neither Valeant nor any Valeant Subsidiary
has been a "distributing corporation" or a "controlled corporation" in a
distribution intended to qualify for tax-free treatment under Section 355 of
the Code.

  

  

(k) Neither Valeant nor any Valeant Subsidiary has participated in or been a
party to a transaction that, as of the date of this Agreement, constitutes a
"listed transaction" within the meaning of Section 6011 of the Code and
applicable Treasury Regulations thereunder (or a similar provision of state or
foreign Law).

  

  

(l) This Agreement (including any exhibits hereto) sets forth the complete
terms of the Merger. Neither Valeant nor any Valeant Subsidiary has taken any
other action or knows of any other fact relating to the Merger that would
reasonably be expected to prevent the Merger from qualifying for the Intended
Tax Treatment.

  

  

(m) No amounts paid or payable by Valeant or any Valeant Subsidiary as
employee compensation, whether under any contract, plan, program or
arrangement, understanding or otherwise (including any Valeant Benefit Plan or
Valeant Benefit Arrangement), individually or in the aggregate, is or would
reasonably be expected to be non-deductible for federal income tax purposes by
virtue of Section 162(m) or 280G of the Code.

  

  

SECTION 4.10. Employee Benefits. (a) Section 4.10(a) of the Valeant Disclosure
Letter sets forth a complete and accurate list of each material Valeant
Benefit Plan and each material Valeant Benefit Agreement.

  

  

(b) With respect to each material Valeant Benefit Plan and material Valeant
Benefit Agreement, Valeant has made available to Biovail complete and accurate
copies of (A) such Valeant Benefit Plan or Valeant Benefit Agreement,
including any material amendment thereto, and, to the extent applicable,
summary plan description thereof, (B) each trust, insurance, annuity or other
funding Contract related thereto, (C) the most recent audited financial
statements and actuarial or other valuation reports prepared with respect
thereto, (D) the two most recent annual reports on Form 5500 required to be
filed with the Internal Revenue Service with respect thereto and the two most
recent annual information returns required to be filed with any Governmental
Entity and (E) the most recently received IRS determination letter.

  

  

(c) Each Valeant Benefit Plan and Valeant Benefit Agreement (and any related
trust or other funding vehicle) has been administered in accordance with its
terms and is in compliance with ERISA, the Code and all other applicable Laws,
other than instances of non-compliance that, individually or in the aggregate,
have not had and would not reasonably be expected to have a Valeant Material
Adverse Effect.

  

  

  

 

 

 

  

 

43  

  

 

 

 

  

  

  

(d) Except for matters that, individually or in the aggregate, have not had
and would not reasonably be expected to have a Valeant Material Adverse
Effect, neither Valeant nor any Valeant Subsidiary nor any Valeant Commonly
Controlled Entity currently sponsors, maintains or contributes to, or has
sponsored, maintained, contributed to or been required to maintain or
contribute to, or has any actual or contingent liability under, any Benefit
Plan that is subject to Section 302 or Title IV of ERISA or Section 412 of the
Code or is otherwise a defined benefit plan (including any such plan
maintained outside the United States).

  

  

(e) None of the Valeant Benefit Plans is a "registered pension plan" within
the meaning of Section 248(1) of the Income Tax Act.

  

  

(f) Neither Valeant nor any Valeant Subsidiary has any liability for providing
health, medical or other welfare benefits after retirement or other
termination of employment (other than for continuation coverage required under
Section 4980(B)(f) of the Code or applicable Law), except for any liabilities
that, individually and in the aggregate, have not had and would not reasonably
be expected to have a Valeant Material Adverse Effect.

  

  

(g) None of the execution and delivery of this Agreement, the performance by
either party of its obligations hereunder or the consummation of the Merger
and the other transactions contemplated by this Agreement (alone or in
conjunction with any other event, including any termination of employment on
or following the Effective Time) will (i) entitle any Valeant Personnel to any
material compensation or benefit, (ii) accelerate the time of payment or
vesting, or trigger any payment or funding, of any material compensation or
benefit or trigger any other material obligation under any Valeant Benefit
Plan or Valeant Benefit Agreement or (iii) result in any breach or violation
of, or default under, or limit Valeant's right to amend, modify or terminate,
any Valeant Benefit Plan or Valeant Benefit Agreement.

  

  

SECTION 4.11. Litigation. There is no, and since January 1, 2008, there has
been no, suit, action or other proceeding pending or, to the Knowledge of
Valeant, threatened against or affecting Valeant or any Valeant Subsidiary (i)
that, individually or in the aggregate, has had or would reasonably be
expected to have a Valeant Material Adverse Effect or (ii) that, as of the
date of this Agreement, challenges or seeks to prevent, enjoin, alter in any
material respect or materially delay the Merger or any of the other
transactions contemplated hereby. There is no, and since January 1, 2008,
there has been no, Judgment outstanding against or, to the Knowledge of
Valeant, investigation by any Governmental Entity involving, Valeant or any
Valeant Subsidiary or any of their respective properties or assets that,
individually or in the aggregate, has had or would reasonably be expected to
have a Valeant Material Adverse Effect.

  

  

  

 

 

 

  

 

44  

  

 

 

 

  

  

  

SECTION 4.12. Compliance with Applicable Laws. Except for matters that,
individually or in the aggregate, have not had and would not reasonably be
expected to have a Valeant Material Adverse Effect, Valeant and the Valeant
Subsidiaries are, and since January 1, 2008, have been, in compliance with all
applicable Laws and Valeant Permits. Except for matters that, individually or
in the aggregate, have not had and would not reasonably be expected to have a
Valeant Material Adverse Effect, there is no, and since January 1, 2008, there
has been no, material action, demand or investigation by or before any
Governmental Entity pending or, to the Knowledge of Valeant, threatened
alleging that Valeant or a Valeant Subsidiary is not in compliance with any
applicable Law or Valeant Permit or which challenges or questions the validity
of any rights of the holder of any Valeant Permit. To the Knowledge of
Valeant, Valeant is, and since January 1, 2008, has been, in material
compliance with the FCPA and any rules and regulations thereunder. This
Section 4.12 does not relate to Tax matters, employee benefits matters,
environmental matters or Intellectual Property matters, which are the subjects
of Sections 4.09, 4.10, 4.13 and 4.16, respectively.

  

  

SECTION 4.13. Environmental Matters. (a) Except for matters that, individually
or in the aggregate, have not had and would not reasonably be expected to have
a Valeant Material Adverse Effect:

  

  

(i) Valeant and the Valeant Subsidiaries are in compliance with all
Environmental Laws (which compliance includes the possession by Valeant and
the Valeant Subsidiaries of all Permits required under applicable
Environmental Laws necessary for their operations as currently conducted, and
compliance with the terms and conditions thereof), and neither Valeant nor any
Valeant Subsidiary has received any written communication, whether from a
Governmental Entity, citizens group, employee or otherwise, alleging that
Valeant or any Valeant Subsidiary is not in such compliance, and, to the
Knowledge of Valeant, there are no past or present circumstances, conditions,
events or incidents that would reasonably be expected to prevent or interfere
with such compliance in the future;

  

  

(ii) there are no Environmental Claims pending or, to the Knowledge of
Valeant, threatened against Valeant or any of the Valeant Subsidiaries or, to
the Knowledge of Valeant, against any Person whose liability for any
Environmental Claim Valeant or any of the Valeant Subsidiaries has or may have
retained or assumed, either contractually or by operation of law;

  

  

(iii) there have been no Releases of any Hazardous Material that would
reasonably be expected to form the basis of any Environmental Claim against
Valeant or any of the Valeant Subsidiaries or, to the Knowledge of Valeant,
against any Person whose liabilities for such Environmental Claims Valeant or
any of the Valeant Subsidiaries has, or may have, retained or assumed, either
contractually or by operation of Law; and

  

  

  

 

 

 

  

 

45  

  

 

 

 

  

  

  

(iv) neither Valeant nor any of the Valeant Subsidiaries has retained or
assumed, either contractually or by operation of law, any liabilities or
obligations that would reasonably be expected to form the basis of any
Environmental Claim against Valeant or any of the Valeant Subsidiaries.

  

  

SECTION 4.14. Contracts. (a) As of the date of this Agreement, neither Valeant
nor any Valeant Subsidiary is a party to any Contract required to be filed by
Valeant as a "material contract" pursuant to Item 601(b)(10) of Regulation S-K
under the Securities Act (a "Filed Valeant Contract") that has not been so
filed.

  

  

(b) Section 4.14(b) of the Valeant Disclosure Letter sets forth, as of the
date of this Agreement, a true and complete list of (i) non-competition
Contracts or any other Contract containing terms that expressly (A) limit or
otherwise restrict Valeant or the Valeant Subsidiaries or (B) to the Knowledge
of Valeant, would, after the Effective Time, by its terms expressly limit or
otherwise restrict the Combined Company from, in the case of either (A) or
(B), engaging or competing in any line of business or in any geographic area
or from developing or commercializing any compounds, any therapeutic area,
class of drugs or mechanism of action, in a manner that would be reasonably
likely to be material, in the case of (A), to Valeant and the Valeant
Subsidiaries, taken as a whole, or in the case of (B), to the Combined
Company, taken as a whole, (ii) each loan and credit agreement, note,
debenture, bond, indenture or other similar agreement pursuant to which any
Indebtedness of Valeant or any of the Valeant Subsidiaries is outstanding or
may be incurred, other than any such agreement between or among Valeant and
the wholly owned Valeant Subsidiaries, and (iii) each partnership, joint
venture or similar agreement or understanding to which Valeant or any of the
Valeant Subsidiaries is a party relating to the formation, creation,
operation, management or control of any partnership or joint venture material
to Valeant and the Valeant Subsidiaries, taken as a whole. Each agreement,
understanding or undertaking of the type described in this Section 4.14(b) and
each Filed Valeant Contract is referred to herein as a "Valeant Material
Contract".

  

  

(c) Except for matters which, individually or in the aggregate, have not had
and would not reasonably be expected to have a Valeant Material Adverse
Effect, (i) each Valeant Material Contract (including, for purposes of this
Section 4.14(c), any Contract entered into after the date of this Agreement
that would have been a Valeant Material Contract if such Contract existed on
the date of this Agreement) is a valid, binding and legally enforceable
obligation of Valeant or one of the Valeant Subsidiaries, as the case may be,
and, to the Knowledge of Valeant, of the other parties thereto, except, in
each case, as enforcement may be limited by bankruptcy, insolvency,
reorganization or similar Laws affecting creditors' rights generally and by
general principles of equity, (ii) each such Valeant Material Contract is in
full force and effect and (iii) none of Valeant or any of the Valeant
Subsidiaries is (with or without notice or lapse of time, or both) in breach
or default under any such Valeant Material Contract and, to the Knowledge of
Valeant, no other party to any such Valeant Material Contract is (with or
without notice or lapse of time, or both) in breach or default thereunder.

  

  

  

 

 

 

  

 

46  

  

 

 

 

  

  

  

SECTION 4.15. Properties. (a) Valeant and each Valeant Subsidiary has good and
valid title to, and with respect to real property owned by Valeant or any
Valeant Subsidiary, marketable and insurable fee simple interest in, or valid
license or leasehold interests in, all their respective properties and assets,
except in respects that, individually or in the aggregate, have not had and
would not reasonably be expected to have a Valeant Material Adverse Effect.
All such properties and assets, other than properties and assets in which
Valeant or any of the Valeant Subsidiaries has a license or leasehold
interest, are free and clear of all conditions, encroachments, easements,
rights of way, restrictions and Liens, except for such conditions,
encroachments, easements, rights of way, restrictions and Liens that,
individually or in the aggregate, have not had and would not reasonably be
expected to have a Valeant Material Adverse Effect. This Section 4.15 does not
relate to Intellectual Property matters, which are the subject of Section
4.16.

  

  

(b) Valeant and each of the Valeant Subsidiaries has complied with the terms
of all leases to which it is a party, and all leases to which Valeant or any
Valeant Subsidiary is a party are in full force and effect, except for such
noncompliance or failure to be in full force and effect that, individually or
in the aggregate, has not had and would not reasonably be expected to have a
Valeant Material Adverse Effect. Valeant and each Valeant Subsidiary is in
possession of the properties or assets purported to be leased under all its
leases, except for such failures to have such possession as, individually or
in the aggregate, have not had and would not reasonably be expected to have a
Valeant Material Adverse Effect.

  

  

SECTION 4.16. Intellectual Property. (a) Except for matters that, individually
or in the aggregate, have not had and would not reasonably be expected to have
a Valeant Material Adverse Effect, (i) to the Knowledge of Valeant, Valeant
and each of the Valeant Subsidiaries owns, or is licensed to use (in each
case, free and clear of any Liens), all Intellectual Property used in or
necessary for the conduct of its business as currently conducted, and to its
Knowledge all such Intellectual Property is valid, enforceable and subsisting;
(ii) to the Knowledge of Valeant, the use of any Intellectual Property by
Valeant and the Valeant Subsidiaries does not infringe on or otherwise violate
the rights of any Person and is in accordance with any applicable license
pursuant to which Valeant or any Valeant Subsidiary acquired the right to use
any Intellectual Property; (iii) to the Knowledge of Valeant, no Person is
challenging, infringing on or otherwise violating any right of Valeant or any
of the Valeant Subsidiaries with respect to any Intellectual Property owned by
or licensed to Valeant or any of the Valeant Subsidiaries; and (iv) to the
Knowledge of Valeant, neither Valeant nor any of the Valeant Subsidiaries has
received any written notice or otherwise has Knowledge of any pending claim,
order or proceeding with respect to any Intellectual Property used by Valeant
and the Valeant Subsidiaries and to its Knowledge no Intellectual Property
owned or licensed by Valeant or the Valeant Subsidiaries is being used or
enforced in a manner that would reasonably be expected to result in the
abandonment, cancellation or unenforceability of such Intellectual Property.
This Section 4.16(a) constitutes the only representation and warranty of
Valeant with respect to any actual or alleged infringement or other violation
of Intellectual Property of any other Person.

  

  

  

 

 

 

  

 

47  

  

 

 

 

  

  

(b) Valeant and the Valeant Subsidiaries have taken reasonable steps to
protect the confidentiality and value of all trade secrets and any other
confidential information that are owned, used or held by Valeant and the
Valeant Subsidiaries in confidence, including entering into licenses and
Contracts that require employees, licensees, contractors and other Persons
with access to trade secrets or other confidential information to safeguard
and maintain the secrecy and confidentiality of such trade secrets and
confidential information. To the Knowledge of Valeant, such trade secrets and
confidential information have not been used, disclosed to or discovered by any
Person except pursuant to a valid non-disclosure, license or other appropriate
Contract which has not been breached.

  

  

(c) To the Knowledge of Valeant, Valeant and the Valeant Subsidiaries are in
compliance with all applicable Law, as well as their own policies, relating to
privacy, data protection, and the collection and use of personal information
collected, used, or held for use by Valeant or the Valeant Subsidiaries, and
as of the date hereof no claims are pending or threatened in writing against
Valeant or the Valeant Subsidiaries alleging a violation of any Person's
privacy or personal information.

  

  

(d) Except for matters that, individually or in the aggregate, have not had
and would not reasonably be expected to have a Valeant Material Adverse Effect
(it being agreed that for purposes of this Section 4.16(d), effects resulting
from or arising in connection with the matters set forth in clause (iv) of the
definition of the term "Material Adverse Effect" shall not be excluded in
determining whether a Valeant Material Adverse Effect has occurred or would
reasonably be expected to occur) and except as set forth in Section 4.16(d) of
the Valeant Disclosure Letter, to the Knowledge of Valeant, the consummation
of the transactions contemplated by this Agreement will not (i) result in the
loss of, or otherwise adversely affect, any rights of Valeant or the Valeant
Subsidiaries in any Intellectual Property, (ii) grant or require Valeant or
the Valeant Subsidiaries to grant to any Person any rights with respect to any
Intellectual Property of Valeant or the Valeant Subsidiaries, (iii) subject
Valeant or any of the Valeant Subsidiaries to any increase in royalties or
other payments in respect of any Intellectual Property, (iv) by the terms of
any Contract to which Valeant or a Subsidiary of Valeant is a party, diminish
any royalties or other payments Valeant or a Subsidiary of Valeant would
otherwise be entitled to in respect of any Intellectual Property or (v) result
in the breach or, by the terms of such Contract, termination of any agreement
relating to the Intellectual Property of Valeant.

  

  

SECTION 4.17. Regulatory Matters. (a) Except as has not had and would not
reasonably be expected to have, individually or in the aggregate, a Valeant
Material Adverse Effect, (i) each of Valeant and the Valeant Subsidiaries
holds all Valeant Permits, including all authorizations under the FDCA, the
PHSA, and the regulations of the FDA promulgated thereunder, the Food and
Drugs Act, the CDSA and the regulations of Health Canada promulgated
thereunder, and any other Governmental Entity that is concerned with the
quality, identity, strength, purity, safety, efficacy, manufacturing,
distribution, sale, import or export of the Valeant Products (any such
Governmental Entity, a "Valeant Regulatory Agency") necessary for the lawful
operating of the businesses of Valeant or any of the Valeant Subsidiaries and
the testing, manufacturing, sale or distribution, as applicable, of each of
the Valeant Products (the "Valeant Regulatory Permits") and (ii) all such
Valeant Regulatory Permits are valid and in full force and effect. Since
January 1, 2009, there has not occurred any violation of, default (with or
without notice or lapse of time or both) under, or event giving to others any
right of termination, amendment or cancellation of, with or without notice or
lapse of time or both, any Valeant Regulatory Permit, except as has not had
and would not reasonably be expected to have, individually or in the
aggregate, a Valeant Material Adverse Effect. Valeant and each of the Valeant
Subsidiaries are in compliance in all material respects with the terms of all
Valeant Regulatory Permits, and no event has occurred that, to the Knowledge
of Valeant, would reasonably be expected to result in a penalty under or the
revocation, cancellation, non-renewal or adverse modification of any Valeant
Regulatory Permit, except as has not had and would not reasonably be expected
to have, individually or in the aggregate, a Valeant Material Adverse Effect.

  

  

  

 

 

 

  

 

48  

  

 

 

 

  

  

  

(b) Except as would not, individually or in the aggregate, reasonably be
expected to have a Valeant Material Adverse Effect, the businesses of each of
Valeant and the Valeant Subsidiaries are being conducted in compliance with
all applicable Laws, including (i) the FDCA, including the rules and
regulations promulgated thereunder; (ii) federal Medicare and Medicaid
statutes and related state or local statutes or regulations; (iii) the Food
and Drugs Act and the CDSA, including the rules and regulations promulgated
thereunder; (iv) provincial formulary and drug pricing statutes, including the
rules and regulations promulgated thereunder; (v) any comparable foreign Laws
for any of the foregoing; (vi) federal, state or provincial criminal or civil
Laws (including the federal Anti-Kickback Statute (42 U.S.C. 1320a-7(b)),
Stark Law (42 U.S.C. 1395nn), False Claims Act (42 U.S.C. 1320a-7b(a)),
Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. 1320d
et. seq. and any comparable state, provincial or local Laws) and (vii) state
or provincial licensing, disclosure and reporting requirements.

  

  

(c) All pre-clinical and clinical investigations conducted or sponsored by
each of Valeant and the Valeant Subsidiaries are being conducted in compliance
in all material respects with all applicable Laws administered or issued by
the applicable Regulatory Authorities, including (i) FDA standards for
conducting non-clinical laboratory studies contained in Title 21 part 58 of
the Code of Federal Regulations, (ii) FDA standards for the design, conduct,
performance, monitoring, auditing, recording, analysis and reporting of
clinical trials contained in Title 21 parts 50, 54, 56, 312, 314 and 320 of
the Code of Federal Regulations, (iii) Division 5 of the Food and Drug
Regulations regarding Drugs for Clinical Trials Involving Human Subjects, and
(iv) federal, state and provincial Laws restricting the collection, use and
disclosure of individually identifiable health information and personal
information.

  

  

  

 

 

 

  

 

49  

  

 

 

 

  

  

  

(d) Neither Valeant nor any of the Valeant Subsidiaries has received any
written information from the FDA, the EMEA or Health Canada or any foreign
agency with jurisdiction over the marketing, sale, use, handling and control,
safety, efficacy, reliability, or manufacturing of drugs which would
reasonably be expected to lead to the denial of any application for marketing
approval currently pending before the FDA, Health Canada or such other Valeant
Regulatory Agency.

  

  

(e) All material reports, documents, claims, permits and notices required to
be filed, maintained or furnished to the FDA, Health Canada or any other
Valeant Regulatory Agency by Valeant and the Valeant Subsidiaries have been so
filed, maintained or furnished. All such reports, documents, claims, permits
and notices were complete and accurate in all material respects on the date
filed (or were corrected in or supplemented by a subsequent filing) such that
no liability exists with respect to such filing. Neither Valeant nor any of
the Valeant Subsidiaries, nor, to the Knowledge of Valeant, any officer,
employee, agent or distributor of Valeant or any of the Valeant Subsidiaries,
has made an untrue statement of a material fact or a fraudulent statement to
the FDA, Health Canada or any other Valeant Regulatory Agency, failed to
disclose a material fact required to be disclosed to the FDA, Health Canada or
any other Valeant Regulatory Agency, or committed an act, made a statement, or
failed to make a statement that, at the time such disclosure was made, would
reasonably be expected to provide a basis for the FDA, Health Canada or any
other Valeant Regulatory Agency to invoke its policy respecting "Fraud, Untrue
Statements of Material Facts, Bribery, and Illegal Gratuities", set forth in
56 Fed. Reg. 46191 (September 10, 1991) or any similar policy. Neither Valeant
nor any of the Valeant Subsidiaries, nor, to the Knowledge of Valeant, any
officer, employee, agent or distributor of Valeant or any of the Valeant
Subsidiaries, has been convicted of any crime or engaged in any conduct for
which debarment is mandated by 21 U.S.C.  335a(a) or any similar Law or
authorized by 21 U.S.C.  335a(b) or any similar Law. Neither Valeant nor any
of the Valeant Subsidiaries, nor, to the Knowledge of Valeant, any officer,
employee, agent or distributor of Valeant or any of the Valeant Subsidiaries,
has been convicted of any crime or engaged in any conduct for which such
Person could be excluded from participating in the federal health care
programs under Section 1128 of the Social Security Act of 1935, as amended, or
any similar Law or program.

  

  

(f) As to each Valeant Product or Valeant Product candidate subject to the
FDCA and the regulations of the FDA promulgated thereunder, the Food and Drugs
Act, the CDSA and the regulations of Health Canada promulgated thereunder, or
similar Law in any foreign jurisdiction that is or has been developed,
manufactured, tested, distributed or marketed by or on behalf of Valeant or
any of the Valeant Subsidiaries, each such Valeant Product or Valeant Product
candidate is being or has been developed, manufactured, tested, distributed or
marketed in compliance in all material respects with all applicable
requirements under the FDCA and the regulations of the FDA promulgated
thereunder, the Food and Drugs Act, the CDSA and the regulations of Health
Canada promulgated thereunder, and similar Laws in any foreign jurisdiction,
including those relating to investigational use, premarket clearance or
marketing approval, good manufacturing practices, good clinical practices,
good laboratory practices, labeling, advertising, record keeping, filing of
reports, and security. There is no action or proceeding pending or threatened,
including any prosecution, injunction, seizure, civil fine, debarment,
suspension or recall, in each case alleging any violation applicable to any
Valeant Product or Valeant Product candidate by Valeant or any of the Valeant
Subsidiaries of any Law, except as would not, individually or in the
aggregate, reasonably be expected to have a Valeant Material Adverse Effect.

  

  

  

 

 

 

  

 

50  

  

 

 

 

  

  

  

(g) Since January 1, 2009, each of Valeant and the Valeant Subsidiaries have
neither voluntarily nor involuntarily initiated, conducted or issued, or
caused to be initiated, conducted or issued, any recall, field notifications,
field corrections, market withdrawal or replacement, safety alert, warning,
"dear doctor" letter, investigator notice, safety alert or other notice or
action relating to an alleged lack of safety, efficacy or regulatory
compliance of any Valeant Product. Each of Valeant and the Valeant
Subsidiaries are not aware of any facts which are reasonably likely to cause
(i) the recall, market withdrawal or replacement of any Valeant Product sold
or intended to be sold by Valeant or the Valeant Subsidiaries, (ii) a change
in the marketing classification or a material change in the labeling of any
such Valeant Products, or (iii) a termination or suspension of the marketing
of such Valeant Products.

  

  

(h) To Valeant's Knowledge, no data generated by Valeant or any of the Valeant
Subsidiaries with respect to the Valeant Products that has been provided to
its customers or otherwise made public or filed with a Valeant Regulatory
Agency is the subject of any regulatory or other action, either pending or
threatened, by any Valeant Regulatory Agency relating to the truthfulness or
scientific adequacy of such data.

  

  

(i) Since January 1, 2009, neither Valeant nor any of the Valeant Subsidiaries
has received any written notice that the FDA, Health Canada or any other
Valeant Regulatory Agency has (i) commenced, or threatened to initiate, any
action to request the recall of any product sold or intended to be sold by
Valeant or the Valeant Subsidiaries, or (ii) commenced, or threatened to
initiate, any action to enjoin manufacture or distribution of any product sold
or intended to be sold by Valeant or the Valeant Subsidiaries.

  

  

(j) Since January 1, 2009, neither Valeant nor any of the Valeant Subsidiaries
has received any written notice from the FDA, Health Canada or any other
Valeant Regulatory Agency regarding inappropriate advertising or marketing of
a Valeant Product or a negative change in reimbursement status of a Valeant
Product.

  

  

  

 

 

 

  

 

51  

  

 

 

 

  

  

  

(k) Except as would not, individually or in the aggregate, reasonably be
expected to have a Valeant Material Adverse Effect, no Valeant Product
manufactured or distributed by Valeant or any of the Valeant Subsidiaries is
(i) adulterated within the meaning of 21 U.S.C.  351 (or any similar Law),
(ii) misbranded within the meaning of 21 U.S.C.  352 (or any similar Law).

  

  

(l) To the Knowledge of Valeant, all of its vendors are in compliance in all
material respects with good manufacturing practice and similar regulations
promulgated by regulatory agencies with jurisdiction over Valeant's vendors.

  

  

(m) This Section 4.17 does not apply to environmental matters, which are the
subject of Section 4.13.

  

  

SECTION 4.18. Insurance. Since January 1, 2009, Valeant and the Valeant
Subsidiaries have maintained continuous insurance coverage, in each case, in
those amounts and covering those risks as are in accordance, in all material
respects, with normal industry practice for companies of the size and
financial condition of Valeant engaged in businesses similar to those of
Valeant and the Valeant Subsidiaries.

  

  

SECTION 4.19. Labor and Employment Matters. Neither Valeant nor any Valeant
Subsidiary is a party to any collective bargaining agreement and, as of the
date of this Agreement, there are not, to the Knowledge of Valeant, any union
organizing activities concerning any employees of Valeant or any of the
Valeant Subsidiaries, other than any such activities that, individually or in
the aggregate, have not had and would not reasonably be expected to have a
Valeant Material Adverse Effect. As of the date of this Agreement, there are
no labor strikes, slowdowns, work stoppages or lockouts pending or, to the
Knowledge of Valeant, threatened in writing against Valeant or any Valeant
Subsidiary, other than any such matters that, individually or in the
aggregate, have not had and would not reasonably be expected to have a Valeant
Material Adverse Effect.

  

  

SECTION 4.20. Brokers' Fees and Expenses. No broker, investment banker,
financial advisor or other Person, other than Goldman, Sachs and Co. and
Jefferies and Company, Inc. (the "Valeant Financial Advisors"), the fees and
expenses of which will be paid by Valeant, is entitled to any broker's,
finder's, financial advisor's or other similar fee or commission in connection
with the Merger or any of the other transactions contemplated by this
Agreement based upon arrangements made by or on behalf of Valeant. Valeant has
furnished to Biovail true and complete copies of all agreements between
Valeant and any of the Valeant Financial Advisors relating to the Merger or
any of the other transactions contemplated by this Agreement.

  

  

SECTION 4.21. Opinion of Financial Advisor. Valeant has received an opinion
from each of the Valeant Financial Advisors, dated the date of this Agreement,
to the effect that, as of such date, subject to the assumptions and
qualifications set forth therein, the Exchange Ratio, together with the Pre-
Merger Special Dividend, is fair to the holders of Valeant Common Stock (other
than Biovail and its affiliates) from a financial point of view.

  

  

  

 

 

 

  

 

52  

  

 

 

 

  

  

  

SECTION 4.22. Affiliate Transactions. Except for (i) Contracts filed or
incorporated by reference as an exhibit to the Filed Valeant Reporting
Documents, (ii) Valeant Benefits Plans, (iii) indemnification agreements
between Valeant or any Valeant Subisidiary, on the one hand, and, on the other
hand, any current or former executive officer or director of Valeant or any
Valeant Subisidiary, or (iv) Contracts or arrangements entered into in the
ordinary course of business with customers, suppliers or service providers,
Section 4.22 of the Valeant Disclosure Letter sets forth a correct and
complete list of the contracts or arrangements that are in existence as of the
date of this Agreement between Valeant or any of its Subsidiaries, on the one
hand, and, on the other hand, any (x) present executive officer or director of
either Valeant or any of the Valeant Subsidiaries or any person that has
served as such an executive officer or director within the last five years or
any of such officer's or director's immediate family members, (y) record or
beneficial owner of more than 5% of the shares of Valeant Common Stock as of
the date hereof or (z) to the Knowledge of Valeant, any affiliate of any such
officer, director or owner (other than Valeant or any of the Valeant
Subsidiaries).

  

  

SECTION 4.23. No Other Representations or Warranties. Except for the
representations and warranties contained in this Article IV, Biovail
acknowledges that none of Valeant, the Valeant Subsidiaries or any other
Person on behalf of Valeant makes any other express or implied representation
or warranty in connection with the transactions contemplated by this
Agreement.

  

  

  

ARTICLE V

  

  

Covenants Relating to Conduct of Business

  

  

SECTION 5.01. Conduct of Business. (a) Conduct of Business by Biovail. Except
for matters set forth in the Biovail Disclosure Letter or otherwise expressly
permitted or expressly contemplated by this Agreement (including matters with
respect to the Financing) or with the prior written consent of Valeant (which
shall not be unreasonably withheld, conditioned or delayed), from the date of
this Agreement to the Effective Time, Biovail shall, and shall cause each
Biovail Subsidiary to, (i) conduct its business in the ordinary course in all
material respects and (ii) use reasonable best efforts to preserve intact its
business organization and advantageous business relationships and keep
available the services of its current officers and employees. In addition, and
without limiting the generality of the foregoing, except for matters set forth
in the Biovail Disclosure Letter or otherwise expressly permitted or expressly
contemplated by this Agreement (including matters with respect to the
Financing) or with the prior written consent of Valeant (which shall not be
unreasonably withheld, conditioned or delayed), from the date of this
Agreement to the Effective Time, Biovail shall not, and shall not permit any
Biovail Subsidiary to, do any of the following:

  

  

  

 

 

 

  

 

53  

  

 

 

 

  

  

  

(i) (A) declare, set aside or pay any dividends on, or make any other
distributions (whether in cash, stock or property or any combination thereof)
in respect of, any of its capital stock, other equity interests or voting
securities, other than (x) regular quarterly cash dividends payable by Biovail
in respect of shares of Biovail Common Stock not exceeding $0.095 per share of
Biovail Common Stock with usual declaration, record and payment dates and in
accordance with Biovail's current dividend policy and (y) dividends and
distributions by a direct or indirect wholly owned Biovail Subsidiary to its
parent, (B) split, combine, consolidate, subdivide or reclassify any of its
capital stock, other equity interests or voting securities or securities
convertible into or exchangeable or exercisable for capital stock or other
equity interests or voting securities or issue or authorize the issuance of
any other securities in respect of, in lieu of or in substitution for its
capital stock, other equity interests or voting securities, other than as
permitted by Section 5.01(a)(ii), or (C) repurchase, redeem or otherwise
acquire, or offer to repurchase, redeem or otherwise acquire, any capital
stock or voting securities of, or equity interests in, Biovail or any Biovail
Subsidiary or any securities of Biovail or any Biovail Subsidiary convertible
into or exchangeable or exercisable for capital stock or voting securities of,
or equity interests in, Biovail or any Biovail Subsidiary, or any warrants,
calls, options or other rights to acquire any such capital stock, securities
or interests, other than (1) the acquisition by Biovail of shares of Biovail
Common Stock in connection with the surrender of shares of Biovail Common
Stock by holders of Biovail Stock Options in order to pay the exercise price
thereof, (2) the withholding of shares of Biovail Common Stock to satisfy tax
obligations with respect to awards granted pursuant to the Biovail Stock Plans
and (3) the acquisition by Biovail of awards granted pursuant to the Biovail
Stock Plans in connection with the forfeiture of such awards;

  

  

(ii) issue, deliver, sell, grant, pledge or otherwise encumber or subject to
any Lien (A) any shares of capital stock of Biovail or any Biovail Subsidiary,
(B) any other equity interests or voting securities of Biovail or any Biovail
Subsidiary, (C) any securities convertible into or exchangeable or exercisable
for capital stock or voting securities of, or other equity interests in,
Biovail or any Biovail Subsidiary, (D) any warrants, calls, options or other
rights to acquire any capital stock or voting securities of, or other equity
interests in, Biovail or any Biovail Subsidiary, (E) any rights issued by
Biovail or any Biovail Subsidiary that are linked in any way to the price of
any class of Biovail Capital Stock or any shares of capital stock of any
Biovail Subsidiary, the value of Biovail, any Biovail Subsidiary or any part
of Biovail or any Biovail Subsidiary or any dividends or other distributions
declared or paid on any shares of capital stock of Biovail or any Biovail
Subsidiary or (F) any Biovail Voting Debt, in each case other than the
issuance of shares of Biovail Common Stock upon the conversion of the Biovail
Convertible Notes, upon the exercise of Biovail Stock Options or pursuant to
Biovail Restricted Stock Units, in each case outstanding on the date of this
Agreement and in accordance with their terms on the date of this Agreement;

  

  

  

 

 

 

  

 

54  

  

 

 

 

  

  

  

(iii) (A) amend the Biovail Charter or the Biovail By-laws or (B) amend the
charter or organizational documents of any Biovail Subsidiary in a manner
which would be reasonably likely to have a Biovail Material Adverse Effect or
to prevent or materially impede, interfere with, hinder or delay the
consummation by Biovail of the Merger or any of the other transactions
contemplated by this Agreement, except, in the case of each of the foregoing
clauses (A) and (B), as may be required by Law or the rules and regulations of
the SEC, the Canadian Securities Authorities, the NYSE or the TSX;

  

  

(iv) (A) grant to any director or executive officer of Biovail any material
increase in compensation, (B) grant to any director or executive officer of
Biovail any material increase in change in control, severance or termination
pay, (C) establish, adopt, enter into or amend in any material respect any
collective bargaining agreement or material Biovail Benefit Plan or Biovail
Benefit Agreement (or any plan or agreement that would be a Biovail Benefit
Plan or Biovail Benefit Agreement if in existence on the date hereof), (D)
take any action to accelerate the time of vesting or payment of any material
compensation or benefits under any Biovail Benefit Plan or Biovail Benefit
Agreement or (E) except as may be required by GAAP, materially change any
actuarial or other assumptions used to calculate funding obligations with
respect to any Biovail Benefit Plan or materially change the manner in which
contributions to such plans are made or the basis on which such contributions
are determined, except in the case of the foregoing clauses (A) through (E)
for (1) actions required pursuant to the terms of any Biovail Benefit Plan or
Biovail Benefit Agreement or other written agreement, in each case in effect
on the date of this Agreement, and (2) actions required by Law; provided,
however, that the foregoing clauses (A) and (B) shall not restrict Biovail or
any Biovail Subsidiary from entering into or making available to newly hired
employees or to employees in the context of promotions based on job
performance or workplace requirements, in each case in the ordinary course of
business, plans, agreements, benefits and compensation arrangements (including
incentive grants) that have a value that is consistent with the past practice
of making compensation and benefits available to newly hired or promoted
employees in similar positions;

  

  

(v) make any change in financial accounting methods, principles or practices,
except insofar as may have been required by a change in GAAP (after the date
of this Agreement);

  

  

(vi) directly or indirectly (i) acquire or agree to acquire in any transaction
any equity interest in or business of any firm, corporation, partnership,
company, limited liability company, trust, joint venture, association or other
entity or division thereof or any properties or assets or (ii) enter into any
in-licensing agreement or similar agreement or arrangement relating to rights
to any active pharmaceutical ingredient (including any formulation or product
containing such active pharmaceutical ingredient), if the aggregate amount of
the consideration paid or transferred by Biovail and the Biovail Subsidiaries
in connection with all such transactions under the preceding clauses (i) and
(ii) would exceed, individually or in the aggregate, $50,000,000 or (iii) out-
license or otherwise encumber any rights in any material Intellectual Property
owned or used by Biovail in the conduct of its Business;

  

  

  

 

 

 

  

 

55  

  

 

 

 

  

  

  

(vii) sell, lease (as lessor), license, mortgage, sell and leaseback or
otherwise encumber or subject to any Lien, or otherwise dispose of any
properties or assets or any interests therein that, individually or in the
aggregate, have a fair market value in excess of $25,000,000, except in
relation to mortgages, liens and pledges to secure Indebtedness for borrowed
money permitted to be incurred under Section 5.01(a)(viii) and except for
pharmaceutical products in the ordinary course of business;

  

  

(viii) incur any Indebtedness, except for (A) Indebtedness incurred in the
ordinary course of business not to exceed $25,000,000 in the aggregate, (B)
Indebtedness in replacement of existing Indebtedness or (C) guarantees by
Biovail of Indebtedness of any wholly owned Biovail Subsidiary;

  

  

(ix) make, or agree or commit to make, any capital expenditure except in
accordance with the capital plan for 2010 previously made available to
Valeant, plus a 10% variance for any such expenditure;

  

  

(x) enter into or amend any Contract, or take any other action or omit to take
any other action (except in connection with Section 5.02 or Article VIII), if
such Contract, amendment of a Contract or action or omission would reasonably
be expected to prevent or materially impede, interfere with, hinder or delay
the consummation of the Merger or any of the other transactions contemplated
by this Agreement or adversely affect in a material respect the expected
benefits (taken as a whole) of the Merger;

  

  

(xi) enter into or amend any material Contract to the extent consummation of
the Merger or compliance by Biovail or any Biovail Subsidiary with the
provisions of this Agreement would reasonably be expected to conflict with, or
result in a violation of or default (with or without notice or lapse of time,
or both) under, or give rise to a right of termination, cancellation or
acceleration of any obligation, any obligation to make an offer to purchase or
redeem any Indebtedness or capital stock or any loss of a material benefit
under, or result in the creation of any Lien upon any of the material
properties or assets of Biovail or any Biovail Subsidiary under, or require
Biovail, Valeant or any of their respective Subsidiaries to license or
transfer any of its material properties or assets under, or give rise to any
increased, additional, accelerated, or guaranteed right or entitlements of any
third party under, or result in any material alteration of, any provision of
such Contract or amendment;

  

  

  

 

 

 

  

 

56  

  

 

 

 

  

  

(xii) waive, release or assign any material claim of Biovail or any of the
Biovail Subsidiaries;

  

  

(xiii) settle or compromise any claim, action or proceeding, other than
settlements or compromises resulting in the payment of monetary damages not to
exceed $15,000,000 in the aggregate;

  

  

(xiv) (i) make, change or rescind any material method of Tax accounting, (ii)
make a request for a Tax ruling or enter into a closing agreement, or settle
or compromise any material audit, assessment, Tax claim or other controversy
relating to Taxes, (iii) file any material amended Tax Return, (iv) surrender
any material right to claim a refund or offset of any Taxes or (v) change the
classification of Biovail or any Biovail Subsidiary for U.S. tax purposes; or

  

  

(xv) authorize any of, or commit, resolve or agree to take any of, or
participate in any negotiations or discussions with any other Person regarding
any of, the foregoing actions.

  

  

(b) Conduct of Business by Valeant. Except for matters set forth in the
Valeant Disclosure Letter or otherwise expressly permitted or expressly
contemplated by this Agreement (including matters with respect to the
Financing and the Pre-Merger Special Dividend) or with the prior written
consent of Biovail (which shall not be unreasonably withheld, conditioned or
delayed), from the date of this Agreement to the Effective Time, Valeant
shall, and shall cause each Valeant Subsidiary to, (i) conduct its business in
the ordinary course in all material respects and (ii) use reasonable best
efforts to preserve intact its business organization and advantageous business
relationships and keep available the services of its current officers and
employees. In addition, and without limiting the generality of the foregoing,
except for matters set forth in the Valeant Disclosure Letter or otherwise
expressly permitted or expressly contemplated by this Agreement (including
matters with respect to the Financing and the Pre-Merger Special Dividend) or
with the prior written consent of Biovail (which shall not be unreasonably
withheld, conditioned or delayed), from the date of this Agreement to the
Effective Time, Valeant shall not, and shall not permit any Valeant Subsidiary
to, do any of the following:

  

  

(i) (A) declare, set aside or pay any dividends on, or make any other
distributions (whether in cash, stock or property or any combination thereof)
in respect of, any of its capital stock, other equity interests or voting
securities, other than (x) the Pre-Merger Special Dividend in respect of each
share of Valeant Common Stock and (y) dividends and distributions by a direct
or indirect wholly owned Valeant Subsidiary to its parent, (B) split, combine,
consolidate, subdivide or reclassify any of its capital stock, other equity
interests or voting securities or securities convertible into or exchangeable
or exercisable for capital stock or other equity interests or voting
securities or issue or authorize the issuance of any other securities in
respect of, in lieu of or in substitution for its capital stock, other equity
interests or voting securities, other than as permitted by Section
5.01(b)(ii), or (C) repurchase, redeem or otherwise acquire, or offer to
repurchase, redeem or otherwise acquire, any capital stock or voting
securities of, or equity interests in, Valeant or any Valeant Subsidiary or
any securities of Valeant or any Valeant Subsidiary convertible into or
exchangeable or exercisable for capital stock or voting securities of, or
equity interests in, Valeant or any Valeant Subsidiary, or any warrants,
calls, options or other rights to acquire any such capital stock, securities
or interests, other than (1) the acquisition by Valeant of shares of Valeant
Common Stock in connection with the surrender of shares of Valeant Common
Stock by holders of Valeant Stock Options or Valeant Warrants in order to pay
the exercise price thereof, (2) the withholding of shares of Valeant Common
Stock to satisfy tax obligations with respect to awards granted pursuant to
the Valeant Stock Plans, (3) the acquisition by Valeant of awards granted
pursuant to the Valeant Stock Plans in connection with the forfeiture of such
awards, (4) the acquisition, redemption or repurchase or cash settlement by
Valeant or any Valeant Subsidiary of its obligations under any Valeant
Convertible Notes or Valeant Warrants, or (5) any payment made to holders of
Valeant Convertible Notes at the maturity dates thereof;

  

  

  

 

 

 

  

 

57  

  

 

 

 

  

  

  

(ii) issue, deliver, sell, grant, pledge or otherwise encumber or subject to
any Lien (A) any shares of capital stock of Valeant or any Valeant Subsidiary,
(B) any other equity interests or voting securities of Valeant or any Valeant
Subsidiary, (C) any securities convertible into or exchangeable or exercisable
for capital stock or voting securities of, or other equity interests in,
Valeant or any Valeant Subsidiary, (D) any warrants, calls, options or other
rights to acquire any capital stock or voting securities of, or other equity
interests in, Valeant or any Valeant Subsidiary, (E) any rights issued by
Valeant or any Valeant Subsidiary that are linked in any way to the price of
any class of Valeant Capital Stock or any shares of capital stock of any
Valeant Subsidiary, the value of Valeant, any Valeant Subsidiary or any part
of Valeant or any Valeant Subsidiary or any dividends or other distributions
declared or paid on any shares of capital stock of Valeant or any Valeant
Subsidiary or (F) any Valeant Voting Debt, in each case other than the
issuance of shares of Valeant Common Stock upon the acquisition or conversion
of the Valeant Convertible Notes, upon the exercise of Valeant Warrants,
Valeant Stock Options or rights under the Valeant ESPP or pursuant to Valeant
Restricted Stock Units, in each case outstanding on the date of this Agreement
and in accordance with their terms on the date of this Agreement;

  

  

(iii) (A) amend the Valeant Charter or the Valeant By-laws or (B) amend the
charter or organizational documents of any Valeant Subsidiary in a manner
which would be reasonably likely to have a Valeant Material Adverse Effect or
to prevent or materially impede, interfere with, hinder or delay the
consummation by Valeant of the Merger or any of the other transactions
contemplated by this Agreement, except, in the case of each of the foregoing
clauses (A) and (B), as may be required by Law or the rules and regulations of
the SEC or the NYSE;

  

  

 

 

 

  

 

58  

  

 

 

 

  

  

  

(iv) (A) grant to any director or executive officer of Valeant any material
increase in compensation, (B) grant to any director or executive officer of
Valeant any material increase in change in control, severance or termination
pay, (C) establish, adopt, enter into or amend in any material respect any
collective bargaining agreement or material Valeant Benefit Plan or Valeant
Benefit Agreement (or any plan or agreement that would be a Valeant Benefit
Plan or Valeant Benefit Agreement if in existence on the date hereof), (D)
take any action to accelerate the time of vesting or payment of any material
compensation or benefits under any Valeant Benefit Plan or Valeant Benefit
Agreement or (E) except as may be required by GAAP, materially change any
actuarial or other assumptions used to calculate funding obligations with
respect to any Valeant Benefit Plan or materially change the manner in which
contributions to such plans are made or the basis on which such contributions
are determined, except in the case of the foregoing clauses (A) through (E)
for (1) actions required pursuant to the terms of any Valeant Benefit Plan or
Valeant Benefit Agreement or other written agreement, in each case in effect
on the date of this Agreement, and (2) actions required by Law; provided,
however, that the foregoing clauses (A) and (B) shall not restrict Valeant or
any Valeant Subsidiary from entering into or making available to newly hired
employees or to employees in the context of promotions based on job
performance or workplace requirements, in each case in the ordinary course of
business, plans, agreements, benefits and compensation arrangements (including
incentive grants) that have a value that is consistent with the past practice
of making compensation and benefits available to newly hired or promoted
employees in similar positions;

  

  

(v) make any change in financial accounting methods, principles or practices,
except insofar as may have been required by a change in GAAP (after the date
of this Agreement);

  

  

(vi) directly or indirectly (i) acquire or agree to acquire in any transaction
any equity interest in or business of any firm, corporation, partnership,
company, limited liability company, trust, joint venture, association or other
entity or division thereof or any properties or assets or (ii) enter into any
in-licensing agreement or similar agreement or arrangement relating to rights
to any active pharmaceutical ingredient (including any formulation or product
containing such active pharmaceutical ingredient), if the aggregate amount of
the consideration paid or transferred by Valeant and the Valeant Subsidiaries
in connection with all such transactions under the preceding clauses (i) and
(ii) would exceed, individually or in the aggregate, $50,000,000 or (iii) out-
license or otherwise encumber any rights in any material Intellectual Property
owned or used by Valeant in the conduct of its Business;

  

  

  

 

 

 

  

 

59  

  

 

 

 

  

  

(vii) sell, lease (as lessor), license, mortgage, sell and leaseback or
otherwise encumber or subject to any Lien, or otherwise dispose of any
properties or assets or any interests therein that, individually or in the
aggregate, have a fair market value in excess of $25,000,000, except in
relation to mortgages, liens and pledges to secure Indebtedness for borrowed
money permitted to be incurred under Section 5.01(b)(viii) and except for
pharmaceutical products in the ordinary course of business;

  

  

(viii) incur any Indebtedness, except for (A) Indebtedness incurred in the
ordinary course of business not to exceed $25,000,000 in the aggregate, (B)
Indebtedness in replacement of existing Indebtedness or (C) guarantees by
Valeant of Indebtedness of any wholly owned Valeant Subsidiary;

  

  

(ix) make, or agree or commit to make, any capital expenditure except in
accordance with the capital plan for 2010 previously made available to
Biovail, plus a 10% variance for any such expenditure;

  

  

(x) enter into or amend any Contract, or take any other action or omit to take
any other action (except in connection with Section 5.03 or Article VIII), if
such Contract, amendment of a Contract or action or omission would reasonably
be expected to prevent or materially impede, interfere with, hinder or delay
the consummation of the Merger or any of the other transactions contemplated
by this Agreement or adversely affect in a material respect the expected
benefits (taken as a whole) of the Merger;

  

  

(xi) enter into or amend any material Contract to the extent consummation of
the Merger or compliance by Valeant or any Valeant Subsidiary with the
provisions of this Agreement would reasonably be expected to conflict with, or
result in a violation of or default (with or without notice or lapse of time,
or both) under, or give rise to a right of termination, cancellation or
acceleration of any obligation, any obligation to make an offer to purchase or
redeem any Indebtedness or capital stock or any loss of a material benefit
under, or result in the creation of any Lien upon any of the material
properties or assets of Valeant or any Valeant Subsidiary under, or require
Biovail, Valeant or any of their respective Subsidiaries to license or
transfer any of its material properties or assets under, or give rise to any
increased, additional, accelerated, or guaranteed right or entitlements of any
third party under, or result in any material alteration of, any provision of
such Contract or amendment;

  

  

(xii) waive, release or assign any material claim of Valeant or any of the
Valeant Subsidiaries;

  

  

(xiii) settle or compromise any claim, action or proceeding, other than
settlements or compromises resulting in the payment of monetary damages not to
exceed $15,000,000 in the aggregate;

  

  

  

 

 

 

  

 

60  

  

 

 

 

  

  

(xiv) (i) make, change or rescind any material method of Tax accounting, (ii)
make a request for a Tax ruling or enter into a closing agreement, or settle
or compromise any material audit, assessment, Tax claim or other controversy
relating to Taxes, (iii) file any material amended Tax Return, (iv) surrender
any material right to claim a refund or offset of any Taxes or (v) change the
classification of Valeant or any Valeant Subsidiary for U.S. tax purposes; or

  

  

(xv) authorize any of, or commit, resolve or agree to take any of, or
participate in any negotiations or discussions with any other Person regarding
any of, the foregoing actions.

  

  

(c) No Control of Biovail's Business. Valeant acknowledges and agrees that (i)
nothing contained in this Agreement is intended to give Valeant, directly or
indirectly, the right to control or direct the operations of Biovail or any
Biovail Subsidiary prior to the Effective Time, and (ii) prior to the
Effective Time, Biovail shall exercise, consistent with the terms and
conditions of this Agreement, complete control and supervision over its and
the Biovail Subsidiaries' respective operations.

  

  

(d) No Control of Valeant's Business. Biovail acknowledges and agrees that (i)
nothing contained in this Agreement is intended to give Biovail, directly or
indirectly, the right to control or direct the operations of Valeant or any
Valeant Subsidiary prior to the Effective Time, and (ii) prior to the
Effective Time, Valeant shall exercise, consistent with the terms and
conditions of this Agreement, complete control and supervision over its and
the Valeant Subsidiaries' respective operations.

  

  

(e) Advice of Changes. Each of Biovail and Valeant shall promptly advise the
other orally and in writing of any change or event that, individually or in
the aggregate with all past changes and events of which Biovail or Valeant, as
the case may be, has notified the other party under this Section 5.01(e), has
had or would reasonably be expected to have a Biovail Material Adverse Effect
or a Valeant Material Adverse Effect, respectively.

  

  

SECTION 5.02. No Solicitation by Biovail; Biovail Board Recommendation. (a)
Biovail shall not, nor shall it authorize or permit any of its Affiliates or
any of its and their respective directors, officers or employees or any of
their respective investment bankers, accountants, attorneys or other advisors,
agents or representatives (collectively, "Representatives") to, (i) directly
or indirectly solicit, initiate, knowingly encourage, induce or facilitate any
Biovail Takeover Proposal or any inquiry or proposal that may reasonably be
expected to lead to a Biovail Takeover Proposal, (ii) directly or indirectly
participate in any discussions or negotiations with any Person (other than
Biovail's Representatives) regarding, or furnish to any Person any information
with respect to, or cooperate in any way with any Person (whether or not a
Person making a Biovail Takeover Proposal) with respect to any Biovail
Takeover Proposal or any inquiry or proposal that may reasonably be expected
to lead to a Biovail Takeover Proposal or (iii) waive, terminate, modify or
fail to enforce any provision of any confidentiality or "standstill" or
similar obligation of any Person (other than the other party hereto) with
respect to Biovail or any Biovail Subsidiary. Biovail (A) shall, and shall
cause its Affiliates and its and their respective Representatives to,
immediately cease and cause to be terminated all existing discussions or
negotiations with any Person conducted heretofore with respect to any Biovail
Takeover Proposal, or any inquiry or proposal that may reasonably be expected
to lead to a Biovail Takeover Proposal, request the prompt return or
destruction of all confidential information previously furnished and
immediately terminate all physical and electronic dataroom access previously
granted to any such Person or its Representatives and (B) shall immediately
take all steps necessary to terminate any approval under any confidentiality
or "standstill" or similar provision that may have been heretofore given by it
or any Biovail Subsidiary under any such provisions authorizing any Person to
make a Takeover Proposal. Notwithstanding the foregoing, at any time prior to
obtaining the Biovail Stockholder Approval, in response to a bona fide written
Biovail Takeover Proposal that the Biovail Board determines in good faith
(after consultation with outside counsel and a financial advisor of nationally
recognized reputation) constitutes or is reasonably likely to lead to a
Superior Biovail Proposal, and which Biovail Takeover Proposal was not
solicited by Biovail, its Affiliates or Representatives after the date of this
Agreement and was made after the date of this Agreement and did not otherwise
result from a breach of this Section 5.02(a), Biovail, and its Representatives
at the request of Biovail, may, subject to compliance with Section 5.02(c),
(A) furnish information with respect to Biovail and the Biovail Subsidiaries
to the Person making such Biovail Takeover Proposal (and its Representatives)
(provided that all such information has previously been provided to Valeant or
is provided to Valeant prior to or substantially concurrent with the time it
is provided to such Person) pursuant to a customary confidentiality agreement
not less restrictive of such Person than the Confidentiality Agreement (other
than with respect to standstill provisions), and (B) participate in
discussions regarding the terms of such Biovail Takeover Proposal and the
negotiation of such terms with, and only with, the Person making such Biovail
Takeover Proposal (and such Person's Representatives). Without limiting the
foregoing, it is agreed that any violation of the restrictions set forth in
this Section 5.02(a) by any Representative of Biovail or any of its Affiliates
shall constitute a breach of this Section 5.02(a) by Biovail.

  

  

  

 

 

 

  

 

61  

  

 

 

 

  

  

  

(b) Except as set forth below, neither the Biovail Board nor any committee
thereof shall (i) (A) withdraw (or modify in any manner adverse to Valeant),
or propose publicly to withdraw (or modify in any manner adverse to Valeant),
the approval, recommendation or declaration of advisability by the Biovail
Board or any such committee thereof with respect to this Agreement or (B)
approve, recommend or declare advisable, or propose publicly to approve,
recommend or declare advisable, any Biovail Takeover Proposal (any action in
this clause (i) being referred to as a "Biovail Adverse Recommendation
Change") or (ii) approve, recommend or declare advisable, or propose publicly
to approve, recommend or declare advisable, or allow Biovail or any of its
Affiliates to execute or enter into, any letter of intent, memorandum of
understanding, agreement in principle, merger agreement, acquisition
agreement, option agreement, joint venture agreement, alliance agreement,
partnership agreement or other agreement or arrangement (other than a
confidentiality agreement referred to in Section 5.02(a)) (an "Acquisition
Agreement") constituting or related to, or that is intended to or would
reasonably be expected to lead to, any Biovail Takeover Proposal, or
requiring, or reasonably expected to cause, Biovail, BAC or Merger Sub to
abandon, terminate, delay or fail to consummate, or that would otherwise
impede, interfere with or be inconsistent with, the Merger or any of the other
transactions contemplated by this Agreement, or requiring, or reasonably
expected to cause, Biovail to fail to comply with this Agreement.
Notwithstanding the foregoing, at any time prior to obtaining the Biovail
Stockholder Approval, the Biovail Board may make a Biovail Adverse
Recommendation Change (A) following receipt of a Biovail Takeover Proposal
after the execution of this Agreement that did not result from a breach of
Section 5.02(a) and that the Biovail Board or an authorized and empowered
committee thereof determines in good faith, after consultation with its
outside financial and legal advisors, constitutes a Superior Biovail Proposal
or (B) solely in response to any material event, development, circumstance,
occurrence or change in circumstances or facts (including any material change
in probability or magnitude of circumstances), not related to a Biovail
Takeover Proposal, and that first occurred following the execution of this
Agreement (a "Biovail Intervening Event"); in each case referred to in the
foregoing clauses (A) and (B), only if the Biovail Board determines in good
faith (after consultation with outside counsel and a financial advisor of
nationally recognized reputation) that the failure to do so would be
inconsistent with its fiduciary duties under applicable Law; provided,
however, that Biovail shall not be entitled to exercise its right to make a
Biovail Adverse Recommendation Change until after the fifth business day
following Valeant's receipt of written notice (a "Biovail Notice of
Recommendation Change") from Biovail advising Valeant that the Biovail Board
intends to make a Biovail Notice of Recommendation Change and specifying the
reasons therefor, including in the case of a Superior Biovail Proposal the
terms and conditions of any Superior Biovail Proposal that is the basis of the
proposed action by the Biovail Board (it being understood and agreed that any
amendment to any material term of such Superior Biovail Proposal shall require
a new Biovail Notice of Recommendation Change and a new five business-day
period). In determining whether to make a Biovail Adverse Recommendation
Change, the Biovail Board shall take into account any changes to the terms of
this Agreement proposed by Valeant in response to a Biovail Notice of
Recommendation Change or otherwise, and if requested by Valeant, Biovail shall
engage in good faith negotiations with Valeant regarding any changes to the
terms of this Agreement proposed by Valeant.

  

  

  

 

 

 

  

 

62  

  

 

 

 

  

  

(c) In addition to the obligations of Biovail set forth in paragraphs (a) and
(b) of this Section 5.02, Biovail shall promptly advise (and in any event
within 24 hours) Valeant orally and in writing of any Biovail Takeover
Proposal, the material terms and conditions of any such Biovail Takeover
Proposal (including any changes thereto) and the identity of the person making
any such Biovail Takeover Proposal. Biovail shall (i) keep Valeant informed in
all material respects on a reasonably current basis of the status and details
(including any change to the terms thereof) of any Biovail Takeover Proposal
and (ii) provide to Valeant as soon as practicable after receipt or delivery
thereof copies of all correspondence and other written material exchanged
between Biovail or any of its Subsidiaries, on the one hand, and the Person
making any such Biovail Takeover Proposal, on the other hand, that describes
any of the terms or conditions of any Biovail Takeover Proposal.
Notwithstanding anything to the contrary contained in this Agreement, neither
the Biovail Board nor any committee thereof shall be entitled to make a
Biovail Adverse Recommendation Change pursuant to Section 5.02(b) with respect
to a Biovail Intervening Event, unless Biovail has provided Valeant with
written information describing such Biovail Intervening Event in reasonable
detail promptly after becoming aware of it, and keeps Valeant reasonably
informed of material developments with respect to such Biovail Intervening
Event.

  

  

  

 

 

 

  

 

63  

  

 

 

 

  

  

  

(d) Nothing contained in this Section 5.02 shall prohibit Biovail from (i)
complying with Rule 14d-9 and Rule 14e-2 promulgated under the Exchange Act or
(ii) making any disclosure to the stockholders of Biovail if, in the good
faith judgment of the Biovail Board (after consultation with outside counsel)
failure to so disclose would be inconsistent with its obligations under
applicable Law; provided, however, that in no event shall Biovail or the
Biovail Board or any committee thereof take, or agree or resolve to take, any
action prohibited by Section 5.02(b).

  

  

(e) For purposes of this Agreement:

  

  

"Biovail Takeover Proposal" means any proposal or offer (whether or not in
writing), with respect to any (i) merger, amalgamation, arrangement,
consolidation, share exchange, other business combination or similar
transaction involving Biovail or any Biovail Subsidiary, (ii) sale, lease,
contribution or other disposition, directly or indirectly (including by way of
merger, consolidation, share exchange, other business combination,
partnership, joint venture, sale of capital stock of or other equity interests
in a Biovail Subsidiary or otherwise) of any business or assets of Biovail or
the Biovail Subsidiaries representing 20% or more of the consolidated
revenues, net income or assets of Biovail and the Biovail Subsidiaries, taken
as a whole, (iii) issuance, sale or other disposition, directly or indirectly,
to any Person (or the stockholders of any Person) or group of securities (or
options, rights or warrants to purchase, or securities convertible into or
exchangeable for, such securities) representing 20% or more of the voting
power of Biovail, (iv) transaction in which any Person (or the stockholders of
any Person) shall acquire, directly or indirectly, beneficial ownership, or
the right to acquire beneficial ownership, or formation of any group which
beneficially owns or has the right to acquire beneficial ownership of, 20% or
more of the Biovail Common Stock or (v) any combination of the foregoing (in
each case, other than the Merger).

  

  

"Superior Biovail Proposal" means a binding bona fide written Biovail Takeover
Proposal (with all references to "20% or more" in the definition of Biovail
Takeover Proposal being deemed to reference "more than 50%") (i) on terms
which the Biovail Board determines in good faith (after consultation with
outside counsel and a financial advisor of nationally recognized reputation)
to be superior from a financial point of view to the holders of Biovail Common
Stock than the Merger, taking into account all the terms and conditions of
such proposal (including the legal, financial, regulatory, timing and other
aspects of the proposal and the identity of the Person making the proposal)
and this Agreement (including any changes proposed by Valeant to the terms of
this Agreement) and (ii) that is fully financed or reasonably capable of being
fully financed, reasonably likely to receive all required governmental
approvals on a timely basis and otherwise reasonably capable of being
completed on the terms proposed.

  

  

  

 

 

 

  

 

64  

  

 

 

 

  

  

  

SECTION 5.03. No Solicitation by Valeant; Valeant Board Recommendation. (a)
Valeant shall not, nor shall it authorize or permit any of its Affiliates or
any of its and their respective Representatives to, (i) directly or indirectly
solicit, initiate, knowingly encourage, induce or facilitate any Valeant
Takeover Proposal or any inquiry or proposal that may reasonably be expected
to lead to a Valeant Takeover Proposal, (ii) directly or indirectly
participate in any discussions or negotiations with any Person (other than
Valeant's Representatives) regarding, or furnish to any Person any information
with respect to, or cooperate in any way with any Person (whether or not a
Person making a Valeant Takeover Proposal) with respect to any Valeant
Takeover Proposal or any inquiry or proposal that may reasonably be expected
to lead to a Valeant Takeover Proposal or (iii) waive, terminate, modify or
fail to enforce any provision of any confidentiality or "standstill" or
similar obligation of any Person (other than the other party hereto) with
respect to Valeant or any Valeant Subsidiary. Valeant (A) shall, and shall
cause its Affiliates and its and their respective Representatives to,
immediately cease and cause to be terminated all existing discussions or
negotiations with any Person conducted heretofore with respect to any Valeant
Takeover Proposal, or any inquiry or proposal that may reasonably be expected
to lead to a Valeant Takeover Proposal, request the prompt return or
destruction of all confidential information previously furnished and
immediately terminate all physical and electronic dataroom access previously
granted to any such Person or its Representatives and (B) shall immediately
take all steps necessary to terminate any approval under any confidentiality
or "standstill" or similar provision that may have been heretofore given by it
or any Valeant Subsidiary under any such provisions authorizing any Person to
make a Takeover Proposal. Notwithstanding the foregoing, at any time prior to
obtaining the Valeant Stockholder Approval, in response to a bona fide written
Valeant Takeover Proposal that the Valeant Board determines in good faith
(after consultation with outside counsel and a financial advisor of nationally
recognized reputation) constitutes or is reasonably likely to lead to a
Superior Valeant Proposal, and which Valeant Takeover Proposal was not
solicited by Valeant, its Affiliates or Representatives after the date of this
Agreement and was made after the date of this Agreement and did not otherwise
result from a breach of this Section 5.03(a), Valeant, and its Representatives
at the request of Valeant, may, subject to compliance with Section 5.03(c),
(A) furnish information with respect to Valeant and the Valeant Subsidiaries
to the Person making such Valeant Takeover Proposal (and its Representatives)
(provided that all such information has previously been provided to Valeant or
is provided to Valeant prior to or substantially concurrent with the time it
is provided to such Person) pursuant to a customary confidentiality agreement
not less restrictive of such Person than the Confidentiality Agreement (other
than with respect to standstill provisions), and (B) participate in
discussions regarding the terms of such Valeant Takeover Proposal and the
negotiation of such terms with, and only with, the Person making such Valeant
Takeover Proposal (and such Person's Representatives). Without limiting the
foregoing, it is agreed that any violation of the restrictions set forth in
this Section 5.03(a) by any Representative of Valeant or any of its Affiliates
shall constitute a breach of this Section 5.03(a) by Valeant.

  

  

  

 

 

 

  

 

65  

  

 

 

 

  

  

  

(b) Except as set forth below, neither the Valeant Board nor any committee
thereof shall (i) (A) withdraw (or modify in any manner adverse to Biovail),
or propose publicly to withdraw (or modify in any manner adverse to Biovail),
the approval, recommendation or declaration of advisability by the Valeant
Board or any such committee thereof with respect to this Agreement or (B)
approve, recommend or declare advisable, or propose publicly to approve,
recommend or declare advisable, any Valeant Takeover Proposal (any action in
this clause (i) being referred to as a "Valeant Adverse Recommendation
Change") or (ii) approve, recommend or declare advisable, or propose publicly
to approve, recommend or declare advisable, or allow Valeant or any of its
Affiliates to execute or enter into, any Acquisition Agreement constituting or
related to, or that is intended to or would reasonably be expected to lead to,
any Valeant Takeover Proposal, or requiring, or reasonably expected to cause,
Valeant to abandon, terminate, delay or fail to consummate, or that would
otherwise impede, interfere with or be inconsistent with, the Merger or any of
the other transactions contemplated by this Agreement, or requiring, or
reasonably expected to cause, Valeant to fail to comply with this Agreement.
Notwithstanding the foregoing, at any time prior to obtaining the Valeant
Stockholder Approval, the Valeant Board may make a Valeant Adverse
Recommendation Change (A) following receipt of a Valeant Takeover Proposal
after the execution of this Agreement that did not result from a breach of
Section 5.03(a) and that the Valeant Board or an authorized and empowered
committee thereof determines in good faith, after consultation with its
outside financial and legal advisors, constitutes a Superior Valeant Proposal
or (B) solely in response to any material event, development, circumstance,
occurrence or change in circumstances or facts (including any material change
in probability or magnitude of circumstances), not related to a Valeant
Takeover Proposal, and that first occurred following the execution of this
Agreement (a "Valeant Intervening Event"); in each case referred to in the
foregoing clauses (A) and (B), only if the Valeant Board determines in good
faith (after consultation with outside counsel and a financial advisor of
nationally recognized reputation) that the failure to do so would be
inconsistent with its fiduciary duties under applicable Law; provided,
however, that Valeant shall not be entitled to exercise its right to make a
Valeant Adverse Recommendation Change until after the fifth business day
following Biovail's receipt of written notice (a "Valeant Notice of
Recommendation Change") from Valeant advising Biovail that the Valeant Board
intends to make a Valeant Notice of Recommendation Change and specifying the
reasons therefor, including in the case of a Superior Valeant Proposal the
terms and conditions of any Superior Valeant Proposal that is the basis of the
proposed action by the Valeant Board (it being understood and agreed that any
amendment to any material term of such Superior Valeant Proposal shall require
a new Valeant Notice of Recommendation Change and a new five business-day
period). In determining whether to make a Valeant Adverse Recommendation
Change, the Valeant Board shall take into account any changes to the terms of
this Agreement proposed by Biovail in response to a Valeant Notice of
Recommendation Change or otherwise, and if requested by Biovail, Valeant shall
engage in good faith negotiations with Biovail regarding any changes to the
terms of this Agreement proposed by Biovail.

  

  

  

 

 

 

  

 

66  

  

 

 

 

  

  

  

(c) In addition to the obligations of Valeant set forth in paragraphs (a) and
(b) of this Section 5.03, Valeant shall promptly advise (and in any event
within 24 hours) Biovail orally and in writing of any Valeant Takeover
Proposal, the material terms and conditions of any such Valeant Takeover
Proposal (including any changes thereto) and the identity of the person making
any such Valeant Takeover Proposal. Valeant shall (i) keep Biovail informed in
all material respects on a reasonably current basis of the status and details
(including any change to the terms thereof) of any Valeant Takeover Proposal,
and (ii) provide to Biovail as soon as practicable after receipt or delivery
thereof copies of all correspondence and other written material exchanged
between Valeant or any of its Subsidiaries, on the one hand, and the Person
making any such Valeant Takeover Proposal, on the other hand, that describes
any of the terms or conditions of any Valeant Takeover Proposal.
Notwithstanding anything to the contrary contained in this Agreement, neither
the Valeant Board nor any committee thereof shall be entitled to make a
Valeant Adverse Recommendation Change pursuant to Section 5.03(b) with respect
to a Valeant Intervening Event, unless Valeant has provided Biovail with
written information describing such Valeant Intervening Event in reasonable
detail promptly after becoming aware of it, and keeps Biovail reasonably
informed of material developments with respect to such Valeant Intervening
Event.

  

  

(d) Nothing contained in this Section 5.03 shall prohibit Valeant from (i)
complying with Rule 14d-9 and Rule 14e-2 promulgated under the Exchange Act,
or (iii) making any disclosure to the stockholders of Valeant if, in the good
faith judgment of the Valeant Board (after consultation with outside counsel)
failure to so disclose would be inconsistent with its obligations under
applicable Law; provided, however, that in no event shall Valeant or the
Valeant Board or any committee thereof take, or agree or resolve to take, any
action prohibited by Section 5.03(b).

  

  

(e) For purposes of this Agreement:

  

  

"Valeant Takeover Proposal" means any proposal or offer (whether or not in
writing), with respect to any (i) merger, amalgamation, arrangement,
consolidation, share exchange, other business combination or similar
transaction involving Valeant or any Valeant Subsidiary, (ii) sale, lease,
contribution or other disposition, directly or indirectly (including by way of
merger, consolidation, share exchange, other business combination,
partnership, joint venture, sale of capital stock of or other equity interests
in a Valeant Subsidiary or otherwise) of any business or assets of Valeant or
the Valeant Subsidiaries representing 20% or more of the consolidated
revenues, net income or assets of Valeant and the Valeant Subsidiaries, taken
as a whole, (iii) issuance, sale or other disposition, directly or indirectly,
to any Person (or the stockholders of any Person) or group of securities (or
options, rights or warrants to purchase, or securities convertible into or
exchangeable for, such securities) representing 20% or more of the voting
power of Valeant, (iv) transaction in which any Person (or the stockholders of
any Person) shall acquire, directly or indirectly, beneficial ownership, or
the right to acquire beneficial ownership, or formation of any group which
beneficially owns or has the right to acquire beneficial ownership of, 20% or
more of the Valeant Common Stock or (v) any combination of the foregoing (in
each case, other than the Merger).

  

  

  

 

 

 

  

 

67  

  

 

 

 

  

  

  

"Superior Valeant Proposal" means a binding bona fide written Valeant Takeover
Proposal (with all references to "20% or more" in the definition of Valeant
Takeover Proposal being deemed to reference "more than 50%") (i) on terms
which the Valeant Board determines in good faith (after consultation with
outside counsel and a financial advisor of nationally recognized reputation)
to be superior from a financial point of view to the holders of Valeant Common
Stock than the Merger, taking into account all the terms and conditions of
such proposal (including the legal, financial, regulatory, timing and other
aspects of the proposal and the identity of the Person making the proposal)
and this Agreement (including any changes proposed by Biovail to the terms of
this Agreement), and (ii) that is fully financed or reasonably capable of
being fully financed, reasonably likely to receive all required governmental
approvals on a timely basis and otherwise reasonably capable of being
completed on the terms proposed.

  

  

  

ARTICLE VI

  

  

Additional Agreements

  

  

SECTION 6.01. Preparation of the Form S-4 and the Joint Proxy Statement;
Stockholders Meetings. (a) As promptly as practicable following the date of
this Agreement, Biovail and Valeant shall jointly prepare and cause to be
filed with the SEC and pursuant to Canadian Securities Laws a joint proxy
statement to be sent to the stockholders of each of Biovail and Valeant
relating to the Biovail Stockholders Meeting and the Valeant Stockholders
Meeting (together with any amendments or supplements thereto, the "Joint Proxy
Statement") and Biovail shall prepare and cause to be filed with the SEC the
Form S-4, in which the Joint Proxy Statement will be included as a prospectus,
and Biovail and Valeant shall use their respective reasonable best efforts to
have the Form S-4 declared effective under the Securities Act as promptly as
practicable after such filing. Each of Valeant and Biovail shall furnish all
information concerning such Person and its Affiliates to the other, and
provide such other assistance, as may be reasonably requested in connection
with the preparation, filing and distribution of the Form S-4 and Joint Proxy
Statement, and the Form S-4 and Joint Proxy Statement shall include all
information reasonably requested by such other party to be included therein.
Each of Valeant and Biovail shall promptly notify the other upon the receipt
of any comments from the SEC or the Canadian Securities Authorities or any
request from the SEC or the Canadian Securities Authorities for amendments or
supplements to the Form S-4 or Joint Proxy Statement and shall provide the
other with copies of all correspondence between it and its Representatives, on
the one hand, and the SEC or the Canadian Securities Authorities, on the other
hand. Each of Valeant and Biovail shall use its reasonable best efforts to
respond as promptly as practicable to any comments from the SEC or the
Canadian Securities Authorities with respect to the Form S-4 or Joint Proxy
Statement. Notwithstanding the foregoing, prior to filing the Form S-4 (or any
amendment or supplement thereto) or mailing the Joint Proxy Statement (or any
amendment or supplement thereto) or responding to any comments of the SEC or
the Canadian Securities Authorities with respect thereto, each of Valeant and
Biovail (i) shall provide the other an opportunity to review and comment on
such document or response (including the proposed final version of such
document or response), (ii) shall consider in good faith all comments
reasonably proposed by the other and (iii) shall not file or mail such
document or respond to the SEC or the Canadian Securities Authorities prior to
receiving the approval of the other, which approval shall not be unreasonably
withheld, conditioned or delayed. Each of Valeant and Biovail shall advise the
other, promptly after receipt of notice thereof, of the time of effectiveness
of the Form S-4, the issuance of any stop order relating thereto or the
suspension of the qualification of the Merger Consideration for offering or
sale in any jurisdiction, and each of Valeant and Biovail shall use its
reasonable best efforts to have any such stop order or suspension lifted,
reversed or otherwise terminated. Each of Valeant and Biovail shall also take
any other action (other than qualifying to do business in any jurisdiction in
which it is not now so qualified) required to be taken under the Securities
Act, the Exchange Act, any applicable foreign or state securities or "blue
sky" laws and the rules and regulations thereunder in connection with the
Merger and the issuance of the Merger Consideration.

  

  

  

 

 

 

  

 

68  

  

 

 

 

  

  

  

(b) If prior to the Effective Time, any event occurs with respect to Biovail
or any Biovail Subsidiary, or any change occurs with respect to other
information supplied by Biovail for inclusion in the Joint Proxy Statement or
the Form S-4, which is required to be described in an amendment of, or a
supplement to, the Joint Proxy Statement or the Form S-4, Biovail shall
promptly notify Valeant of such event, and Biovail and Valeant shall cooperate
in the prompt filing with the SEC and the Canadian Securities Authorities of
any necessary amendment or supplement to the Joint Proxy Statement or the Form
S-4 and, as required by Law, in disseminating the information contained in
such amendment or supplement to Biovail's stockholders and Valeant's
stockholders. Nothing in this Section 6.01(b) shall limit the obligations of
any party under Section 6.01(a).

  

  

  

 

 

 

  

 

69  

  

 

 

 

  

  

  

(c) If prior to the Effective Time, any event occurs with respect to Valeant
or any Valeant Subsidiary, or any change occurs with respect to other
information supplied by Valeant for inclusion in the Joint Proxy Statement or
the Form S-4, which is required to be described in an amendment of, or a
supplement to, the Joint Proxy Statement or the Form S-4, Valeant shall
promptly notify Biovail of such event, and Valeant and Biovail shall cooperate
in the prompt filing with the SEC and the Canadian Securities Authorities of
any necessary amendment or supplement to the Joint Proxy Statement or the Form
S-4 and, as required by Law, in disseminating the information contained in
such amendment or supplement to Biovail's stockholders and Valeant's
stockholders. Nothing in this Section 6.01(c) shall limit the obligations of
any party under Section 6.01(a).

  

  

(d) Biovail shall, as soon as practicable following the date of this
Agreement, duly call, give notice of, convene and hold the Biovail
Stockholders Meeting for the sole purpose of seeking the Biovail Stockholder
Approval. Biovail shall use its reasonable best efforts to (i) cause the Joint
Proxy Statement to be mailed to Biovail's stockholders and to hold the Biovail
Stockholders Meeting as soon as practicable after the Form S-4 is declared
effective under the Securities Act, in each case in accordance with applicable
Law, the Biovail Charter and the Biovail Bylaws and (ii) solicit the Biovail
Stockholder Approval. Biovail shall, through the Biovail Board, recommend to
its stockholders that they give the Biovail Stockholder Approval and shall
include such recommendation in the Joint Proxy Statement, except to the extent
that the Biovail Board shall have made a Biovail Adverse Recommendation Change
as permitted by Section 5.02(b). Except as expressly contemplated by the
foregoing sentence, Biovail agrees that its obligations pursuant to this
Section 6.01 shall not be affected by the commencement, public proposal,
public disclosure or communication to Biovail of any Biovail Takeover
Proposal, the occurrence of a Biovail Intervening Event or by the making of
any Biovail Adverse Recommendation Change by the Biovail Board; provided,
however, that if the public announcement of a Biovail Adverse Recommendation
Change or the delivery of a Biovail Notice of Recommendation Change is less
than ten Business Days prior to the Biovail Stockholders Meeting, Biovail
shall be entitled to postpone the Biovail Stockholders Meeting to a date not
more than ten Business Days after such event.

  

  

(e) Valeant shall, as soon as practicable following the date of this
Agreement, duly call, give notice of, convene and hold the Valeant
Stockholders Meeting for the sole purpose of seeking the Valeant Stockholder
Approval. Valeant shall use its reasonable best efforts to (i) cause the Joint
Proxy Statement to be mailed to Valeant's stockholders and to hold the Valeant
Stockholders Meeting as soon as practicable after the Form S-4 is declared
effective under the Securities Act, in each case in accordance with applicable
Law, the Valeant Charter and the Valeant Bylaws, and (ii) solicit the Valeant
Stockholder Approval. Valeant shall, through the Valeant Board, recommend to
its stockholders that they give the Valeant Stockholder Approval and shall
include such recommendation in the Joint Proxy Statement, except to the extent
that the Valeant Board shall have made a Valeant Adverse Recommendation Change
as permitted by Section 5.03(b). Except as expressly contemplated by the
foregoing sentence, Valeant agrees that its obligations pursuant to this
Section 6.01 shall not be affected by the commencement, public proposal,
public disclosure or communication to Valeant of any Valeant Takeover
Proposal, the occurrence of a Valeant Intervening Event or by the making of
any Valeant Adverse Recommendation Change by the Valeant Board; provided,
however, that if the public announcement of a Valeant Adverse Recommendation
Change or the delivery of a Valeant Notice of Recommendation Change is less
than ten Business Days prior to the Valeant Stockholders Meeting, Valeant
shall be entitled to postpone the Valeant Stockholders Meeting to a date not
more than ten Business Days after such event.

  

  

  

 

 

 

  

 

70  

  

 

 

 

  

  

  

(f) Each of Valeant and Biovail shall use commercially reasonable efforts to
hold the Valeant Stockholders Meeting and the Biovail Stockholders Meeting,
respectively, at the same time and on the same date as the other party.

  

  

(g) Biovail shall take all action to ensure that all Biovail Common Stock
constituting the Merger Consideration and all Biovail Common Stock issued upon
the conversion of Valeant Convertible Notes, the exercise of Valeant Warrants
or Valeant Stock Options or the vesting of Valeant Restricted Stock Units, in
each case, issued or distributed to Canadian residents, will be free from
restriction on the first trade of such Biovail Common Stock by such resident.

  

  

SECTION 6.02. Access to Information; Confidentiality. Subject to applicable
Law, each of Biovail and Valeant shall, and shall cause each of its respective
Subsidiaries to, afford to the other party and to the Representatives of such
other party reasonable access, upon reasonable advance notice, during the
period from the date of this Agreement to the earlier of the Effective Time or
termination of this Agreement pursuant to Section 8.01, to all their
respective properties, books, contracts, commitments, personnel and records
and, during such period, each of Biovail and Valeant shall, and shall cause
each of its respective Subsidiaries to, make available promptly to the other
party (a) to the extent not publicly available, a copy of each report,
schedule, registration statement and other document filed by it during such
period pursuant to the requirements of securities laws and (b) all other
information concerning its business, properties and personnel as such other
party may reasonably request; provided, however, that either party may
withhold any document or information that is subject to the terms of a
confidentiality agreement with a third party (provided that the withholding
party shall use its reasonable best efforts to obtain the required consent of
such third party to such access or disclosure) or subject to any attorney-
client privilege (provided that the withholding party shall use its reasonable
best efforts to allow for such access or disclosure (or as much of it as
possible) in a manner that does not result in a loss of attorney-client
privilege). If any material is withheld by such party pursuant to the proviso
to the preceding sentence, such party shall inform the other party as to the
general nature of what is being withheld. Without limiting the generality of
the foregoing, each of Valeant and Biovail shall, within two Business Days of
request by the other party therefor, provide to such other party the
information described in Rule 14a-7(a)(2)(ii) under the Exchange Act and any
information to which a holder of Valeant Common Stock would be entitled under
Section 220 of the DGCL (assuming such holder met the requirements of such
section). All information exchanged pursuant to this Section 6.02 shall be
subject to the confidentiality agreement dated September 28, 2009, as amended
on February 18, 2010, between Biovail and Valeant Pharmaceuticals North
America (the "Confidentiality Agreement").

  

  

  

 

 

 

  

 

71  

  

 

 

 

  

  

  

SECTION 6.03. Required Actions. (a) Subject to the terms and conditions of
this Agreement, each of the parties shall use their respective reasonable best
efforts to take, or cause to be taken, all actions, and do, or cause to be
done, and assist and cooperate with the other parties in doing, all things
reasonably appropriate to consummate and make effective, as soon as reasonably
possible, the Merger and the other transactions contemplated by this
Agreement.

  

  

(b) In connection with and without limiting Section 6.03(a), Valeant and the
Valeant Board and Biovail and the Biovail Board, as the case may be, shall use
their respective reasonable best efforts to (x) take all action reasonably
appropriate to ensure that no takeover statute or similar statute or
regulation is or becomes applicable to this Agreement or any transaction
contemplated by this Agreement and (y) if any takeover statute or similar
statute or regulation becomes applicable to this Agreement or any transaction
contemplated by this Agreement, take all action reasonably appropriate to
ensure that the Merger and the other transactions contemplated by this
Agreement may be consummated as promptly as practicable on the terms
contemplated by this Agreement.

  

  

(c) In connection with and without limiting Section 6.03(a), promptly
following the execution and delivery by the parties of this Agreement, Valeant
and Biovail shall use their respective reasonable best efforts to enter into
discussions with the Governmental Entities from whom Consents or nonactions
are required to be obtained in connection with the consummation of the Merger
and the other transactions contemplated by this Agreement in order to obtain
all such required Consents or nonactions from such Governmental Entities, in
each case with respect to the Merger, so as to enable the Closing to occur as
soon as reasonably possible. To the extent necessary in order to accomplish
the foregoing and subject to the limitations set forth in Section 6.03(e),
Valeant and Biovail shall use their respective reasonable best efforts to
jointly propose, negotiate, commit to and effect, by consent decree, hold
separate order or otherwise, the sale, divestiture or disposition of, or
prohibition or limitation on the ownership or operation by Valeant, Biovail or
any of their respective Subsidiaries of, any portion of the business,
properties or assets of Valeant, Biovail or any of their respective
Subsidiaries; provided, however, that neither Biovail nor Valeant shall be
required pursuant to this Section 6.03(c) to propose, commit to or effect any
action that is not conditioned upon the consummation of the Merger or that
would reasonably be expected (after giving effect to any reasonably expected
proceeds of any divestiture or sale of assets) to have a Combined Company
Material Adverse Effect.

  

  

  

 

 

 

  

 

72  

  

 

 

 

  

  

  

(d) In connection with and without limiting the generality of the foregoing,
each of Biovail and Valeant shall:

  

  

(i) make or cause to be made, in consultation and cooperation with the other
and as promptly as practicable after the date of this Agreement, (A) an
appropriate filing of a Notification and Report Form pursuant to the HSR Act
relating to the Merger, (B) if required, a notification pursuant to Section
114(1) of the Competition Act and an application for an advance ruling
certificate pursuant to Section 102 of the Competition Act relating to the
Merger and (C) all other necessary registrations, declarations, notices,
applications and filings relating to the Merger with other Governmental
Entities under any other antitrust, competition, foreign investment, trade
regulation or similar Laws;

  

  

(ii) use its reasonable best efforts to furnish to the other all assistance,
cooperation and information required for any such registration, declaration,
notice or filing and in order to achieve the effects set forth in Section
6.03(c);

  

  

(iii) give the other reasonable prior notice of any such registration,
declaration, notice or filing and, to the extent reasonably practicable, of
any communication with any Governmental Entity regarding the Merger (including
with respect to any of the actions referred to in Section 6.03(c) and in this
Section 6.03(d)), and permit the other to review and discuss in advance, and
consider in good faith the views of, and secure the participation of, the
other in connection with any such registration, declaration, notice, filing or
communication;

  

  

(iv) respond as promptly as practicable under the circumstances to any
inquiries received from any Governmental Entity or any other authority
enforcing applicable antitrust, competition, foreign investment, trade
regulation or similar Laws for additional information or documentation in
connection with antitrust, competition, foreign investment, trade regulation
or similar matters (including a "second request" under the HSR Act and a
"Supplementary Information Request" under the Competition Act), and not extend
any waiting period under the HSR Act or Competition Act or enter into any
agreement with such Governmental Entities or other authorities not to
consummate any of the transactions contemplated by this Agreement, except with
the prior written consent of the other parties hereto, which consent shall not
be unreasonably withheld or delayed; and

  

  

(v) unless prohibited by applicable Law or by the applicable Governmental
Entity, (A) to the extent reasonably practicable, not participate in or attend
any meeting, or engage in any substantive conversation with any Governmental
Entity in respect of the Merger (including with respect to any of the actions
referred to in Section 6.03(c) and in this Section 6.03(d)) without the other,
(B) to the extent reasonably practicable, give the other reasonable prior
notice of any such meeting or conversation, (C) in the event one party is
prohibited by applicable Law or by the applicable Governmental Entity from
participating in or attending any such meeting or engaging in any such
conversation, keep such party reasonably apprised with respect thereto, (D)
cooperate in the filing of any substantive memoranda, white papers, filings,
correspondence or other written communications explaining or defending this
Agreement and the Merger, articulating any regulatory or competitive argument
or responding to requests or objections made by any Governmental Entity and
(E) furnish the other party with copies of all correspondence, filings and
communications (and memoranda setting forth the substance thereof) between it
and its Affiliates and their respective Representatives on the one hand, and
any Governmental Entity or members of any Governmental Entity's staff, on the
other hand, with respect to this Agreement and the Merger.

  

  

 

 

 

  

 

73  

  

 

 

 

  

  

  

(e) Notwithstanding anything else contained herein, the provisions of this
Section 6.03 shall not be construed to (i) require Valeant or any Valeant
Subsidiary or Biovail or any Biovail Subsidiary or (ii) permit Valeant or any
Valeant Subsidiary without the prior written consent of Biovail, or permit
Biovail or any Biovail Subsidiary without the prior written consent of
Valeant, to undertake any efforts or to take any action if the taking of such
efforts or action would or would reasonably be expected to result (after
giving effect to any reasonably expected proceeds of any divestiture or sale
of assets) in a Combined Company Material Adverse Effect.

  

  

(f) Notwithstanding anything else contained in this Agreement, (i) neither
Biovail nor any of its Affiliates or any of their respective Representatives
shall cooperate with any third party in seeking regulatory clearance of any
Biovail Takeover Proposal and (ii) neither Valeant nor any of its Affiliates
or any of their respective Representatives shall cooperate with any third
party in seeking regulatory clearance of any Valeant Takeover Proposal.

  

  

(g) Biovail shall give prompt notice to Valeant, and Valeant shall give prompt
notice to Biovail, of (i) any representation or warranty made by it contained
in this Agreement that is qualified as to materiality or Biovail Material
Adverse Effect or Valeant Material Adverse Effect, as applicable, becoming
untrue or inaccurate in any respect or any such representation or warranty
that is not so qualified becoming untrue or inaccurate in any material respect
or (ii) the failure by it to comply with or satisfy in any material respect
any covenant, condition or agreement to be complied with or satisfied by it
under this Agreement; provided, however, that no such notification shall
affect the representations, warranties, covenants or agreements of the parties
or the conditions to the obligations of the parties under this Agreement.

  

  

  

 

 

 

  

 

74  

  

 

 

 

  

  

  

SECTION 6.04. Equity Awards; Change in Control Provisions.

  

  

(a) Options.

  

  

(i) Prior to the Pre-Merger Special Dividend Time, the Valeant Board (or, if
appropriate, any committee thereof) shall adopt such resolutions or take such
other actions (including using reasonable efforts to obtain any required
consents) to adjust the terms of all outstanding Valeant Stock Options to
provide that, at the Pre-Merger Special Dividend Time and prior to the
Effective Time, each Valeant Stock Option outstanding immediately prior to the
Pre-Merger Special Dividend Time shall be converted into an option to acquire,
on the same terms and conditions as were applicable under such Valeant Stock
Option immediately prior to the Pre-Merger Special Dividend Time, a number of
shares of Valeant Common Stock, rounded down to the nearest whole share,
determined by multiplying the number of shares of Valeant Common Stock subject
to such Valeant Stock Option immediately prior to the Pre-Merger Special
Dividend Time by the Pre-Merger Special Dividend Adjustment Ratio, at a per
share exercise price, rounded up to the nearest whole cent, determined by
dividing the per share exercise price of such Valeant Stock Option by the Pre-
Merger Special Dividend Adjustment Ratio; provided, however, that the
adjustments provided in this Section 6.04(a)(i) with respect to any Valeant
Stock Options, whether or not they are "incentive stock options" as defined in
Section 422 of the Code, are intended to be effected in a manner that is
consistent with Section 424(a) of the Code and Section 409A of the Code.

  

  

(ii) Prior to the Effective Time, the Valeant Board (or, if appropriate, any
committee thereof) shall adopt such resolutions or take such other actions
(including using reasonable efforts to obtain any required consents) to adjust
the terms of all outstanding Valeant Stock Options to provide that, at the
Effective Time, each Valeant Stock Option outstanding immediately prior to the
Effective Time shall be converted into an option to acquire, on the same terms
and conditions as were applicable under such Valeant Stock Option following
the Pre-Merger Special Dividend Time and immediately prior to the Effective
Time, a number of shares of Biovail Common Stock, rounded down to the nearest
whole share, determined by multiplying the number of shares of Valeant Common
Stock subject to such Valeant Stock Option following the Pre-Merger Special
Dividend Time and immediately prior to the Effective Time by the Equity Award
Exchange Ratio, at a per share exercise price, rounded up to the nearest whole
cent, determined by dividing the per share exercise price of such Valeant
Stock Option by the Equity Award Exchange Ratio; provided, however, that the
adjustments provided in this Section 6.04(a)(ii) with respect to any Valeant
Stock Options, whether or not they are "incentive stock options" as defined in
Section 422 of the Code, are intended to be effected in a manner that is
consistent with Section 424(a) of the Code and Section 409A of the Code.

  

  

(b) Time-Based Restricted Stock Units.

  

  

(i) Prior to the Pre-Merger Special Dividend Time, the Valeant Board (or, if
appropriate, any committee thereof) shall adopt such resolutions or take such
other actions (including using reasonable efforts to obtain any required
consents) to adjust the terms of all outstanding Valeant Restricted Stock
Units that are scheduled to vest, or which have already become vested, solely
based on the passage of time ("Valeant Time-Based Restricted Stock Units") to
provide that, unless otherwise agreed to by the award holder:

  

  

(A) at the Pre-Merger Special Dividend Time and prior to the Effective Time,
except as provided in subparagraph (B) below, each award of Valeant Time-Based
Restricted Stock Units outstanding immediately prior to the Pre-Merger Special
Dividend Time shall represent the right to receive, on the same terms and
conditions as were applicable under such award immediately prior to the Pre-
Merger Special Dividend Time, a number of shares of Valeant Common Stock,
rounded down to the nearest whole share, determined by multiplying the number
of shares of Valeant Common Stock subject to such award of Valeant Time-Based
Restricted Stock Units immediately prior to the Pre-Merger Special Dividend
Time by the Pre-Merger Special Dividend Adjustment Ratio; and

  

  

  

 

 

 

  

 

75  

  

 

 

 

  

  

  

(B) with respect to each award of Valeant Time-Based Restricted Stock Units
that, by its terms as in effect on the date hereof, will vest (in whole or in
part) as a result of the Merger (each such award, a "Single-Trigger RSU"),
such Single-Trigger RSU shall vest as of the day prior to the date on which
occurs the Pre-Merger Special Dividend Time to the extent provided under the
terms of such Single-Trigger RSU as in effect on the date hereof, as if such
day was the date on which the Effective Time occurs (the portion so vested, an
"Accelerated RSU") and shall represent, immediately after the Pre-Merger
Special Dividend Time and prior to the Effective Time, the right to receive,
(1) the same number of shares of Valeant Common Stock underlying the
Accelerated RSU (the "Accelerated Valeant RSU Shares") plus (2) an amount of
cash equal to the product of the Pre-Merger Special Dividend and the number of
Accelerated Valeant RSU Shares, which cash amount shall be paid (net of
applicable withholding) to or on behalf of the holder of the Accelerated RSU
on the date on which occurs the Pre-Merger Special Dividend Time. Any portion
of the Single-Trigger RSU that does not become an Accelerated RSU (and any
right to the associated Pre-Merger Special Dividend) shall be forfeited for no
consideration at the Pre-Merger Dividend Time.

  

  

(ii) Prior to the Effective Time, the Valeant Board (or, if appropriate, any
committee thereof) shall adopt such resolutions or take such other actions
(including using reasonable efforts to obtain any required consents) to adjust
the terms of all outstanding Valeant Time-Based Restricted Stock Units to
provide that, at the Effective Time each award of Valeant Time-Based
Restricted Stock Units outstanding immediately prior to the Effective Time
shall represent, immediately after the Effective Time, the right to receive,
on the same terms and conditions as were applicable under such award following
the Pre-Merger Special Dividend Time and immediately prior to the Effective
Time, a number of shares of Biovail Common Stock, rounded down to the nearest
whole share, determined by multiplying the number of shares of Valeant Common
Stock subject to such award of Valeant Time-Based Restricted Stock Units
following the Pre-Merger Special Dividend Time and immediately prior to the
Effective Time by the Equity Award Exchange Ratio. For the sake of clarity,
holders of Accelerated RSUs shall be entitled to receive shares of Biovail
Common Stock (net of applicable withholding) in settlement of such Accelerated
RSUs as soon as practicable following the date on which the Effective Time
occurs.

  

  

  

 

 

 

  

 

76  

  

 

 

 

  

  

  

(c) Performance-Based Restricted Stock Units.

  

  

(i) Prior to the Pre-Merger Special Dividend Time, the Valeant Board (or, if
appropriate, any committee thereof) shall adopt such resolutions or take such
other actions (including using reasonable efforts to obtain any required
consents) to adjust the terms of all outstanding Valeant Restricted Stock
Units that are scheduled to vest based in whole or in part on the achievement
of performance criteria ("Valeant Performance-Based Restricted Stock Units")
to provide that, except as disclosed in Section 6.04(c) of the Valeant
Disclosure Letter or unless otherwise agreed to by the award holder:

  

  

(A) all relevant performance periods applicable to the Valeant Performance-
Based Restricted Stock Units shall end on the day immediately preceding the
date on which occurs the Pre-Merger Special Dividend Time, as if such day were
the date on which the Effective Time occurs, and, as of such day, the number
of shares of Valeant Common Stock underlying each award of Valeant
Performance-Based Restricted Stock Units shall be adjusted to reflect
performance through such day in accordance with the terms of such Valeant
Performance-Based Restricted Stock Unit as in effect on the date hereof (the
Valeant Performance-Based Restricted Stock award, as so adjusted, being
referred to as the "Valeant Adjusted PSU"). Any additional Valeant
Performance-Based Restricted Stock Units which could have been earned through
performance but which are not so earned (and any right to the associated Pre-
Merger Special Dividend) shall be forfeited for no consideration at the Pre-
Merger Special Dividend Time; and

  

  

(B) each Valeant Adjusted PSU outstanding immediately prior to the Pre-Merger
Special Dividend Time shall represent, immediately after the Pre-Merger
Special Dividend Time, the right to receive, on the same terms and conditions
as were applicable to such Valeant Performance-Based Restricted Stock Unit
immediately prior to the Pre-Merger Special Dividend Time (but determined as
if the Effective Time had occurred), (1) the same number of shares of Valeant
Common Stock underlying the Valeant Adjusted PSU (the "Valeant Adjusted PSU
Shares"), plus (2) an amount of cash equal to the product of the Pre-Merger
Special Dividend multiplied by the number of Valeant Adjusted PSU Shares,
which cash amount shall be paid (net of any applicable withholdings) to or on
behalf of the holders of Valeant Adjusted PSUs on the date on which occurs the
Pre-Merger Special Dividend Time.

  

  

 

 

 

  

 

77  

  

 

 

 

  

  

(ii) Prior to the Effective Time, the Valeant Board (or, if appropriate, any
committee thereof) shall adopt such resolutions or take such other actions
(including using reasonable efforts to obtain any required consents) to adjust
the terms of all outstanding Valeant Adjusted PSUs to provide that, at the
Effective Time, each award of Valeant Adjusted PSUs outstanding immediately
prior to the Effective Time shall represent the right to receive, as soon as
practicable following the Effective Time and net of applicable withholding, a
number of shares of Biovail Common Stock, rounded down to the nearest whole
share, determined by multiplying the number of Valeant Adjusted PSU Shares
subject to such award by the Equity Award Exchange Ratio.

  

  

(d) Prior to the Effective Time, the Valeant Board (or, if appropriate, any
committee thereof) shall adopt such resolutions or take such other actions
(including using reasonable efforts to obtain any required consents) to effect
the following, without further action by any Person:

  

  

(i) after the date hereof, no future offering periods shall be commenced under
the Valeant ESPP. The current offering period in effect on the date hereof
under the Valeant ESPP will continue in accordance with its terms, and options
under the current offering period will be exercisable at the normally
scheduled time under the Valeant ESPP in accordance with its terms; provided,
however, that in all events the expiration of such offering period and the
final exercise under the Valeant ESPP shall occur prior to the Effective Time.
The Valeant ESPP shall terminate, effective immediately as of the Effective
Time;

  

  

(ii) ensure that, following the Effective Time, no holder of a Valeant Stock
Option or Valeant Restricted Stock Unit (or former holder of a Valeant Stock
Option or Valeant Restricted Stock Unit or any current or former participant
in the Valeant Stock Plan, or in any other Valeant Benefit Plan or Valeant
Benefit Agreement), will have any right thereunder to acquire any capital
stock of Valeant or any Valeant Subsidiary or any other equity interest
therein; and

  

  

(iii) make such other changes to the Valeant Stock Plans as it deems
appropriate to give effect to the Merger.

  

  

 

 

 

  

 

78  

  

 

 

 

  

  

  

(e) At the Effective Time, Biovail shall assume all the obligations of Valeant
under the Valeant Stock Plans, each Valeant Stock Option and Valeant
Restricted Stock Unit outstanding at the Effective Time and the agreements
evidencing the grants thereof (the "Valeant Stock Plan Assumption"). As soon
as practicable after the Effective Time, Biovail shall deliver to the holders
of Valeant Stock Options and Valeant Restricted Stock Units appropriate
notices setting forth such holders' rights pursuant to the respective Valeant
Stock Plans, and the agreements evidencing the grants of such Valeant Stock
Options and Valeant Restricted Stock Units shall continue in effect on the
same terms and conditions (subject to the adjustments required by this Section
6.04 after giving effect to the Merger).

  

  

(f) Biovail shall take all corporate action necessary to reserve for issuance
a sufficient number of shares of Biovail Common Stock for delivery upon
exercise or settlement of the Valeant Stock Options and Valeant Restricted
Stock Units assumed in accordance with this Section 6.04. As soon as
reasonably practicable after the Effective Time, Biovail shall file a
registration statement on Form S-8 (or any successor or other appropriate
form) with respect to the shares of Biovail Common Stock subject to Valeant
Stock Options and Valeant Restricted Stock Units and shall use its reasonable
best efforts to maintain the effectiveness of such registration statement or
registration statements (and maintain the current status of the prospectus or
prospectuses contained therein) for so long as such Valeant Stock Options and
Valeant Restricted Stock Units remain outstanding.

  

  

(g) Prior to the Effective Time, each of the Biovail Board and the Valeant
Board shall irrevocably declare that the transactions contemplated by this
Agreement constitute a change in control (or the equivalent thereof) under the
Biovail Benefit Plans (and awards thereunder), the Biovail Benefit Agreements,
the Valeant Benefit Plans (and awards thereunder) and the Valeant Benefit
Agreements, as the case may be.

  

  

SECTION 6.05. Indemnification, Exculpation and Insurance. (a) For a period of
six years from the Effective Time, Biovail shall maintain in effect the
exculpation, indemnification and advancement of expenses provisions of any
certificate of incorporation and by-laws or similar organization documents of
each of Biovail, the Biovail Subsidiaries, Valeant and the Valeant
Subsidiaries in effect immediately prior to the Effective Time and with
respect to acts or omissions prior to the Effective Time or in any
indemnification agreements of Biovail, the Biovail Subsidiaries, Valeant or
the Valeant Subsidiaries with any of their respective directors, officers or
employees in effect immediately prior to the Effective Time and with respect
to acts or omissions prior to the Effective Time, and shall not amend, repeal
or otherwise modify any such provisions or the exculpation, indemnification or
advancement of expenses provisions of Biovail's or the Surviving Company's
certificate of incorporation and by-laws in any manner that would adversely
affect the rights thereunder of any individuals who at the Effective Time were
current or former directors, officers or employees of Biovail, any of the
Biovail Subsidiaries, Valeant or any of the Valeant Subsidiaries.

  

  

  

 

 

 

  

 

79  

  

 

 

 

  

  

(b) For a period of six years after the Effective Time, Biovail shall
indemnify and hold harmless the individuals who on or prior to the Effective
Time were officers, directors and employees of Biovail or the Biovail
Subsidiaries or were serving at the request of Biovail as an officer, director
or employee of any other corporation, partnership or joint venture, trust,
employee benefit plan or other enterprise (collectively, the "Biovail
Indemnitees") with respect to all acts or omissions by them in their
capacities as such or taken at the request of Biovail or any of the Biovail
Subsidiaries at any time prior to the Effective Time to the extent provided
under the Biovail Charter or Biovail Bylaws in effect on the date of this
Agreement (including with respect to the advancement of expenses).

  

  

(c) For a period of six years after the Effective Time, Biovail shall, and
shall cause the Surviving Company to, indemnify and hold harmless the
individuals who on or prior to the Effective Time were officers, directors and
employees of Valeant or the Valeant Subsidiaries or were serving at the
request of Valeant as an officer, director or employee of any other
corporation, partnership or joint venture, trust, employee benefit plan or
other enterprise (collectively, the "Valeant Indemnitees" and, together with
the Biovail Indemnitees, the "Indemnitees") with respect to all acts or
omissions by them in their capacities as such or taken at the request of
Valeant or any of the Valeant Subsidiaries at any time prior to the Effective
Time to the extent provided under the Valeant Charter or Valeant Bylaws in
effect on the date of this Agreement (including with respect to the
advancement of expenses). Biovail shall, and shall cause the Surviving Company
to, honor all indemnification agreements with the Indemnitees (including under
the Valeant Bylaws) in effect as of the date of this Agreement in accordance
with the terms thereof.

  

  

(d) For six years after the Effective Time, Biovail shall procure the
provision of officers' and directors' liability insurance in respect of acts
or omissions occurring prior to the Effective Time covering each such Person
currently covered by Biovail's officers' and directors' liability insurance
policy on terms with respect to coverage and in amounts no less than those of
the policy in effect on the date of this Agreement. In lieu of such insurance,
prior to the Closing Date, Biovail may, following consultation with Valeant,
purchase a "tail" directors' and officers' liability insurance policy and
fiduciary liability insurance policy for Biovail and its respective current
and former directors and officers who are currently covered by the directors'
and officers' and fiduciary liability insurance coverage currently maintained
by Biovail, in which event Biovail shall cease to have any obligations under
the first sentence of this Section 6.05(d).

  

  

(e) For six years after the Effective Time, Biovail shall procure the
provision of officers' and directors' liability insurance in respect of acts
or omissions occurring prior to the Effective Time covering each such Person
currently covered by Valeant's officers' and directors' liability insurance
policy on terms with respect to coverage and in amounts no less than those of
the policy in effect on the date of this Agreement. In lieu of such insurance,
prior to the Closing Date, Valeant may, following consultation with Biovail,
purchase a "tail" directors' and officers' liability insurance policy and
fiduciary liability insurance policy for Valeant and its respective current
and former directors and officers who are currently covered by the directors'
and officers' and fiduciary liability insurance coverage currently maintained
by Valeant, in which event Biovail or the Surviving Company, as the case may
be, shall cease to have any obligations under the first sentence of this
Section 6.05(e).

  

  

  

 

 

 

  

 

80  

  

 

 

 

  

  

  

(f) In the event that Biovail or the Surviving Company or any of its
successors or assigns (i) consolidates with or merges into any other Person
and is not the continuing or surviving corporation or entity of such
consolidation or merger or (ii) transfers or conveys all or substantially all
its properties and assets to any Person, then, and in each such case, Biovail
shall cause proper provision to be made so that the successors and assigns of
Biovail or the Surviving Company, as the case may be, assume the obligations
set forth in this Section 6.05.

  

  

(g) The provisions of this Section 6.05 (i) shall survive consummation of the
Merger, (ii) are intended to be for the benefit of, and will be enforceable
by, each Indemnitee, his or her heirs and his or her representatives and (iii)
are in addition to, and not in substitution for, any other rights to
indemnification or contribution that any such Person may have by contract or
otherwise. Biovail shall pay all reasonable expenses, including reasonable
attorneys' fees, that may be incurred by any Indemnitee in enforcing the
indemnity and other obligations provided in this Section 6.05, provided that
such Indemnitee is successful in enforcing any such enforcement claim.

  

  

SECTION 6.06. Fees and Expenses. (a) Except as provided below, all fees and
expenses incurred in connection with the Merger and the other transactions
contemplated by this Agreement shall be paid by the party incurring such fees
or expenses, whether or not such transactions are consummated.

  

  

(b) BAC shall pay (provided that if BAC fails to pay when due, Biovail will
pay when due on behalf of BAC) to Valeant a fee of $100,000,000 (the "Biovail
Termination Fee") if:

  

  

(i) Valeant terminates this Agreement pursuant to Section 8.01(e); provided
that if either Valeant or Biovail terminates this Agreement pursuant to
Section 8.01(b)(iii) at any time after Valeant would have been permitted to
terminate this Agreement pursuant to Section 8.01(e), this Agreement shall be
deemed terminated pursuant to Section 8.01(e) for purposes of this Section
6.06(b)(i); or

  

  

  

 

 

 

  

 

81  

  

 

 

 

  

  

(ii) (A) prior to the Biovail Stockholders Meeting, a Biovail Takeover
Proposal shall have been made to Biovail or shall have been made directly to
the stockholders of Biovail generally or shall otherwise become publicly known
or any Person shall have publicly announced an intention (whether or not
conditional) to make a Biovail Takeover Proposal, (B) this Agreement is
terminated by Biovail pursuant to (1) Section 8.01(b)(i) and the Biovail
Stockholders Meeting has not been held on or prior to the fifth Business Day
prior to the date of such termination or (2) Section 8.01(b)(iii) and (C)
within 12 months of such termination, Biovail enters into a definitive
Contract to consummate a Biovail Takeover Proposal or any Biovail Takeover
Proposal is consummated. For the purposes of Section 6.06(b)(ii)(C) only, the
term "Biovail Takeover Proposal" shall have the meaning assigned to such term
in Section 5.02(e) except that all references to "20%" therein shall be deemed
to be references to "40%".

  

  

Any Biovail Termination Fee due under this Section 6.06(b) shall be paid by
wire transfer of same-day funds (x) in the case of clause (i) above, on the
Business Day immediately following the date of termination of this Agreement
and (y) in the case of clause (ii) above, on the date of the first to occur of
the events referred to in clause (ii)(C) above.

  

  

(c) Valeant shall pay to Biovail a fee of $100,000,000 (the "Valeant
Termination Fee") if:

  

  

(i) Biovail terminates this Agreement pursuant to Section 8.01(f); provided
that if either Valeant or Biovail terminates this Agreement pursuant to
Section 8.01(b)(iv) at any time after Biovail would have been permitted to
terminate this Agreement pursuant to Section 8.01(f), this Agreement shall be
deemed terminated pursuant to Section 8.01(f) for purposes of this Section
6.06(c)(i); or

  

  

(ii) (A) prior to the Valeant Stockholders Meeting, a Valeant Takeover
Proposal shall have been made to Valeant or shall have been made directly to
the stockholders of Valeant generally or shall otherwise become publicly known
or any Person shall have publicly announced an intention (whether or not
conditional) to make a Valeant Takeover Proposal, (B) this Agreement is
terminated pursuant to (1) Section 8.01(b)(i) and the Valeant Stockholders
Meeting has not been held at or prior to the fifth Business Day prior to the
date of such termination or (2) Section 8.01(b)(iv) and (C) within 12 months
of such termination, Valeant enters into a definitive Contract to consummate a
Valeant Takeover Proposal or a Valeant Takeover Proposal is consummated. For
the purposes of Section 6.06(c)(ii)(C) only, the term "Valeant Takeover
Proposal" shall have the meaning assigned to such term in Section 5.03(e)
except that all references to "20%" therein shall be deemed to be references
to "40%".

  

  

  

 

 

 

  

 

82  

  

 

 

 

  

  

Any Valeant Termination Fee due under this Section 6.06(c) shall be paid by
wire transfer of same-day funds (x) in the case of clause (i) above, on the
Business Day immediately following the date of termination of this Agreement
and (y) in the case of clause (ii) above, on the date of the first to occur of
the events referred to in clause (ii)(C) above.

  

  

(d) Biovail and Valeant acknowledge and agree that the agreements contained in
Sections 6.06(b) and 6.06(c) are an integral part of the transactions
contemplated by this Agreement, and that, without these agreements, neither
Valeant nor Biovail would enter into this Agreement. Accordingly, if Biovail
fails promptly to pay the amount due pursuant to Section 6.06(b) or Valeant
fails promptly to pay the amount due pursuant to Section 6.06(c), and, in
order to obtain such payment, the Person owed such payment commences a suit,
action or other proceeding that results in a Judgment in its favor for such
payment, the Person owing such payment shall pay to the Person owed such
payment its costs and expenses (including attorneys' fees and expenses) in
connection with such suit, action or other proceeding, together with interest
on the amount of such payment from the date such payment was required to be
made until the date of payment at the prime rate of JPMorgan Chase Bank, N.A.
in effect on the date such payment was required to be made. In no event shall
either party be obligated to pay more than one termination fee pursuant to
this Section 6.06.

  

  

SECTION 6.07. Certain Tax Matters. Each of Valeant, Biovail, BAC and Merger
Sub shall use its reasonable best efforts to cause the Merger to qualify for
the Intended Tax Treatment and to obtain the Tax opinions described in
Sections 7.02(d) and 7.03(d), including by (i) making representations and
covenants requested by Tax counsel in order to render such Tax opinions, (ii)
not taking any action that such party knows is reasonably likely to prevent
such qualification or to prevent the obtaining of such Tax opinions and (iii)
executing such amendments to this Agreement as may be reasonably required in
order to obtain such qualification (it being understood that no party will be
required to agree to any such amendment). Each of Valeant, Biovail, BAC and
Merger Sub shall use its reasonable best efforts not to take or cause to be
taken any action that would cause to be untrue (or fail to take or cause not
to be taken any action which inaction would cause to be untrue) any of the
representations and covenants made to Tax counsel in furtherance of such Tax
opinions. Each of Valeant, Biovail, BAC and Merger Sub will report the Merger
and the other transactions contemplated by this Agreement in a manner
consistent with the Intended Tax Treatment.

  

  

SECTION 6.08. Transaction Litigation. Biovail shall give Valeant the
opportunity to participate in the defense or settlement of any litigation
against Biovail or its directors relating to the Merger and the other
transactions contemplated by this Agreement, and no such settlement shall be
agreed to without the prior written consent of Valeant, which consent shall
not be unreasonably withheld, conditioned or delayed. Valeant shall give
Biovail the opportunity to participate in the defense or settlement of any
stockholder litigation against Valeant or its directors relating to the Merger
and the other transactions contemplated by this Agreement, and no such
settlement shall be agreed to without the prior written consent of Biovail,
which consent shall not be unreasonably withheld, conditioned or delayed.
Without limiting in any way the parties' obligations under Section 6.03, each
of Biovail and Valeant shall cooperate, shall cause the Biovail Subsidiaries
and Valeant Subsidiaries, as applicable, to cooperate, and shall use its
reasonable best efforts to cause its Representatives to cooperate, in the
defense against such litigation.

  

  

  

 

 

 

  

 

83  

  

 

 

 

  

  

  

SECTION 6.09. Section 16 Matters. Prior to the Effective Time, Valeant,
Biovail and Merger Sub each shall take all such steps as may be required to
cause (a) any dispositions of Valeant Common Stock (including derivative
securities with respect to Valeant Common Stock) resulting from the Merger and
the other transactions contemplated by this Agreement by each individual who
will be subject to the reporting requirements of Section 16(a) of the Exchange
Act with respect to Valeant immediately prior to the Effective Time to be
exempt under Rule 16b-3 promulgated under the Exchange Act and (b) any
acquisitions of Biovail Common Stock (including derivative securities with
respect to Biovail Common Stock) resulting from the Merger and the other
transactions contemplated by this Agreement by each individual who may become
or is reasonably expected to become subject to the reporting requirements of
Section 16(a) of the Exchange Act with respect to Biovail to be exempt under
Rule 16b-3 promulgated under the Exchange Act.

  

  

SECTION 6.10. Governance Matters. Biovail, Merger Sub and Valeant shall take
all actions necessary so that the matters set forth on Exhibit A occur on the
Closing Date.

  

  

SECTION 6.11. Financing. (a) From the date hereof until the earlier of (a) the
Closing Date and (b) termination of this Agreement pursuant to Section 8.01,
Biovail and Valeant shall use, and shall cause the Biovail Subsidiaries and
Valeant Subsidiaries, respectively, to use, their respective reasonable best
efforts to take, or cause to be taken, all actions and to do, or cause to be
done, all things necessary, proper or advisable to arrange the financing and
related transactions (including the payment, refinancing and tendering of
existing indebtedness) (the "Financing") described in the executed commitment
letter attached hereto as Exhibit C (the "Commitment Letter"), including using
reasonable best efforts to (i) negotiate and enter into definitive agreements
with respect thereto on the terms and conditions contemplated by the
Commitment Letter, (ii) satisfy on a timely basis all conditions to obtaining
the Financing set forth therein and (iii) consummate the Financing at or prior
to Closing, including (A) participating in a reasonable number of meetings,
road shows, rating agency sessions and drafting sessions, and participating in
reasonable and customary due diligence, (B) furnishing the financial
institutions providing or arranging the Financing (the "Financing Sources")
with such financial and other pertinent information as may be reasonably
requested to consummate the Financing, including all financial statements and
financial data of the type required by Regulation S-X and Regulation S-K under
the Securities Act (including any required audits thereof, which shall be
unqualified) and of the type and form customarily included in private
placements pursuant to Rule 144A promulgated under the Securities Act, (C)
assisting the Financing Sources in the preparation of (1) an offering document
for any portion of the Financing and (2) materials for rating agency
presentations, (D) reasonably cooperating with the marketing efforts for any
portion of the Financing and (E) causing their respective independent
accountants to provide assistance and cooperation in the Financing, including
(1) participating in a reasonable number of drafting sessions and accounting
due diligence sessions, (2) providing any necessary consents to use their
audit reports relating to Biovail or Valeant, as applicable, and (3) providing
any necessary "comfort letters." Biovail and Valeant shall, and shall cause
their respective Subsidiaries to, refrain from taking, directly or indirectly,
any action that would reasonably be expected to result in the failure of any
of the conditions contained in the Commitment Letter or in any definitive
agreement related to the Financing. In the event any portion of the Financing
becomes unavailable on the terms and conditions set forth in the Commitment
Letter, Biovail and Valeant shall use their reasonable best efforts to obtain
alternative financing from alternative sources as promptly as reasonably
practicable following the occurrence of such event. Biovail shall give Valeant
prompt notice of any material breach by any party to the Commitment Letter of
which Biovail becomes aware. Valeant shall give Biovail prompt notice of any
material breach by any party to the Commitment Letter of which Valeant becomes
aware.

  

  

  

 

 

 

  

 

84  

  

 

 

 

  

  

(b) All non-public or otherwise confidential information regarding Valeant
obtained by Biovail pursuant to the arrangement of the Financing shall be kept
confidential in accordance with the Confidentiality Agreement; provided,
however, that disclosure shall be permitted as necessary and consistent with
customary practices in connection with the Financing upon the prior written
consent of Valeant (such consent not to be unreasonably withheld, conditioned
or delayed). All non-public or otherwise confidential information regarding
Biovail obtained by Valeant pursuant to the arrangement of the Financing shall
be kept confidential in accordance with the Confidentiality Agreement;
provided, however, that disclosure shall be permitted as necessary and
consistent with customary practices in connection with the Financing upon the
prior written consent of Biovail (such consent not to be unreasonably
withheld, conditioned or delayed).

  

  

SECTION 6.12. Public Announcements. Except with respect to any Valeant Adverse
Recommendation Change or Biovail Adverse Recommendation Change made in
accordance with the terms of this Agreement, Biovail and Valeant shall consult
with each other before issuing, and give each other the opportunity to review
and comment upon, any press release or other public statements with respect to
the transactions contemplated by this Agreement, including the Merger, and
shall not issue any such press release or make any such public statement prior
to such consultation, except as such party may reasonably conclude may be
required by applicable Law, court process or by obligations pursuant to any
listing agreement with any national securities exchange or national securities
quotation system. Valeant and Biovail agree that the initial press release to
be issued with respect to the transactions contemplated by this Agreement
shall be in a form agreed to by the parties.

  

  

  

 

 

 

  

 

85  

  

 

 

 

  

  

  

 

SECTION 6.13. Stock Exchange Listing. Biovail shall use its reasonable best
efforts to cause the shares of Biovail Common Stock to be issued (a) in the
Merger and (b) upon the conversion of Valeant Convertible Notes, the exercise
of Valeant Warrants or Valeant Stock Options or the vesting of Valeant
Restricted Stock Units, in each case under this clause (b) following the
Effective Time, to be approved for listing on the NYSE and the TSX, in each
case subject to official notice of issuance, prior to the Closing Date.
Valeant shall cooperate with Biovail in connection with the foregoing,
including the provision of information reasonably requested by Biovail in
connection therewith.

  

  

SECTION 6.14. Joinder Agreement. In the event that Biovail and Valeant agree
in writing that a newly-formed, direct or indirect and wholly owned subsidiary
of Biovail incorporated under the laws of Delaware ("New Merger Sub") shall be
substituted for Merger Sub for purposes of this Agreement, (i) Biovail and
Valeant shall, and Biovail shall cause New Merger Sub to, execute and deliver
a joinder agreement with respect to this Agreement, substantially in the form
set forth on Exhibit C (the "Joinder Agreement"), (ii) Biovail, as sole
stockholder of New Merger Sub, shall, immediately following the execution and
delivery of the Joinder Agreement, adopt the Joinder Agreement, and (iii) all
references to "Merger Sub" in this Agreement shall be deemed to refer to "New
Merger Sub".

  

  

SECTION 6.15. Entity Name. The parties shall take all action necessary so that
the name of the Combined Company shall be Valeant Pharmaceuticals
International, Inc. on the Closing Date.

  

  

SECTION 6.16. Valeant Warrants and Valeant Convertible Notes.

  

  

(a) As and when required by the Valeant Warrants as in effect on the date of
this Agreement, and only to the extent any such Valeant Warrants remain
outstanding at such time, (i) Valeant shall deliver notice of the proposed
record date for the Pre-Merger Special Dividend to the registered holders of
any then-outstanding Valeant Warrants, and (ii) Valeant shall furnish to the
registered holders of any then-outstanding Valeant Warrants the certificate
required by the Valeant Warrants as in effect on the date of this Agreement
setting forth the adjustment of the Purchase Price (as defined in the Valeant
Warrants) resulting from payment of the Pre-Merger Special Dividend and
showing the facts upon which such adjustment is based.

  

  

(b) As and when required by the Valeant Convertible Notes Indenture, as in
effect on the date of this Agreement, (i) Valeant shall mail notice of the
proposed record date for the Pre-Merger Special Dividend to the Initial
Purchasers (as defined in the Valeant Convertible Notes Indenture) and to the
Holders (as defined in the Valeant Convertible Notes Indenture) of any then-
outstanding Valeant Convertible Notes and shall file such notice with the
Trustee (as defined in the Valeant Convertible Notes Indenture), and (ii)
Valeant shall notify the Initial Purchasers and the Trustee and mail to
Holders of any then-outstanding Valeant Convertible Notes the notice required
by the Valeant Convertible Notes Indenture as in effect on the date of this
Agreement of the adjustment of the Conversion Rate (as defined in the Valeant
Convertible Notes Indenture) resulting from payment of the Pre-Merger Special
Dividend and file with the Trustee the required certificate stating the facts
requiring such adjustment and the manner of computing it.

  

  

  

 

 

 

  

 

86  

  

 

 

 

  

  

(c) As and when required by the Valeant Warrants as in effect on the date of
this Agreement, and only to the extent any such Valeant Warrants remain
outstanding at such time, (i) Valeant shall deliver notice of the proposed
record date for approval of the Merger to the registered holders of any then-
outstanding Valeant Warrants, and (ii) Valeant shall furnish to the registered
holders of any then-outstanding Valeant Warrants the certificate required by
the Valeant Warrants as in effect on the date of this Agreement setting forth
the adjustment to the Valeant Warrants resulting from the Merger and showing
the facts upon which such adjustment is based.

  

  

(d) As and when required by the Valeant Convertible Notes Indenture as in
effect on the date of this Agreement, (i) Valeant shall mail notice of the
proposed record date for approval of the Merger to the Initial Purchasers and
to the Holders of any then-outstanding Valeant Convertible Notes and shall
file such notice with the Trustee, and (ii) prior to the Effective Time,
Biovail and Valeant shall execute and deliver to the Trustee a supplemental
indenture to the Valeant Convertible Notes Indenture containing the provisions
required by the Valeant Convertible Notes Indenture as in effect on the date
of this Agreement, providing that, at the Effective Time, each then-
outstanding Valeant Convertible Note shall no longer be convertible into
shares of Valeant Common Stock and shall thereafter be convertible solely into
the number of shares of Biovail Common Stock that the Holder of such Valeant
Convertible Note would have received pursuant to the Merger if such Holder had
converted such Valeant Convertible Note immediately before the Effective Time.

  

 

  

SECTION 6.17. Pre-Merger Special Dividend. As promptly as practicable
following the satisfaction of the conditions set forth in Section 7.01,
Section 7.02 and Section 7.03 (other than (a) those conditions that by their
nature are to be satisfied by actions taken at the Closing but which
conditions would be satisfied (including the delivery of officers'
certificates without qualifications or exceptions) if such date were the
Closing Date and (b) the contemplated payment of the Pre-Merger Special
Dividend), the Valeant Board intends to, subject to applicable Law and the
Valeant Charter and Valeant Bylaws, declare a special dividend in an amount
equal to $16.77 per share of Valeant Common Stock (subject to customary
adjustments for any stock dividend, subdivision, reclassification,
recapitalization, split, combination, exchange of shares or similar event
following the date of this Agreement) (any such dividend, the "Pre-Merger
Special Dividend"), and set the record date and payment date for such Pre-
Merger Special Dividend in its sole discretion; provided, that each of the
record date and payment date for such Pre-Merger Special Dividend shall be one
Business Day immediately prior to the Closing Date.

  

  

  

 

 

 

  

 

87  

  

 

 

 

  

  

  

ARTICLE VII

  

  

Conditions Precedent

  

  

SECTION 7.01. Conditions to Each Party's Obligation to Effect the Merger. The
respective obligation of each party to effect the Merger is subject to the
satisfaction or waiver on or prior to the Closing Date of the following
conditions:

  

  

(a) Stockholder Approvals. The Biovail Stockholder Approval and the Valeant
Stockholder Approval shall have been obtained.

  

  

(b) Listing. The shares of Biovail Common Stock issuable (i) as Merger
Consideration pursuant to this Agreement and (ii) upon the conversion of
Valeant Convertible Notes, the exercise of Valeant Warrants or Valeant Stock
Options or the vesting of Valeant Restricted Stock Units, in each case under
this clause (ii) following the Effective Time, shall have been approved for
listing on the NYSE and the TSX, in each case subject to official notice of
issuance and, in the case of the TSX, to the making of certain prescribed
filings following the Effective Time.

  

  

(c) Governmental Approvals. Any waiting period (and any extension thereof)
applicable to the Merger under the HSR Act shall have been terminated or shall
have expired. If the Merger is subject to the notification provisions of Part
IX of the Competition Act, either (i) the Commissioner of Competition or a
person authorized by her (the "Commissioner") shall have issued an advance
ruling certificate under Section 102 of the Competition Act or (ii) the
applicable waiting period under subsection 123(1) of the Competition Act shall
have expired or shall have been terminated early under subsection 123(2) of
the Competition Act, or the obligation to submit a notification under Part IX
of the Competition Act shall have been waived pursuant to paragraph 113(c) of
the Competition Act and, unless waived by Biovail, the Commissioner shall have
issued a No-Action Letter. For the purposes of the preceding sentence, a "No-
Action Letter" means written advice to Biovail that the Commissioner presently
does not have sufficient grounds on which to apply to the Competition Tribunal
under Section 92 or any other section of Part VIII of the Competition Act and,
therefore, does not, at such time, intend to make such application with
respect to the Merger, such advice not being conditional upon or having terms
and conditions that would reasonably be expected to result in a Combined
Company Material Adverse Effect. All Consents, if any, required to be obtained
(i) under any other foreign antitrust, competition, foreign investment, trade
regulation or similar Laws or (ii) from or of any other Governmental Entity,
in each case in connection with the consummation of the Merger and the
transactions contemplated by this Agreement, shall have been obtained, except
for those Consents which are immaterial to the Combined Company.

  

  

  

 

 

 

  

 

88  

  

 

 

 

  

  

(d) No Legal Restraints. No applicable Law and no Judgment, preliminary,
temporary or permanent, issued by any court or tribunal of competent
jurisdiction (collectively, the "Legal Restraints") shall be in effect, and no
suit, action or other proceeding shall have been instituted by any
Governmental Entity and remain pending which is reasonably likely to result in
a Legal Restraint, in each case, that prevents, makes illegal, or prohibits
the consummation of the Merger or that is (i) seeking to prohibit, materially
restrain or otherwise materially interfere with the Merger or the ownership or
operation of all or any material portion of the business or assets of Valeant
or any of the Valeant Subsidiaries or of Biovail or any of the Biovail
Subsidiaries or to compel Biovail or any Biovail Subsidiary to dispose of or
hold separate all or any material portion of the business or assets of Valeant
or any of the Valeant Subsidiaries or of Biovail or any of the Biovail
Subsidiaries, or (ii) seeking divestiture of any shares of Valeant Common
Stock (or shares of stock of the Surviving Company) or seeking to impose or
confirm limitations on the ability of Biovail or any Biovail Subsidiary
effectively to exercise full rights of ownership of the shares of Valeant
Common Stock (or shares of stock of the Surviving Company), including the
right to vote, in the case of clause (i) or clause (ii), which would
reasonably be expected (after giving effect to any reasonably expected
proceeds of any divestiture or sale of assets) to have a Combined Company
Material Adverse Effect.

  

  

(e) Form S-4. The Form S-4 shall have become effective under the Securities
Act and shall not be the subject of any stop order or proceedings seeking a
stop order, and Biovail shall have received all state securities or "blue sky"
authorizations necessary for the issuance of the Merger Consideration.

  

  

(f) Financing. The Financing (or, in the event that alternative financing has
been jointly arranged by Biovail and Valeant, the alternative financing) shall
have been consummated.

  

  

(g) Pre-Merger Special Dividend. The Pre-Merger Special Dividend shall have
been paid to holders of Valeant Common Stock in accordance with Section 6.17.
For purposes of this Section 7.01(g), the Pre-Merger Special Dividend shall be
deemed to have been paid to holders of Valeant Common Stock at the time
Valeant irrevocably transfers cash for the Pre-Merger Special Dividend to the
relevant paying agent for the benefit of such stockholders.

  

  

SECTION 7.02. Conditions to Obligations of Valeant. The obligation of Valeant
to consummate the Merger is further subject to the following conditions:

  

  

(a) Representations and Warranties. The representations and warranties of
Biovail, BAC and Merger Sub contained in this Agreement (except for the
representations and warranties contained in Section 3.03 and 3.17(c)) shall be
true and correct (without giving effect to any limitation as to "materiality"
or "Biovail Material Adverse Effect" set forth therein) at and as of the date
of this Agreement and at and as of the Closing Date as if made at and as of
such time (except to the extent expressly made as of an earlier date, in which
case as of such earlier date), except where the failure of such
representations and warranties to be true and correct (without giving effect
to any limitation as to "materiality" or "Biovail Material Adverse Effect" set
forth therein), individually or in the aggregate, has not had and would not
reasonably be expected to have a Biovail Material Adverse Effect, and the
representations and warranties of Biovail, BAC and Merger Sub contained in
Section 3.03 and Section 3.17(c) shall be true and correct in all material
respects at and as of the date of this Agreement and at and as of the Closing
Date as if made at and as of such time (except to the extent expressly made as
of an earlier date, in which case as of such earlier date). Valeant shall have
received a certificate signed on behalf of each of Biovail, BAC and Merger Sub
by an executive officer of each of Biovail, BAC and Merger Sub, respectively,
to such effect.

  

  

  

 

 

 

  

 

89  

  

 

 

 

  

  

  

(b) Performance of Obligations of Biovail, BAC and Merger Sub. Biovail and
Merger Sub shall have performed in all material respects all obligations
required to be performed by them under this Agreement at or prior to the
Closing Date, and Valeant shall have received a certificate signed on behalf
of each of Biovail, BAC and Merger Sub by an executive officer of each of
Biovail, BAC and Merger Sub, respectively, to such effect.

  

  

(c) Absence of Biovail Material Adverse Effect. Since the date of this
Agreement, there shall not have occurred any fact, circumstance, effect,
change, event or development that, individually or in the aggregate, has had
or would reasonably be expected to have a Biovail Material Adverse Effect.

  

  

(d) Tax Opinion. Valeant shall have received the opinion of Skadden, Arps,
Slate, Meagher and Flom LLP, or such other nationally recognized Tax counsel
reasonably satisfactory to Valeant, as of the Closing Date to the effect that
the Merger should qualify for the Intended Tax Treatment. In rendering the
opinion described in this Section 7.02(d), the Tax counsel rendering such
opinion may require and rely upon (and may incorporate by reference)
reasonable and customary representations and covenants, including those
contained in certificates of officers of Valeant and Biovail.

  

  

SECTION 7.03. Conditions to Obligation of Biovail, BAC and Merger Sub. The
obligations of Biovail, BAC and Merger Sub to consummate the Merger are
further subject to the following conditions:

  

  

(a) Representations and Warranties. The representations and warranties of
Valeant contained in this Agreement (except for the representations and
warranties contained in Section 4.03 and the third sentence of Section 4.12)
shall be true and correct (without giving effect to any limitation as to
"materiality" or "Valeant Material Adverse Effect" set forth therein) at and
as of the date of this Agreement and at and as of the Closing Date as if made
at and as of such time (except to the extent expressly made as of an earlier
date, in which case as of such earlier date), except where the failure of such
representations and warranties to be true and correct (without giving effect
to any limitation as to "materiality" or "Valeant Material Adverse Effect" set
forth therein), individually or in the aggregate, has not had and would not
reasonably be expected to have a Valeant Material Adverse Effect, and the
representations and warranties of Valeant contained in Sections 4.03 and the
third sentence of Section 4.12 shall be true and correct in all material
respects at and as of the date of this Agreement and at and as of the Closing
Date as if made at and as of such time (except to the extent expressly made as
of an earlier date, in which case as of such earlier date). Biovail shall have
received a certificate signed on behalf of Valeant by an executive officer of
Valeant to such effect.

  

  

  

 

 

 

  

 

90  

  

 

 

 

  

  

  

(b) Performance of Obligations of Valeant. Valeant shall have performed in all
material respects all obligations required to be performed by it under this
Agreement at or prior to the Closing Date, and Biovail shall have received a
certificate signed on behalf of Valeant by an executive officer of Valeant to
such effect.

  

  

(c) Absence of Valeant Material Adverse Effect. Since the date of this
Agreement, there shall not have occurred any fact, circumstance, effect,
change, event or development that, individually or in the aggregate, has had
or would reasonably be expected to have a Valeant Material Adverse Effect.

  

  

(d) Tax Opinion. Biovail shall have received the opinion of Cravath, Swaine and
Moore LLP, or such other nationally recognized Tax counsel reasonably
satisfactory to Biovail, as of the Closing Date to the effect that the Merger
should qualify for the Intended Tax Treatment. In rendering the opinion
described in this Section 7.03(d), the Tax counsel rendering such opinion may
require and rely upon (and may incorporate by reference) reasonable and
customary representations and covenants, including those contained in
certificates of officers of Valeant and Biovail.

  

  

  

ARTICLE VIII

  

  

Termination, Amendment and Waiver

  

  

SECTION 8.01. Termination. This Agreement may be terminated at any time prior
to the Effective Time, whether before or after receipt of the Biovail
Stockholder Approval or the Valeant Stockholder Approval:

  

  

(a) by mutual written consent of Valeant and Biovail;

  

  

  

 

 

 

  

 

91  

  

 

 

 

  

  

  

(b) by either Valeant or Biovail:

  

  

(i) if the Merger is not consummated on or before the End Date. The "End Date"
shall mean February 28, 2011; provided, however, that the right to terminate
this Agreement under this Section 8.01(b)(i) shall not be available to any
party if such failure of the Merger to occur on or before the End Date is the
result of a breach of this Agreement by such party or the failure of any
representation or warranty of such party contained in this Agreement to be
true and correct;

  

  

(ii) if the condition set forth in Section 7.01(d) is not satisfied and the
Legal Restraint giving rise to such non-satisfaction shall have become final
and non-appealable; provided that the terminating party shall have complied
with its obligations to use its reasonable best efforts pursuant to Section
6.03;

  

  

(iii) if the Biovail Stockholder Approval is not obtained at the Biovail
Stockholders Meeting duly convened (unless such Biovail Stockholders Meeting
has been adjourned, in which case at the final adjournment thereof); or

  

  

(iv) if the Valeant Stockholder Approval is not obtained at the Valeant
Stockholders Meeting duly convened (unless such Valeant Stockholders Meeting
has been adjourned, in which case at the final adjournment thereof);

  

  

(c) by Valeant, if Biovail, BAC or Merger Sub breaches or fails to perform any
of its covenants or agreements contained in this Agreement, or if any of the
representations or warranties of Biovail, BAC or Merger Sub contained herein
fails to be true and correct, which breach or failure (i) would give rise to
the failure of a condition set forth in Section 7.02(a) or 7.02(b) and (ii) is
not reasonably capable of being cured by Biovail, BAC or Merger Sub, as the
case may be, by the End Date or is not cured by Biovail, BAC or Merger Sub, as
the case may be, within forty-five days after receiving written notice from
Valeant (provided that Valeant is not then in breach of any covenant or
agreement contained in this Agreement and no representation or warranty of
Valeant contained herein then fails to be true and correct such that the
conditions set forth in Section 7.03(a) or 7.03(b) could not then be
satisfied);

  

  

(d) by Biovail, if Valeant breaches or fails to perform any of its covenants
or agreements contained in this Agreement, or if any of the representations or
warranties of Valeant contained herein fails to be true and correct, which
breach or failure (i) would give rise to the failure of a condition set forth
in Section 7.03(a) or 7.03(b) and (ii) is not reasonably capable of being
cured by Valeant by the End Date or is not cured by Valeant within forty-five
days after receiving written notice from Biovail (provided that Biovail is not
then in breach of any covenant or agreement contained in this Agreement and no
representation or warranty of Biovail contained herein then fails to be true
and correct such that the conditions set forth in Section 7.02(a) or 7.02(b)
could not then be satisfied);

  

  

  

 

 

 

  

 

92  

  

 

 

 

  

  

  

(e) by Valeant, in the event that a Biovail Adverse Recommendation Change
shall have occurred; provided that Valeant shall no longer be entitled to
terminate this Agreement pursuant to this Section 8.01(e) if the Biovail
Stockholder Approval is obtained at the Biovail Stockholders Meeting; or

  

  

(f) by Biovail, in the event that a Valeant Adverse Recommendation Change
shall have occurred; provided that Biovail shall no longer be entitled to
terminate this Agreement pursuant to this Section 8.01(f) if the Valeant
Stockholder Approval is obtained at the Valeant Stockholders Meeting.

  

  

The party desiring to terminate this Agreement pursuant to clause (b), (c),
(d), (e) or (f) of this Section 8.01 shall give written notice of such
termination to the other parties in accordance with Section 9.02, specifying
the provision of this Agreement pursuant to which such termination is
effected.

  

  

SECTION 8.02. Effect of Termination. In the event of termination of this
Agreement by either Biovail or Valeant as provided in Section 8.01, this
Agreement shall forthwith become void and have no effect, without any
liability or obligation on the part of Valeant or Biovail, other than Section
3.20, Section 4.20, the last sentence of Section 6.02, Section 6.06, this
Section 8.02 and Article IX, which provisions shall survive such termination,
and except in the case of fraud or any intentional misrepresentation by a
party or any intentional breach by a party of any covenant or agreement set
forth in this Agreement.

  

  

SECTION 8.03. Amendment. This Agreement may be amended by the parties at any
time before or after receipt of the Biovail Stockholder Approval or the
Valeant Stockholder Approval; provided, however, that (i) after receipt of the
Biovail Stockholder Approval, there shall be made no amendment that by Law
requires further approval by the stockholders of Biovail without the further
approval of such stockholders, (ii) after receipt of the Valeant Stockholder
Approval, there shall be made no amendment that by Law requires further
approval by the stockholders of Valeant without the further approval of such
stockholders, (iii) no amendment shall be made to this Agreement after the
Effective Time and (iv) except as provided above, no amendment of this
Agreement shall require the approval of the stockholders of Biovail or the
stockholders of Valeant. This Agreement may not be amended except by an
instrument in writing signed on behalf of each of the parties.

  

  

SECTION 8.04. Extension; Waiver. At any time prior to the Effective Time, the
parties may (a) extend the time for the performance of any of the obligations
or other acts of the other parties, (b) waive any inaccuracies in the
representations and warranties contained in this Agreement or in any document
delivered pursuant to this Agreement, (c) waive compliance with any covenants
and agreements contained in this Agreement or (d) waive the satisfaction of
any of the conditions contained in this Agreement. No extension or waiver by
Biovail shall require the approval of the stockholders of Biovail unless such
approval is required by Law and no extension or waiver by Valeant shall
require the approval of the stockholders of Valeant unless such approval is
required by Law. Any agreement on the part of a party to any such extension or
waiver shall be valid only if set forth in an instrument in writing signed on
behalf of such party. The failure of any party to this Agreement to assert any
of its rights under this Agreement or otherwise shall not constitute a waiver
of such rights.

  

  

  

 

 

 

  

 

93  

  

 

 

 

  

  

  

SECTION 8.05. Procedure for Termination, Amendment, Extension or Waiver. A
termination of this Agreement pursuant to Section 8.01, an amendment of this
Agreement pursuant to Section 8.03 or an extension or waiver pursuant to
Section 8.04 shall, in order to be effective, require, in the case of Valeant,
Biovail, BAC or Merger Sub, action by its Board of Directors or the duly
authorized designee of its Board of Directors. Termination of this Agreement
prior to the Effective Time shall not require the approval of the stockholders
of Biovail or Valeant.

  

  

SECTION 8.06. Alternative Structure. The parties hereby agree to cooperate in
the consideration of alternative structures to implement the transactions
contemplated by this Agreement as long as there is no change in the economic
terms thereof and such alternative structure does not impose any material
delay on, or condition to, the consummation of the Merger, or adversely affect
any of the parties hereto or either Biovail's or Valeant's stockholders or
result in additional liability to Biovail's or Valeant's directors or
officers.

  

  

  

ARTICLE IX

  

  

General Provisions

  

  

SECTION 9.01. Nonsurvival of Representations and Warranties. None of the
representations and warranties in this Agreement or in any instrument
delivered pursuant to this Agreement shall survive the Effective Time. This
Section 9.01 shall not limit Section 8.02 or any covenant or agreement of the
parties which by its terms contemplates performance after the Effective Time.

  

  

SECTION 9.02. Notices. All notices, requests, claims, demands and other
communications under this Agreement shall be in writing and shall be deemed
given upon receipt by the parties at the following addresses (or at such other
address for a party as shall be specified by like notice):

  

  

  

 

 

 

  

 

94  

  

 

 

 

  

  

  

(a) if to Valeant, to:

  

  

Valeant Pharmaceuticals International

  

One Enterprise

  

Aliso Viejo, California 92656

  

Phone: (973) 549-5292

  

Facsimile: (949) 315-3818

  

  

Attention: Steve T. Min

  

  

with a copy to:

  

  

Skadden, Arps, Slate, Meagher and Flom LLP

  

Four Times Square

  

New York, New York 10036

  

Phone: (212) 735-3000

  

Facsimile: (212) 735-2000

  

  

Attention: Stephen F. Arcano, Esq.

  

Jeffrey A. Brill, Esq.

  

  

(b) if to Biovail, BAC or Merger Sub, to:

  

  

Biovail Corporation

  

7150 Mississauga Road

  

Mississauga, Ontario

  

L5N 8M5

  

Phone: (905) 286-3202

  

Facsimile: (905) 286-3061

  

  

Attention: Gregory Gubitz

  

  


 

  

with a copy to:

  

  

Cravath, Swaine and Moore LLP

  

Worldwide Plaza

  

825 Eighth Avenue

  

New York, New York 10019

  

Phone: (212) 474-1000

  

Facsimile: (212) 474-3700

  

  

Attention: Erik R. Tavzel, Esq.

  

Eric L. Schiele, Esq.

  

  

  

 

 

 

  

 

95  

  

 

 

 

  

  

  

SECTION 9.03. Definitions. For purposes of this Agreement:

  

  

An "Affiliate" of any Person means another Person that directly or indirectly,
through one or more intermediaries, controls, is controlled by, or is under
common control with, such first Person; provided that neither ValueAct Capital
Master Fund L.P. ("ValueAct") nor any entity (other than Valeant or the
Valeant Subsidiaries) that directly or indirectly controls or is controlled by
ValueAct shall be deemed to be an "Affiliate" of Valeant.

  

  

"Biovail Benefit Agreement" means each employment, consulting, bonus,
incentive or deferred compensation, equity or equity-based compensation,
severance, change in control, retention, termination or other material
Contract between Biovail or any Biovail Subsidiary, on the one hand, and any
Biovail Personnel, on the other hand.

  

  

"Biovail Benefit Plan" means each (i) pension plan (as defined in Section 3(2)
of ERISA) or post-retirement or employment health or medical plan, program,
policy or arrangement, (ii) bonus, incentive or deferred compensation or
equity or equity-based compensation plan, program, policy or arrangement,
(iii) severance, change in control, retention or termination plan, program,
policy or arrangement or (iv) other material compensation, pension, retirement
savings or other benefit plan, program, policy or arrangement, in each case,
sponsored, maintained, contributed to or required to be maintained or
contributed to by Biovail, any Biovail Subsidiary or any Biovail Commonly
Controlled Entity for the benefit of any Biovail Personnel.

  

  

"Biovail Commonly Controlled Entity" means any person or entity, other than
Biovail and the Biovail Subsidiaries, that, together with Biovail, is treated
as a single employer under Section 414 of the Code.

  

  

"Biovail Deferred Share Unit" means any deferred share unit payable in shares
of Biovail Common Stock or the value of which is determined with reference to
the value of shares of Biovail Common Stock, whether granted under any Biovail
Stock Plan or otherwise.

  

  

"Biovail Material Adverse Effect" means a Material Adverse Effect with respect
to Biovail.

  

  

"Biovail Personnel" means any current or former director, officer or employee
of Biovail or any Biovail Subsidiary.

  

  

"Biovail Product" means any biological, drug or consumer product being tested
in clinical trials, manufactured, sold or distributed by Biovail or any of the
Biovail Subsidiaries.

  

  

"Biovail Restricted Stock Unit" means any restricted stock unit payable in
shares of Biovail Common Stock or the value of which is determined with
reference to the value of shares of Biovail Common Stock, whether granted
under any Biovail Stock Plan or otherwise.

  

  

  

 

 

 

  

 

96  

  

 

 

 

  

  

  

"Biovail Stock Option" means any option to purchase Biovail Common Stock,
whether granted under any Biovail Stock Plan or otherwise.

  

  

"Biovail Stock Plans" means the Biovail 2007 Equity Compensation Plan, the
Biovail 2004 Stock Option Plan, the Biovail 1993 Stock Option Plan, the
Biovail Deferred Share Unit Plan for Canadian Directors, the Biovail Deferred
Share Unit Plan for U.S. Directors and the Biovail Laboratories International
SRL Deferred Share Unit Plan.

  

  

"Business Day" means any day other than (i) a Saturday or a Sunday or (ii) a
day on which banking and savings and loan institutions are authorized or
required by Law to be closed in New York City.

  

  

"Code" means the Internal Revenue Code of 1986, as amended.

  

  

"Combined Company" means Valeant, the Valeant Subsidiaries, Biovail and the
Biovail Subsidiaries, taken as a whole, combined in the manner currently
intended by the parties.

  

  

"Combined Company Material Adverse Effect" means a Material Adverse Effect
with respect to the Combined Company.

  

  

"Equity Award Exchange Ratio" means 1.7809.

  

  

"ERISA" means the Employee Retirement Income Security Act of 1974, as amended.

  

  

"Indebtedness" means, with respect to any Person, without duplication, (i) all
obligations of such Person for borrowed money, or with respect to deposits or
advances of any kind to such Person, (ii) all obligations of such Person
evidenced by bonds, debentures, notes or similar instruments, (iii) all
capitalized lease obligations of such Person, (iv) all guarantees and
arrangements having the economic effect of a guarantee of such Person of any
Indebtedness of any other Person, or (v) all obligations or undertakings of
such Person to maintain or cause to be maintained the financial position or
covenants of others or to purchase the obligations or property of others.

  

  

The "Knowledge" of any Person that is not an individual means, with respect to
any matter in question, the actual knowledge of the individuals set forth in
Section 9.03 of the Valeant Disclosure Letter or Section 9.03 of the Biovail
Disclosure Letter, as applicable, after having made due inquiry of those
persons reporting directly to such individual, but without further
investigation by such individual.

  

  

  

 

 

 

  

 

97  

  

 

 

 

  

  

  

"Material Adverse Effect" with respect to any Person means any fact,
circumstance, effect, change, event or development that materially adversely
affects the business, properties, financial condition or results of operations
of such Person and its Subsidiaries, taken as a whole, excluding any effect
that results from or arises in connection with (i) changes or conditions
generally affecting the industries in which such Person and any of its
Subsidiaries operate, except to the extent such effect has a materially
disproportionate effect on such Person and its Subsidiaries, taken as a whole,
relative to others in the industries in which such Person and any of its
Subsidiaries operate, (ii) general economic or regulatory, legislative or
political conditions or securities, credit, financial or other capital markets
conditions, in each case in the United States, Canada or any foreign
jurisdiction, except to the extent such effect has a materially
disproportionate effect on such Person and its Subsidiaries, taken as a whole,
relative to others in the industries in which such Person and any of its
Subsidiaries operate, (iii) any failure, in and of itself, by such Person to
meet any internal or published projections, forecasts, estimates or
predictions in respect of revenues, earnings or other financial or operating
metrics for any period (it being understood that the facts or occurrences
giving rise to or contributing to such failure may be deemed to constitute, or
be taken into account in determining whether there has been or will be, a
Material Adverse Effect), (iv) the execution and delivery of this Agreement or
the public announcement or pendency of the Merger or any of the other
transactions contemplated by this Agreement, including the impact thereof on
the relationships, contractual or otherwise, of such Person or any of its
Subsidiaries with employees, labor unions, customers, suppliers or partners,
(v) any change, in and of itself, in the market price, credit rating or
trading volume of such Person's securities (it being understood that the facts
or occurrences giving rise to or contributing to such change may be deemed to
constitute, or be taken into account in determining whether there has been or
will be, a Material Adverse Effect), (vi) any change in applicable Law,
regulation or GAAP (or authoritative interpretation thereof), except to the
extent such effect has a materially disproportionate effect on such Person and
its Subsidiaries, taken as a whole, relative to others in the industries in
which such Person and any of its Subsidiaries operate, (vii) geopolitical
conditions, the outbreak or escalation of hostilities, any acts of war,
sabotage or terrorism, or any escalation or worsening of any such acts of war,
sabotage or terrorism threatened or underway as of the date of this Agreement
or (viii) any hurricane, tornado, flood, earthquake or other natural disaster.

  

  

"Person" means any natural person, firm, corporation, partnership, company,
limited liability company, trust, joint venture, association, Governmental
Entity or other entity.

  

  

"Post-Merger Special Dividend" means, subject to the discretion of the Board
of the Combined Company and to applicable Law, an amount contemplated to be
$1.00 per share of Biovail Common Stock, payable to holders of record of
Biovail Common Stock on December 1, 2010 and contemplated to be paid on
December 31, 2010, or such other record date and payment date as the Board of
the Combined Company shall determine (subject to customary adjustments for any
stock dividend, subdivision, reclassification, recapitalization, split,
combination, exchange of shares or similar event).

  

  

  

 

 

 

  

 

98  

  

 

 

 

  

  

  

"Pre-Merger Special Dividend Adjustment Ratio" means 1.5710.

  

  

"Pre-Merger Special Dividend Time" means the time at which payment of the Pre-
Merger Special Dividend occurs.

  

  

A "Subsidiary" of any Person means another Person, an amount of the voting
securities, other voting ownership or voting partnership interests of which is
sufficient to elect at least a majority of its Board of Directors or other
governing body (or, if there are no such voting interests, more than 50% of
the equity interests of which) is owned directly or indirectly by such first
Person.

  

  

"Tax Return" means all Tax returns, declarations, statements, reports,
schedules, forms and information returns and any amended Tax return relating
to Taxes.

  

  

"Taxes" means all taxes, customs, tariffs, imposts, levies, duties, fees or
other like assessments or charges of any kind imposed by a Governmental
Entity, together with all interest, penalties and additions imposed with
respect to such amounts.

  

  

"Valeant Benefit Agreement" means each employment, consulting, bonus,
incentive or deferred compensation, equity or equity-based compensation,
severance, change in control, retention, termination or other material
Contract between Valeant or any Valeant Subsidiary, on the one hand, and any
Valeant Personnel, on the other hand.

  

  

"Valeant Benefit Plan" means each (i) pension plan (as defined in Section 3(2)
of ERISA) or post-retirement or employment health or medical plan, program,
policy or arrangement, (ii) bonus, incentive or deferred compensation or
equity or equity-based compensation plan, program, policy or arrangement,
(iii) severance, change in control, retention or termination plan, program,
policy or arrangement or (iv) other material compensation, pension, retirement
savings or other benefit plan, program, policy or arrangement, in each case,
sponsored, maintained, contributed to or required to be maintained or
contributed to by Valeant, any Valeant Subsidiary or any Valeant Commonly
Controlled Entity for the benefit of any Valeant Personnel.

  

  

"Valeant Commonly Controlled Entity" means any person or entity, other than
Valeant and the Valeant Subsidiaries, that, together with Valeant, is treated
as a single employer under Section 414 of the Code.

  

  

"Valeant ESPP" means the Valeant 2009 Employee Stock Purchase Plan.

  

  

"Valeant Material Adverse Effect" means a Material Adverse Effect with respect
to Valeant.

  

  

  

 

 

 

  

 

99  

  

 

 

 

  

  

"Valeant Personnel" means any current or former director, officer or employee
of Valeant or any Valeant Subsidiary.

  

  

"Valeant Product" means any biological, drug or consumer product being tested
in clinical trials, manufactured, sold or distributed by Valeant or any of the
Valeant Subsidiaries.

  

  

"Valeant Restricted Stock Unit" means any restricted stock unit payable in
shares of Valeant Common Stock or the value of which is determined with
reference to the value of shares of Valeant Common Stock, whether granted
under any Valeant Stock Plan or otherwise.

  

  

"Valeant Stock Option" means any option to purchase Valeant Common Stock,
whether granted under any Valeant Stock Plan or otherwise.

  

  

"Valeant Stock Plans" means the Valeant 2006 Equity Incentive Plan and the
Valeant 2003 Equity Incentive Plan.

  

  

SECTION 9.04. Interpretation. When a reference is made in this Agreement to an
Article or a Section, such reference shall be to an Article or a Section of
this Agreement unless otherwise indicated. The table of contents, index of
defined terms and headings contained in this Agreement are for reference
purposes only and shall not affect in any way the meaning or interpretation of
this Agreement. Any capitalized term used in any Exhibit but not otherwise
defined therein shall have the meaning assigned to such term in this
Agreement. Whenever the words "include", "includes" or "including" are used in
this Agreement, they shall be deemed to be followed by the words "without
limitation". The words "hereof", "hereto", "hereby", "herein" and "hereunder"
and words of similar import when used in this Agreement shall refer to this
Agreement as a whole and not to any particular provision of this Agreement.
The term "or" is not exclusive. The word "extent" in the phrase "to the
extent" shall mean the degree to which a subject or other thing extends, and
such phrase shall not mean simply "if". The definitions contained in this
Agreement are applicable to the singular as well as the plural forms of such
terms. Any agreement, instrument or Law defined or referred to herein means
such agreement, instrument or Law as from time to time amended, modified or
supplemented, unless otherwise specifically indicated. References to a person
are also to its permitted successors and assigns. Unless otherwise
specifically indicated, all references to "dollars" and "$" will be deemed
references to the lawful money of the United States of America.

  

  

SECTION 9.05. Severability. If any term or other provision of this Agreement
is invalid, illegal or incapable of being enforced by any rule or Law, or
public policy, all other conditions and provisions of this Agreement shall
nevertheless remain in full force and effect so long as the economic or legal
substance of the transactions contemplated hereby is not affected in any
manner materially adverse to any party or such party waives its rights under
this Section 9.05 with respect thereto. Upon such determination that any term
or other provision is invalid, illegal or incapable of being enforced, the
parties hereto shall negotiate in good faith to modify this Agreement so as to
effect the original intent of the parties as closely as possible in an
acceptable manner to the end that transactions contemplated by this Agreement
are fulfilled to the extent possible.

  

  

  

 

 

 

  

 

100  

  

 

 

 

  

  

  

SECTION 9.06. Counterparts. This Agreement may be executed in one or more
counterparts, all of which shall be considered one and the same agreement, and
shall become effective when one or more counterparts have been signed by each
of the parties and delivered to the other parties.

  

  

SECTION 9.07. Entire Agreement; No Third-Party Beneficiaries. This Agreement,
taken together with the Biovail Disclosure Letter, the Valeant Disclosure
Letter and the Confidentiality Agreement, (a) constitutes the entire
agreement, and supersedes all prior agreements and understandings, both
written and oral, between the parties with respect to the Merger and the other
transactions contemplated by this Agreement and (b) except for Section 6.05,
is not intended to confer upon any Person other than the parties any rights or
remedies.

  

  

SECTION 9.08. GOVERNING LAW. THIS AGREEMENT SHALL BE GOVERNED BY, AND
CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF DELAWARE, REGARDLESS OF
THE LAWS THAT MIGHT OTHERWISE GOVERN UNDER ANY APPLICABLE PRINCIPLES OF
CONFLICTS OF LAWS OF THE STATE OF DELAWARE.

  

  

SECTION 9.09. Assignment. Neither this Agreement nor any of the rights,
interests or obligations under this Agreement shall be assigned, in whole or
in part, by operation of Law or otherwise by any of the parties without the
prior written consent of the other parties. Any purported assignment without
such consent shall be void. Subject to the preceding sentences, this Agreement
will be binding upon, inure to the benefit of, and be enforceable by, the
parties and their respective successors and assigns.

  

  

SECTION 9.10. Specific Enforcement. The parties acknowledge and agree that
irreparable damage would occur in the event that any of the provisions of this
Agreement were not performed in accordance with their specific terms or were
otherwise breached, and that monetary damages, even if available, would not be
an adequate remedy therefor. It is accordingly agreed that, prior to the
termination of this Agreement pursuant to Article VIII, the parties shall be
entitled to an injunction or injunctions to prevent breaches of this Agreement
and to enforce specifically the performance of terms and provisions of this
Agreement in any court referred to in clause (a) below, without proof of
actual damages (and each party hereby waives any requirement for the securing
or posting of any bond in connection with such remedy), this being in addition
to any other remedy to which they are entitled at law or in equity. The
parties further agree not to assert that a remedy of specific enforcement is
unenforceable, invalid, contrary to Law or inequitable for any reason, nor to
assert that a remedy of monetary damages would provide an adequate remedy for
any such breach. In addition, each of the parties hereto (a) consents to
submit itself to the personal jurisdiction of any Delaware state court or any
Federal court located in the State of Delaware in the event any dispute arises
out of this Agreement, the Merger or any of the other transactions
contemplated by this Agreement, (b) agrees that it will not attempt to deny or
defeat such personal jurisdiction by motion or other request for leave from
any such court and (c) agrees that it will not bring any action relating to
this Agreement, the Merger or any of the other transactions contemplated by
this Agreement in any court other than any Delaware state court or any Federal
court sitting in the State of Delaware.

  

  

  

 

 

 

  

 

101  

  

 

 

 

  

  

  

SECTION 9.11. Waiver of Jury Trial. Each party hereto hereby waives, to the
fullest extent permitted by applicable Law, any right it may have to a trial
by jury in respect of any suit, action or other proceeding arising out of this
Agreement, the Merger or any of the other transactions contemplated by this
Agreement. Each party hereto (a) certifies that no representative, agent or
attorney of any other party has represented, expressly or otherwise, that such
party would not, in the event of any action, suit or proceeding, seek to
enforce the foregoing waiver and (b) acknowledges that it and the other
parties hereto have been induced to enter into this Agreement by, among other
things, the mutual waiver and certifications in this Section 9.11.

  

  


 

  

[Remainder of page left intentionally blank]

  

  

  

 

 

 

  

 

102  

  

 

 

 

  


 

  

IN WITNESS WHEREOF, Valeant, Biovail, BAC and Merger Sub have duly executed
this Agreement, both as of the date first written above.

  

  

  

 

    

VALEANT PHARMACEUTICALS INTERNATIONAL,

   
--- 
    
  

by

   
   |  

/s/ J. Michael Pearson

   
   |  

Name: J. Michael Pearson

   
   |  

Title: Chief Executive Officer

   
 

  

  

  

 

    

BIOVAIL CORPORATION,

   
--- 
    
  

by

   
   |  

/s/ William M. Wells

   
   |  

Name: William M. Wells

   
   |  

Title: Chief Executive Officer

   
 

  

  

  

 

    

BIOVAIL AMERICAS CORP.,

   
--- 
    
  

by

   
   |  

/s/ Gilbert Godin

   
   |  

Name: Gilbert Godin

   
   |  

Title: President

   
 

  

  

  

 

    

BEACH MERGER CORP.,

   
--- 
    
  

by

   
   |  

/s/ William M. Wells

   
   |  

Name: William M. Wells

   
   |  

Title: President

   
 

  

  

  

 

 

 

  

 

103  

  

 

 

 

  

  

 

 

 

 

  

Index of Defined Terms

  

  

   Term |  | Section   
---|---|--- 
   |   
  

Accelerated RSU

  |  

6.04(b)

   
  

Accelerated Valeant RSU Shares

  |  

6.04(b)

   
  

Acquisition Agreement

  |  

5.02(b)

   
  

Affiliate

  |  

9.03

   
  

Agreement

  |  

Preamble

   
  

Appraisal Shares

  |  

2.01(d)

   
  

BAC

  |  

Preamble

   
  

Biovail

  |  

Preamble

   
  

Biovail Adverse Recommendation Change

  |  

5.02(b)

   
  

Biovail Benefit Agreement

  |  

9.03

   
  

Biovail Benefit Plan

  |  

9.03

   
  

Biovail Board

  |  

3.04(a)

   
  

Biovail By-laws

  |  

3.01

   
  

Biovail Capital Stock

  |  

3.03(a)

   
  

Biovail Charter

  |  

3.01

   
  

Biovail Class A Stock

  |  

3.03(a)

   
  

Biovail Common Stock

  |  

2.01(c)

   
  

Biovail Commonly Controlled Entity

  |  

9.03

   
  

Biovail Convertible Notes

  |  

3.03(a)

   
  

Biovail Deferred Share Unit

  |  

9.03

   
  

Biovail Disclosure Letter

  |  

Article III

   
  

Biovail Financial Advisor

  |  

3.20

   
  

Biovail Indemnitees

  |  

6.05(b)

   
  

Biovail Intervening Event

  |  

5.02(b)

   
  

Biovail Material Adverse Effect

  |  

9.03

   
  

Biovail Material Contract

  |  

3.14(b)

   
  

Biovail Notice of Recommendation Change

  |  

5.02(b)

   
  

Biovail Permits

  |  

3.01

   
  

Biovail Personnel

  |  

9.03

   
  

Biovail Product

  |  

9.03

   
  

Biovail Regulatory Agency

  |  

3.17(a)

   
  

Biovail Regulatory Permits

  |  

3.17(a)

   
  

Biovail Reporting Documents

  |  

3.06(a)

   
  

Biovail Restricted Stock Unit

  |  

9.03

   
  

Biovail-selected Directors

  |  

Exhibit A

   
  

Biovail Stock Option

  |  

9.03

   
  

Biovail Stock Plans

  |  

9.03

   
  

Biovail Stockholder Approval

  |  

3.04(a)

   
  

Biovail Stockholders Meeting

  |  

3.04(a)

   
  

Biovail Subsidiaries

  |  

3.01(a)

   
  

Biovail Takeover Proposal

  |  

5.02(e)

   
  

Biovail Termination Fee

  |  

6.06(b)

   
  

Biovail Voting Debt

  |  

3.03(b)

   
  

Business Day

  |  

9.03

   
  

Canadian Securities Authorities

  |  

3.05(b)

   
  

Canadian Securities Laws

  |  

3.05(b)

   
  

CBCA

  |  

3.03(b)

   
  

CDSA

  |  

3.17(a)

   
 

  

  

  

 

 

 

  

   

  

 

 

 

  


 

  

    

Certificate

  |  

2.01(c)

   
---|--- 
  

Certificate of Merger

  |  

1.03

   
  

chief executive officer

  |  

3.06(d)

   
  

chief financial officer

  |  

3.06(d)

   
  

Closing

  |  

1.02

   
  

Closing Date

  |  

1.02

   
  

Code

  |  

9.03

   
  

Combined Company

  |  

9.03

   
  

Combined Company Material Adverse Effect

  |  

9.03

   
  

Commissioner

  |  

7.01(c)

   
  

Commitment Letter

  |  

6.11(a)

   
  

Competition Act

  |  

3.05(b)

   
  

Confidentiality Agreement

  |  

6.02

   
  

Consent

  |  

3.05(b)

   
  

Contract

  |  

3.05(a)

   
  

Converted Shares

  |  

2.01(a)

   
  

DGCL

  |  

1.01

   
  

Effective Time

  |  

1.03

   
  

End Date

  |  

8.01(b)

   
  

Environmental Claim

  |  

3.13(b)

   
  

Environmental Laws

  |  

3.13(b)

   
  

Equity Award Exchange Ratio

  |  

9.03

   
  

ERISA

  |  

9.03

   
  

Exchange Act

  |  

3.05(b)

   
  

Exchange Agent

  |  

2.02(a)

   
  

Exchange Fund

  |  

2.02(a)

   
  

Exchange Ratio

  |  

2.01(c)

   
  

FCPA

  |  

3.12

   
  

FDA

  |  

3.17(a)

   
  

FDCA

  |  

3.17(a)

   
  

Filed Biovail Contract

  |  

3.14(a)

   
  

Filed Biovail Reporting Documents

  |  

Article III

   
  

Filed Valeant Contract

  |  

4.14(a)

   
  

Filed Valeant Reporting Documents

  |  

Article IV

   
  

Financing

  |  

6.11(a)

   
  

Financing Sources

  |  

6.11(a)

   
  

Food and Drug Act

  |  

3.17(a)

   
  

Form S-4

  |  

3.05(b)

   
  

GAAP

  |  

3.06(b)

   
  

Governmental Entity

  |  

3.05(b)

   
  

Hazardous Materials

  |  

3.13(b)

   
  

HSR Act

  |  

3.05(b)

   
  

Indebtedness

  |  

9.03

   
  

Income Tax Act

  |  

3.10(e)

   
  

Indemnitees

  |  

6.05(c)

   
  

Intellectual Property

  |  

3.16(a)

   
  

Intended Tax Treatment

  |  

Recitals

   
  

Issued Shares

  |  

2.01(a)

   
  

Joinder Agreement

  |  

6.14

   
  

Joint Proxy Statement

  |  

6.01(a)

   
  

Judgment

  |  

3.05(a)

   
  

Knowledge

  |  

9.03

   
  

Law

  |  

3.05(a)

   
 

  


 

  

 

 

 

  

   

  

 

 

 

  

  

  

    

Legal Restraints

  |  

7.01(d)

   
---|--- 
  

Liens

  |  

3.02(a)

   
  

Material Adverse Effect

  |  

9.03

   
  

material weakness

  |  

3.06(h)

   
  

Merger

  |  

1.01

   
  

Merger Consideration

  |  

2.01(c)

   
  

Merger Sub

  |  

Preamble

   
  

Merger Sub Common Stock

  |  

2.01(a)

   
  

Name Change

  |  

3.04(a)

   
  

New Independent Director

  |  

Exhibit A

   
  

New Merger Sub

  |  

6.14

   
  

No-Action Letter

  |  

7.01(c)

   
  

NYSE

  |  

2.02(e)

   
  

Permits

  |  

3.01

   
  

Person

  |  

9.03

   
  

PHSA

  |  

3.17(a)

   
  

Post-Merger Special Dividend

  |  

9.03

   
  

Pre-Merger Special Dividend

  |  

6.17

   
  

Pre-Merger Special Dividend Adjustment Ratio

  |  

9.03

   
  

Pre-Merger Special Dividend Time

  |  

9.03

   
  

Release

  |  

3.13(b)

   
  

Representatives

  |  

5.02(a)

   
  

SEC

  |  

3.05(b)

   
  

Section 262

  |  

2.01(d)

   
  

Securities Act

  |  

3.05(b)

   
  

Share Issuance

  |  

3.04(a)

   
  

Single Trigger RSU

  |  

6.04(b)

   
  

significant deficiency

  |  

3.06(h)

   
  

SOX

  |  

3.06(b)

   
  

Subsidiary

  |  

9.03

   
  

Superior Biovail Proposal

  |  

5.02(e)

   
  

Superior Valeant Proposal

  |  

5.03(e)

   
  

Surviving Company

  |  

1.01

   
  

Surviving Company Common Stock

  |  

2.01(a)

   
  

Tax Return

  |  

9.03

   
  

Taxes

  |  

9.03

   
  

TSX

  |  

3.04(a)

   
  

Valeant

  |  

Preamble

   
  

Valeant 3.0% Convertible Notes

  |  

4.03(a)

   
  

Valeant Adverse Recommendation Change

  |  

5.03(b)

   
  

Valeant Adjusted PSU

  |  

6.04(c)

   
  

Valeant Adjusted PSU Shares

  |  

6.04(c)

   
  

Valeant Benefit Agreement

  |  

9.03

   
  

Valeant Benefit Plan

  |  

9.03

   
  

Valeant Board

  |  

4.04(a)

   
  

Valeant Board Nomination Agreement

  |  

4.03(c)

   
  

Valeant By-laws

  |  

4.01

   
  

Valeant Capital Stock

  |  

4.03(a)

   
  

Valeant Charter

  |  

4.01

   
  

Valeant Common Stock

  |  

2.01(b)

   
  

Valeant Commonly Controlled Entity

  |  

9.03

   
  

Valeant Convertible Notes

  |  

4.03(a)

   
  

Valeant Convertible Notes Indenture

  |  

4.03(b)

   
 

  


 

  

  

 

 

 

  

   

  

 

 

 

  


 

  

    

Valeant Disclosure Letter

  |  

Article IV

   
---|--- 
  

Valeant ESPP

  |  

9.03

   
  

Valeant Financial Advisors

  |  

4.20

   
  

Valeant Indemnitees

  |  

6.05(c)

   
  

Valeant Intervening Event

  |  

5.03(b)

   
  

Valeant Material Adverse Effect

  |  

9.03

   
  

Valeant Material Contract

  |  

4.14(b)

   
  

Valeant Notice of Recommendation Change

  |  

5.03(b)

   
  

Valeant Performance-Based Restricted Stock Unit

  |  

6.04(c)

   
  

Valeant Permits

  |  

4.01

   
  

Valeant Personnel

  |  

9.03

   
  

Valeant Preferred Stock

  |  

4.03(a)

   
  

Valeant Product

  |  

9.03

   
  

Valeant Regulatory Agency

  |  

4.17(a)

   
  

Valeant Regulatory Permits

  |  

4.17(a)

   
  

Valeant Reporting Documents

  |  

4.06(a)

   
  

Valeant Restricted Stock Unit

  |  

9.03

   
  

Valeant Stock Option

  |  

9.03

   
  

Valeant Stock Plan Assumption

  |  

6.04(e)

   
  

Valeant Stock Plans

  |  

9.03

   
  

Valeant Stockholder Approval

  |  

4.04(a)

   
  

Valeant Stockholders Meeting

  |  

4.04(a)

   
  

Valeant Subsidiaries

  |  

4.01

   
  

Valeant Takeover Proposal

  |  

5.03(e)

   
  

Valeant Time-Based Restricted Stock Units

  |  

6.04(b)

   
  

Valeant Termination Fee

  |  

6.06(c)

   
  

Valeant Voting Debt

  |  

4.03(c)

   
  

Valeant Warrants

  |  

4.03(a)

   
  

Valeant-selected Directors

  |  

Exhibit A

   
 

  

  

  

 

 

 

  

   

  

 

 

 

  

  

  

EXHIBIT A

  


 

  

Governance Matters

  


 

  

(a) Biovail shall take all necessary action to cause, effective at the
Effective Time, William M. Wells to be appointed as non-executive Chairman of
the Board of the Combined Company. If Mr. William M. Wells is not a member of
the Biovail Board immediately prior to the Effective Time, Valeant and Biovail
shall agree upon a replacement from the Biovail Board to be appointed non-
executive Chairman of the Board of the Combined Company at the Effective Time.

  

  

(b) Biovail shall take all necessary action to cause, effective at the
Effective Time, J. Michael Pearson to be appointed the Chief Executive Officer
of the Combined Company. If Mr. Pearson is not the Chief Executive Officer of
Valeant immediately prior to the Effective Time, Valeant and Biovail shall
agree upon a replacement to be appointed Chief Executive Officer of the
Combined Company at the Effective Time.

  

  

(c) Biovail shall take all necessary action to cause, effective at the
Effective Time, Robert A. Ingram to be appointed as Lead Director of the Board
of the Combined Company. If Mr. Ingram is not a member of the Valeant Board
immediately prior to the Effective Time, Valeant and Biovail shall agree upon
a replacement from the Valeant Board to be appointed Lead Director of the
Board of the Combined Company at the Effective Time.

  

  

(d) Biovail shall take all necessary action to cause, effective at the
Effective Time, Michael R. Van Every, a resident Canadian (as defined under
the Canada Business Corporations Act), to continue as Chairman of the Audit
Committee of the Board of the Combined Company. If Mr. Van Every is not a
member of the Biovail Board immediately prior to the Effective Time, Valeant
and Biovail shall agree upon a replacement from the Biovail Board to be
appointed Chairman of the Audit Committee of the Board of the Combined Company
at the Effective Time.

  

  

(e) Biovail shall take all necessary action to cause, effective at the
Effective Time, the Board of the Combined Company to consist of (i) the four
individuals listed above, (ii) three directors selected by Biovail (together
with Mr. Van Every (or his replacement), the "Biovail-selected Directors"),
one of whom is a resident Canadian (as defined under the Canada Business
Corporations Act), (iii) three directors selected by Valeant (together with
Mr. Ingram (or his replacement), the "Valeant-selected Directors"), and (iv)
one independent director who is recruited by a search firm that is mutually
retained by Biovail and Valeant, which director (A) shall be selected by
Valeant from a list of candidates presented by such firm, (B) shall be subject
to the approval of Biovail and (C) shall be a resident Canadian (as defined
under the Canada Business Corporations Act) (the "New Independent Director").

  

  

(f) Biovail shall take all necessary action to cause, effective at the
Effective Time, the Chairman of the Compensation Committee of the Board of the
Combined Company to be a Biovail-selected Director. Biovail shall take all
necessary action to cause, effective at the Effective Time, the Chairman of
each of the Risk and Compliance Committee and the Nominating and Corporate
Governance Committee to be a Valeant-selected Director.

  

  

  

 

 

 

  

 

A-1  

  

 

 

 

  

  

  

(g) Biovail shall take all necessary action to cause, effective at the
Effective Time, each committee of the Board of the Combined Company (other
than the Compensation Committee) to have an equal number of Valeant-selected
Directors and Biovail-selected Directors as members, provided that such
committees may also include the New Independent Director.

  

  

(h) Biovail shall take all necessary action to cause, effective at the
Effective Time, the Compensation Committee of the Board of the Combined
Company to consist of only three members, and Biovail shall take all necessary
action to cause, effective at the Effective Time, two of the members of the
Compensation Committee of the Board of the Combined Company to be Valeant-
selected Directors.

  

  

(i) No committee of the Board of the Combined Company other than those
identified in this Exhibit A shall be formed prior to the first meeting of the
Biovail Board following such time as the Valeant-selected Directors are
appointed to the Board of the Combined Company without the written consent of
Valeant.

  

  

  

 

 

 

  

 

A-2  

  

 

 

 

  

  

  

EXHIBIT B

  


 

  

Form of Joinder Agreement

  

  


 

  

 

 

 

  

 

B-1  

  

 

 

 

  


 

  

  

JOINDER AGREEMENT (this "Agreement"), dated as of [*], 2010, among Valeant
Pharmaceuticals International, a Delaware corporation ("Valeant"), Biovail
Corporation, a Canadian corporation ("Biovail"), and [New Merger Sub], a
Delaware corporation ("New Merger Sub").

  

  

  

WHEREAS, Section 6.14 of the Agreement and Plan of Merger (the "Merger
Agreement"), dated as of June 20, 2010, between Valeant, Biovail, Biovail
Americas Corp., a Delaware corporation, and Beach Merger Corp., a Delaware
corporation ("Merger Sub"), contemplates that New Merger Sub will become a
party to the Merger Agreement; and

  

  

  

WHEREAS, Valeant, Biovail and New Merger Sub have agreed that New Merger Sub
will become a party to the Merger Agreement.

  

  

  

NOW, THEREFORE, in consideration of the foregoing, the parties hereto agree as
follows:

  

  

  

SECTION 1.01. Each capitalized term used but not defined herein shall has the
meaning assigned to it in the Merger Agreement.

  

  

  

SECTION 1.02. All references in the Merger Agreement to "Merger Sub" shall be
deemed to refer to "New Merger Sub."

  

  

  

SECTION 1.02. Biovail and New Merger Sub jointly and severally represent and
warrant to Valeant that the statements contained in this Section 1.03 are true
and correct:

  

  

  

(a) BAC is the sole stockholder of New Merger Sub. Since its date of
formation, New Merger Sub has not carried on any business nor conducted any
operations other than the execution of this Agreement, the performance of its
obligations under this Agreement and the Merger Agreement and matters
ancillary thereto.

  

  

  

(b) New Merger Sub has all requisite corporate power and authority to execute
and deliver this Agreement, to perform its respective obligations under this
Agreement and the Merger Agreement and to consummate the Merger and the other
transactions contemplated by this Agreement and the Merger Agreement, subject,
in the case of the Share Issuance, to the receipt of the Biovail Stockholder
Approval and, in the case of the Merger, for the approval of this Agreement by
Biovail as the sole stockholder of New Merger Sub. The Board of Directors of
New Merger Sub has adopted resolutions, by unanimous written consent, (i)
approving this Agreement, (ii) determining that the terms of this Agreement
are in the best interests of New Merger Sub and Biovail, as its sole
stockholder, (iii) declaring this Agreement advisable and (iv) recommending
that Biovail, as sole stockholder of New Merger Sub, adopt this Agreement and
directing that this Agreement be submitted to Biovail, as sole stockholder of
New Merger Sub, for adoption. Such resolutions have not been amended or
withdrawn. Except (A) solely in the case of the Share Issuance, for the
Biovail Stockholder Approval and (B) solely in the case of the Merger, for the
adoption of the Joinder Agreement by Biovail as the sole stockholder of New
Merger Sub, no other corporate proceedings on the part of New Merger Sub are
necessary to authorize, adopt or approve, as applicable, this Agreement or to
consummate the Merger and the other transactions contemplated by this
Agreement and Merger Agreement (except for the filing of the appropriate
merger documents as required by the DGCL). New Merger Sub has duly executed
and delivered this Agreement and, assuming the due authorization, execution
and delivery by Biovail and Valeant, this Agreement constitutes its legal,
valid and binding obligation, enforceable against it in accordance with its
terms.

  

  

  

 

 

 

  

 

B-2  

  

 

 

 

  

  

  

SECTION 1.03. New Merger Sub hereby becomes a party to the Merger Agreement
with the same force and effect as if originally named as a party therein and
hereby agrees to all the terms and provisions of the Merger Agreement
applicable to it.

  

  

SECTION 1.04. This Agreement shall for all purposes be deemed to be a part of
the Merger Agreement and shall be subject to all of the provisions thereof.

  

  

[Remainder of page left intentionally blank]

  

  

  

  

  

  

  

  

  

 

 

 

  

 

B-3  

  

 

 

 

  

  

  

IN WITNESS WHEREOF, Valeant, Biovail and Merger Sub have duly executed this
Agreement, all as of the date first written above.

  

  

  

 

  

 

    

VALEANT PHARMACEUTICALS INTERNATIONAL,

   
--- 
    
  

by

   
   |   
   |  

Name:

   
   |  

Title:

   
 

  

  

  

 

    

BIOVAIL CORPORATION,

   
--- 
    
  

by

   
   |   
   |  

Name:

   
   |  

Title:

   
 

  

  

  

 

    

BIOVAIL AMERICAS CORP.,

   
--- 
    
  

by

   
   |   
   |  

Name:

   
   |  

Title:

   
 

  

  

  

 

    

BEACH MERGER CORP.,

   
--- 
    
  

by

   
   |   
   |  

Name:

   
   |  

Title:

   
 

  

 

 

 

  

  

  

  

  

  

B-4

  

  

  

  

 

 

 

  

   

  

 

 

 

 

 

 

  

  

  

  

  

 

EXHIBIT C

  

  

  

Commitent Letter

  

  

  

  

 

  

 

  

  

 

    

GOLDMAN SACHS BANK USA

  

GOLDMAN SACHS LENDING

  

PARTNERS LLC

  

200 West Street

  

New York, New York 10282

  |  

MORGAN STANLEY

  

SENIOR FUNDING, INC.

  

1585 Broadway

  

New York, New York 10036

  

  |  

JEFFERIES GROUP, INC.

  

520 Madison Avenue

  

New York, New York 10022

  

   
---|---|--- 
 

  


 

  


 

  

  

PERSONAL AND CONFIDENTIAL

  

  

June 20, 2010

  

  

Valeant Pharmaceuticals International

  

One Enterprise

  

Aliso Viejo, California 92656

  

Attention: Peter Blott

  


 

  

  

Biovail Corporation

  

7150 Mississauga Road

  

Mississauga, Ontario

  

L5N 8M5

  

Attention: Peggy Mulligan

  

  

Ladies and Gentlemen:

  

  

We are pleased to confirm the arrangements under which each of Goldman Sachs
Bank USA ("GS Bank"), Goldman Sachs Lending Partners LLC ("GSLP" and, together
with GS Bank, "Goldman Sachs"), Jefferies Group, Inc. ("Jefferies") and Morgan
Stanley Senior Funding, Inc. ("Morgan Stanley", and together with Goldman
Sachs and Jefferies, the "Commitment Parties") is exclusively authorized by
Valeant Pharmaceuticals International, a Delaware corporation (the "Company")
and Biovail Corporation, a Canadian corporation (together with its
subsidiaries, the "Merger Party" and, together with the Company, "you"), to
act as joint lead arranger, joint bookrunner and joint syndication agent in
connection with, and commits to provide the financing for, certain
transactions described herein, in each case on the terms and subject to the
conditions set forth in this letter and the attached Annexes A, B and C hereto
(collectively, this "Commitment Letter"). Capitalized terms used but not
defined herein have the respective meanings given in the Annexes hereto.

  

  

You have informed the Commitment Parties that the Company intends to
consummate a merger transaction with the Merger Party, pursuant to which the
Company will merge (the "Merger") with and into a newly-formed, wholly-owned
subsidiary of the Merger Party, with the Company as the surviving entity. In
connection with, and immediately prior to, the Merger, the Company will (i)
tender for or call for redemption all of the Company's 8.375% Senior Notes due
2016 (the "2016 Notes") and all of the Company's 7.625% Senior Notes due 2020
(the "2020 Notes" and, together with the 2016 Notes, the "Existing Notes") and
solicit consents from the holders of the Existing Notes to amend the
indentures pursuant to which the Existing Notes were issued (the repayment of
such Existing Notes, along with any related fees, expenses and premiums, and
the consent solicitation of the holders of the Existing Notes, along with any
related fees and expenses, collectively, the "Refinancing") upon terms and
conditions reasonably satisfactory to the Commitment Parties and (ii) pay a
cash dividend of $1,314.0 million to the Company's existing shareholders (the
"Dividend"). You have also informed us that the Refinancing, the Dividend, the
Post-Merger Special Dividend (as defined in the Merger Agreement), the
Transaction Expenses and the working capital requirements of the Company and
the Merger Party after consummation of the Merger will be financed from the
following sources:

  

  

  

 

 

 

  

   

  

 

 

 

  

  

  

  

    

  |  



  |  

$500.0 million under a senior secured term loan A facility (the "Term A
Facility") having the terms set forth on Annex B;

   
---|---|--- 
 

  

  

    

  |  



  |  

up to $2,272.0 million under a senior secured term loan B facility (the "Term
B Facility" and, together with the Term A Facility, the "Term Facilities")
having the terms set forth on Annex B, which shall be available to the Company
as follows:

   
---|---|--- 
 

  

  

    

  |  



  |  

up to $1,972.0 million shall be available on the Closing Date to fund the
Refinancing and the Dividend;

   
---|---|--- 
 

  

  

    

  |  



  |  

$300.0 million shall be available on or prior to the later of (i) December 31,
2010 or (ii) 60 days after the Closing Date, to fund the Post-Merger Special
Dividend to the shareholders of Parent after the consummation of the Merger;

   
---|---|--- 
 

  

  

provided that the amount of the Term B Facility available to the Company on
the Closing Date shall be reduced on a dollar-for-dollar basis by (i) the net
proceeds of any issuance of debt securities (the "Securities") consummated by
the Company after the date hereof and on or prior to the Closing Date, (ii)
the aggregate principal amount of Existing Notes that remain outstanding on
the Closing Date, after giving effect to the making of the loans under the
Senior Facilities and the Refinancing and (iii) 50% of the net proceeds from
the sale of properties or assets or any interests therein that, individually
or in a series of related transactions, generate net proceeds in excess of
$25.0 million, until the aggregate net proceeds after the date hereof equals
$400.0 million and then 100% of any additional asset sale proceeds (except for
sales of pharmaceutical products in the ordinary course of business, which
shall not be subject to this clause (iii)); and

  

  

    

  |  



  |  

$250.0 million under a senior secured revolving credit facility (the
"Revolving Facility"; and, together with the Term Facilities, the "Senior
Facilities") having the terms set forth on Annex B.

   
---|---|--- 
 

  

  

 

1. Commitments: Titles and Roles.

  

  

Each of GSLP, Morgan Stanley and Jefferies is pleased to confirm its
commitment to act, and you hereby appoint each of GSLP, Morgan Stanley and
Jefferies to act, as joint lead arranger, joint bookrunner and joint
syndication agent in connection with the Senior Facilities and (i) GS Bank is
pleased to advise you of its several (but not joint) commitment to provide the
Borrower with 45% of the Senior Facilities, (ii) Morgan Stanley is pleased to
advise you of its several (but not joint) commitment to provide the Borrower
with 45% of the Senior Facilities, and (iii) Jefferies is pleased to advise
you of its several (but not joint) commitment to provide the Borrower with 10%
of the Senior Facilities, in each case on the terms and subject to the
conditions contained in this Commitment Letter and the Fee Letter (referred to
below). In addition, you hereby appoint GSLP to act as administrative agent
(the "Administrative Agent") for the Senior Facilities. You agree that GSLP
will have "left" placement in any and all marketing materials or other
documentation used in connection with the Senior Facilities. You further agree
that no other titles will be awarded and no compensation (other than that
expressly contemplated by this Commitment Letter and the Fee Letter referred
to below) will be paid in connection with the Senior Facilities unless you and
we shall so agree. Our fees for our commitment and for services related to the
Senior Facilities are set forth in a separate fee letter (the "Fee Letter")
entered into by the Company, the Merger Party and the Commitment Parties on
the date hereof.

  

  

  

 

 

 

  

 

2  

  

 

 

 

  

  

  

2. Conditions Precedent.

  

  

Each Commitment Party's commitment and agreements hereunder are subject to the
following condition: since January 1, 2010, there has not occurred any fact,
circumstance, effect, change, event or development that, individually or in
the aggregate, has had or would reasonably be expected to have a Material
Adverse Effect (as defined below) on either the Company and its subsidiaries
or the Merger Party. Each Commitment Party's commitments and agreements are
also subject to the satisfactory negotiation, execution and delivery of
appropriate definitive loan documents relating to the Senior Facilities
including, without limitation, credit agreements, guarantees, security
agreements, pledge agreements, real property security agreements, opinions of
counsel and other related definitive documents (collectively, the "Loan
Documents") to be based upon and substantially consistent with the terms set
forth in this Commitment Letter (it being agreed that the Loan Documents shall
not contain any conditions precedent to the initial borrowing under the Senior
Facilities on the Closing Date other than the conditions precedent expressly
set forth herein and in Annexes B and C hereto, and the terms of the Loan
Documents will be such that they do not impair the availability of the Senior
Facilities on the Closing Date if such conditions are satisfied, it being
understood that, to the extent the creation or perfection of any security
interest in the collateral (as contemplated in Annex B hereto) is not or
cannot be provided or perfected on the Closing Date (other than (i) the pledge
and perfection of collateral with respect to which a lien may be perfected
solely by the filing of financing statements under the Uniform Commercial
Code, (ii) filings with the U.S. patent and trademark office and the U.S.
copyright office with respect to intellectual property collateral and (iii) to
the extent applicable, the delivery of certificated securities representing
intercompany debt or equity interests required to constitute collateral and
related security powers) after your use of commercially reasonable efforts to
do so, then the creation or perfection, as the case may be, of such security
interest shall not constitute a condition precedent to the availability of the
Senior Facilities on the Closing Date, but shall instead be provided as
promptly as reasonably practicable after the Closing Date (and in any event
within 30 days after the Closing Date plus any extensions granted by the
Administrative Agent in its sole discretion) pursuant to arrangements to be
mutually agreed upon by the Company and the Administrative Agent). Each
Commitment Party's commitment is also subject to the Company having entered
into an engagement letter with one or more investment banks (the "Investment
Banks") reasonably acceptable to the Commitment Parties, pursuant to which the
Company engaged the Investment Banks in connection with a potential issuance
of Securities.

  

  

As used in the prior paragraph, "Material Adverse Effect" means, with respect
to any person, any fact, circumstance, effect, change, event or development
that materially adversely affects the business, properties, financial
condition or results of operations of such person and its subsidiaries, taken
as a whole, excluding any effect that results from or arises in connection
with (i) changes or conditions generally affecting the industries in which
such person and any of its subsidiaries operate, except to the extent such
effect has a materially disproportionate effect on such person and its
subsidiaries, taken as a whole, relative to others in the industries in which
such person and any of its subsidiaries operate, (ii) general economic or
regulatory, legislative or political conditions or securities, credit,
financial or other capital markets conditions, in each case in the United
States, Canada or any foreign jurisdiction, except to the extent such effect
has a materially disproportionate effect on such person and its subsidiaries,
taken as a whole, relative to others in the industries in which such person
and any of its subsidiaries operate, (iii) any failure, in and of itself, by
such person to meet any internal or published projections, forecasts,
estimates or predictions in respect of revenues, earnings or other financial
or operating metrics for any period (it being understood that the facts or
occurrences giving rise to or contributing to such failure may be deemed to
constitute, or be taken into account in determining whether there has been or
will be, a Material Adverse Effect), (iv) the execution and delivery of the
Merger Agreement or the public announcement or pendency of the Merger or any
of the other transactions contemplated by the Merger Agreement, including the
impact thereof on the relationships, contractual or otherwise, of such person
or any of its subsidiaries with employees, labor unions, customers, suppliers
or partners, (v) any change, in and of itself, in the market price, credit
rating or trading volume of such person's securities (it being understood that
the facts or occurrences giving rise to or contributing to such change may be
deemed to constitute, or be taken into account in determining whether there
has been or will be, a Material Adverse Effect), (vi) any change in applicable
Law (as defined in the Merger Agreement), regulation or GAAP (or authoritative
interpretation thereof), except to the extent such effect has a materially
disproportionate effect on such person and its subsidiaries, taken as a whole,
relative to others in the industries in which such person and any of its
subsidiaries operate, (vii) geopolitical conditions, the outbreak or
escalation of hostilities, any acts of war, sabotage or terrorism, or any
escalation or worsening of any such acts of war, sabotage or terrorism
threatened or underway as of the date of the Merger Agreement or (viii) any
hurricane, tornado, flood, earthquake or other natural disaster.

  

  

  

  

 

 

 

  

 

3  

  

 

 

 

  

  

  

Notwithstanding anything in this Commitment Letter, the Fee Letter or the Loan
Documents to the contrary, the only representations relating to the Company,
the Merger Party and their respective subsidiaries the accuracy of which will
be a condition to the availability of the Senior Facilities on the Closing
Date will be (i) the representations made by or with respect to the Company,
the Merger Party and their respective subsidiaries in the Merger Agreement
(but only to the extent that the Company or the Merger Party has the right to
terminate its obligations under the Merger Agreement or decline to consummate
the Merger as a result of a breach of such representations and warranties in
the Merger Agreement) and (ii) the Specified Representations (as defined
below).

  

  

As used herein, "Specified Representations" means representations relating to
incorporation or formation; organizational power and authority to enter into
the documentation relating to the Senior Facilities; due execution; delivery
and enforceability of such documentation; solvency; no conflicts with laws;
charter documents or material agreements; Federal Reserve margin regulations;
the Investment Company Act, Patriot Act; status of the Senior Facilities as
first lien senior debt; and, except as provided above, the creation,
perfection and priority of the security interests granted in the proposed
collateral.

  

  

3. Syndication.

  

  

The Arrangers intend, and reserve the right, to syndicate the Senior
Facilities to the Lenders promptly following the date hereof, and you
acknowledge and agree that the commencement of syndication shall occur in the
discretion of the Arrangers. The Arrangers will select the Lenders after
consultation with you. The Arrangers will lead the syndication, including
determining the timing of all offers to potential Lenders, any title of agent
or similar designations or roles awarded to any Lender and the acceptance of
commitments, the amounts offered and the compensation provided to each Lender
from the amounts to be paid to the Arrangers pursuant to the terms of this
Commitment Letter and the Fee Letter. The Arrangers will, in consultation with
you, determine the final commitment allocations and will notify the Company of
such determinations. You agree to use commercially reasonable efforts to
ensure that the Arrangers' syndication efforts benefit from the existing
lending relationships of the Company and the Merger Party and their respective
subsidiaries. To facilitate an orderly and successful syndication of the
Senior Facilities, you agree that, until the earliest of (x) the termination
of the syndication as determined by the Arrangers, (y) the consummation of a
Successful Syndication (as defined in the Fee Letter) and (z) 90 days after
the Closing Date, neither the Company nor the Merger Party (including, in each
case, their respective subsidiaries) will syndicate or issue, attempt to
syndicate or issue, announce or authorize the announcement of the syndication
or issuance of, any debt facility or any debt or equity security of the Merger
Party or the Company or any of their respective subsidiaries or affiliates
(other than (a) the Senior Facilities and other indebtedness contemplated
hereby to remain outstanding after the Closing Date and (b) the issuance of
(i) common equity of the Merger Party to shareholders of the Company on the
Closing Date, (ii) the Securities (if any), (iii) equity issued in connection
with the conversion of any convertible debt securities of the Company or the
Merger Party, hedging arrangements or warrants and (iv) equity pursuant to
employee stock plans of the Company and the Merger Party and other similar
arrangements to be mutually agreed upon by you and the Arrangers) without the
prior written consent of the Arrangers.

  

  

  

 

 

 

  

 

4  

  

 

 

 

  

  

  

You agree to cooperate with the Commitment Parties, in connection with (i) the
preparation of one or more information packages regarding the business,
operations and financial projections of the Company and the Merger Party
(collectively, the "Confidential Information Memorandum") including, without
limitation, all information relating to the transactions contemplated
hereunder prepared by or on behalf of the Company or the Merger Party deemed
reasonably necessary by the Commitment Parties to complete the syndication of
the Senior Facilities including, without limitation, using commercially
reasonable efforts to obtain (a) a public corporate family rating from Moody's
Investor Services, Inc. ("Moody's") for the Company, (b) a public corporate
credit rating from Standard and Poor's Ratings Group, a division of The McGraw
Hill Corporation ("SandP")) for the Company and (c) a public credit rating for
the Senior Facilities from each of Moody's and SandP, and (ii) the presentation
of one or more information packages reasonably acceptable in format and
content to the Commitment Parties (collectively, the "Lender Presentation") in
meetings and other communications with prospective Lenders or agents in
connection with the syndication of the Senior Facilities (including, without
limitation, direct contact between senior management and representatives, with
appropriate seniority and expertise, of the Company and the Merger Party with
prospective Lenders and participation of such persons in meetings). You
further agree that the commitments and agreements of the Commitment Parties
hereunder are conditioned upon your satisfaction of the requirements of the
foregoing provisions of this paragraph by a date sufficient to afford the
Arrangers a period of at least 30 consecutive days following the launch of the
general syndication of the Senior Facilities to syndicate the Senior
Facilities prior to the Closing Date (as defined in Annex B); provided that
such period will not include any day from and including August 23, 2010
through September 6, 2010 or December 18, 2010 through January 3, 2011. You
will be solely responsible for the contents of any such Confidential
Information Memorandum and Lender Presentation (other than, in each case, any
information contained therein that has been provided for inclusion therein by
the Commitment Parties solely to the extent such information relates to the
Commitment Parties) and all other information, documentation or materials
delivered to the Arrangers in connection therewith (collectively, the
"Information") and you acknowledge that the Commitment Parties will be using
and relying upon the Information without independent verification thereof. You
agree that Information regarding the Senior Facilities and Information
provided by the Company and the Merger Party or their respective
representatives to the Arrangers in connection with the Senior Facilities
(including, without limitation, draft and execution versions of the Loan
Documents, the Confidential Information Memorandum, the Lender Presentation,
publicly filed financial statements, and draft or final offering materials
relating to contemporaneous securities issuances by the Company or the Merger
Party) may be disseminated to potential Lenders and other persons through one
or more internet sites (including an IntraLinks, SyndTrak or other electronic
workspace (the "Platform")) created for purposes of syndicating the Senior
Facilities or otherwise, in accordance with the Arrangers' standard
syndication practices, and you acknowledge that neither the Arrangers nor any
of their affiliates will be responsible or liable to you or any other person
or entity for damages arising from the use by others of any Information or
other materials obtained on the Platform, except, in the case of damages to
you but not to any other person, to the extent such damages are found by a
final judgment of a court of competent jurisdiction to arise from the gross
negligence or willful misconduct of any Arranger or any of its affiliates or
any of their respective directors, employees, advisors or agents.

  

  

You acknowledge that certain of the Lenders may be "public side" Lenders (i.e.
Lenders that do not wish to receive material non-public information with
respect to the Company, the Merger Party or their respective affiliates or any
of its or their respective securities) (each, a "Public Lender"). At the
request of the Arrangers, you agree to prepare an additional version of the
Confidential Information Memorandum and the Lender Presentation to be used by
Public Lenders that does not contain material non-public information
concerning the Company, the Merger Party or their respective affiliates or
securities. It is understood that in connection with your assistance described
above, at the request of the Arrangers, you will provide, and cause all other
applicable persons to provide, authorization letters to the Arrangers
authorizing the distribution of the Information to prospective Lenders,
containing a representation to the Arrangers that the public-side version does
not include material non-public information about the Company, the Merger
Party or their respective affiliates or its or their respective securities. In
addition, you will clearly designate as such all Information provided to the
Commitment Parties by or on behalf of the Company or the Merger Party which is
suitable to make available to Public Lenders. You acknowledge and agree that
the following documents may be distributed to Public Lenders, unless you
advise the Arrangers in writing (including by email) within a reasonable time
prior to their intended distributions that such material should only be
distributed to prospective Lenders that are not Public Lenders: (a) drafts and
final versions of the Loan Documents; (b) administrative materials prepared by
the Arrangers for prospective Lenders (such as a lender meeting invitation,
allocations and funding and closing memoranda); and (c) term sheets and
notification of changes in the terms of the Senior Facilities.

  

  

  

  

 

 

 

  

 

5  

  

 

 

 

  

  

  

4. Information.

  

  

You represent and covenant that (i) all written Information (other than
financial projections and information of a general economic or industry
specific nature) provided directly or indirectly by the Merger Party or the
Company to the Commitment Parties or the Lenders in connection with the
transactions contemplated hereunder is and will be, when furnished and when
taken as a whole and giving effect to all supplements thereto, complete and
correct in all material respects and does not and will not contain any untrue
statement of a material fact or omit to state a material fact necessary to
make the statements contained therein, in light of the circumstances under
which they were made, not materially misleading and (ii) the financial
projections that have been or will be made available to the Arrangers or the
Lenders in connection with the transactions contemplated hereunder by or on
behalf of the Company or the Merger Party have been and will be prepared in
good faith based upon assumptions that are believed by the preparer thereof to
be reasonable at the time such financial projections are furnished to the
Commitment Parties or the Lenders, it being understood and agreed that
financial projections are not a guarantee of financial performance and actual
results may differ from financial projections and such differences may be
material. You agree that if at any time prior to the Successful Syndication of
the Senior Facilities as determined by the Arrangers, any of the
representations in the preceding sentence would be incorrect in any material
respect if the Information and financial projections were being furnished, and
such representations were being made, at such time, then you will promptly
supplement, or cause to be supplemented, the Information and financial
projections so that such representations will be correct in all material
respects under those circumstances.

  

  

5. Indemnification and Related Matters.

  

  

In connection with arrangements such as this, it is the Commitment Parties'
policy to receive indemnification. You agree to the provisions with respect to
our indemnity and other matters set forth in Annex A, which is incorporated by
reference into this Commitment Letter.

  

  

6. Assignments; Amendments.

  

  

This Commitment Letter may not be assigned by you without the prior written
consent of the Commitment Parties (and any purported assignment without such
consent will be null and void), is intended to be solely for the benefit of
the Commitment Parties and the other parties hereto and, except as set forth
in Annex A hereto, is not intended to confer any benefits upon, or create any
rights in favor of, any person other than the parties hereto. Each of the
Commitment Parties may assign its commitments and agreements hereunder, in
whole or in part, to any of its affiliates (provided that such affiliates
agree to abide by the confidentiality provisions of Section 7 of this
Commitment Letter) and, as provided above, to any Lender prior to the Closing
Date; provided that any assignment by a Commitment Party to any potential
Lender made prior to the Closing Date shall not relieve such Commitment Party
of its obligations set forth herein to fund that portion of the commitments so
assigned. Neither this Commitment Letter nor the Fee Letter may be amended or
any term or provision hereof or thereof waived or otherwise modified except by
an instrument in writing signed by each of the parties hereto or thereto, as
applicable, and any term or provision hereof or thereof may be amended or
waived only by a written agreement executed and delivered by all parties
hereto or thereto.

  

  

  

  

 

 

 

  

 

6  

  

 

 

 

  

  

  

7. Confidentiality.

  


 

  

Please note that this Commitment Letter, the Fee Letter and any written
communications provided by, or oral discussions with, the Commitment Parties
in connection with this arrangement are exclusively for the information of the
Company and the Merger Party and may not be disclosed to any third party or
circulated or referred to publicly without our prior written consent except,
after providing written notice to the Commitment Parties, pursuant to a
subpoena or order issued by a court of competent jurisdiction or by a
judicial, administrative or legislative body or committee; provided that we
hereby consent to your disclosure of (i) this Commitment Letter, the Fee
Letter and such communications and discussions to the Company's and the Merger
Party's respective directors, employees, agents and advisors who are directly
involved in the consideration of the Senior Facilities and who have been
informed by you of the confidential nature of such advice and the Commitment
Letter and Fee Letter and who have agreed to treat such information
confidentially, (ii) this Commitment Letter, the Fee Letter and such
communications and discussions as required by applicable law, rule or
regulation or compulsory legal process (in which case you agree to inform us
promptly thereof to the extent not prohibited by law), (iii) the terms of this
Commitment Letter (but not the Fee Letter or the terms thereof, other than the
aggregate amount of financing fees payable to the Commitment Parties) and
related communications or discussions in connection with the preparation,
filing and distribution of the Form S-4 and Joint Proxy Statement and any
amendments or supplements thereto contemplated by the Merger Agreement and
(iv) the information contained in Annex B to Moody's and SandP; provided that
such information is supplied only on a confidential basis after consultation
with the Commitment Parties.

  

  

Each Commitment Party agrees that it will treat as confidential all
information provided to it hereunder by or on behalf of you or any of your
respective subsidiaries or affiliates; provided, however, that nothing herein
will prevent any Commitment Party from disclosing any such information (a)
pursuant to the order of any court or administrative agency or in any pending
legal or administrative proceeding, or otherwise as required by applicable law
or compulsory legal process (in which case such person agrees to inform you
promptly thereof to the extent not prohibited by law), (b) upon the request or
demand of any regulatory authority having jurisdiction over such person or any
of its affiliates, (c) to the extent that such information is publicly
available or becomes publicly available other than by reason of improper
disclosure by such person, (d) to such person's affiliates and their
respective officers, directors, partners, employees, legal counsel,
independent auditors and other experts or agents who need to know such
information and on a confidential basis, (e) to potential and prospective
Lenders, participants and any direct or indirect contractual counterparties to
any swap or derivative transaction relating to the borrower and its
obligations under the Senior Facilities, in each case, who are advised of the
confidential nature of such information, (f) to Moody's and SandP; provided that
such information is limited to Annex B and is supplied only on a confidential
basis after consultation with you or (g) for purposes of establishing a "due
diligence" defense. Each Commitment Party's obligation under this provision
shall remain in effect until the earlier of (i) one year from the date hereof
and (ii) the date the definitive Loan Documents are entered into by the
Commitment Parties, at which time any confidentiality undertaking in the
definitive Loan Documents shall supersede this provision.

  

  

  

  

 

 

 

  

 

7  

  

 

 

 

  

  

  

8. Absence of Fiduciary Relationship; Affiliates; Etc.

  

  

As you know, each Commitment Party, together with its respective affiliates
(each collectively, a "Commitment Party Group"), is a full service financial
services firm engaged, either directly or through affiliates, in various
activities, including securities trading, investment banking and financial
advisory, investment management, principal investment, hedging, financing and
brokerage activities and financial planning and benefits counseling for both
companies and individuals. In the ordinary course of these activities, each
Commitment Party Group may make or hold a broad array of investments and
actively trade debt and equity securities (or related derivative securities)
and/or financial instruments (including bank loans) for their own account and
for the accounts of their customers and may at any time hold long and short
positions in such securities and/or instruments. Such investment and other
activities may involve securities and instruments of the Company or the Merger
Party, as well as of other entities and persons and their affiliates which may
(i) be involved in transactions arising from or relating to the engagement
contemplated by this Commitment Letter, (ii) be customers or competitors of
the Company or the Merger Party, or (iii) have other relationships with either
of you. In addition, each Commitment Party Group may provide investment
banking, underwriting and financial advisory services to such other entities
and persons. Each Commitment Party Group may also co-invest with, make direct
investments in, and invest or co-invest client monies in or with funds or
other investment vehicles managed by other parties, and such funds or other
investment vehicles may trade or make investments in securities of the
Company, the Merger Party or such other entities. The transactions
contemplated by this Commitment Letter may have a direct or indirect impact on
the investments, securities or instruments referred to in this paragraph.
Although each Commitment Party Group in the course of such other activities
and relationships may acquire information about the transaction contemplated
by this Commitment Letter or other entities and persons which may be the
subject of the transactions contemplated by this Commitment Letter, no
Commitment Party Group shall have any obligation to disclose such information,
or the fact that such Commitment Party Group is in possession of such
information, to the Company or the Merger Party or to use such information on
the Company's or the Merger Party's behalf.

  

  

Consistent with their respective policies to hold in confidence the affairs of
its customers, no Commitment Party Group will furnish confidential information
obtained from you by virtue of the transactions contemplated by this
Commitment Letter to any of its other customers. Furthermore, you acknowledge
that no Commitment Party Group and none of their respective affiliates has an
obligation to use in connection with the transactions contemplated by this
Commitment Letter, or to furnish to you, confidential information obtained or
that may be obtained by them from any other person.

  

  

Each Commitment Party Group may have economic interests that conflict with
yours, or your respective equity holders and/or affiliates. You agree that
each Commitment Party Group will act under this Commitment Letter as an
independent contractor and that nothing in this Commitment Letter or the Fee
Letter or otherwise will be deemed to create an advisory, fiduciary or agency
relationship or fiduciary or other implied duty between any Commitment Party
Group and the Company or the Merger Party or your respective equity holders or
affiliates. You acknowledge and agree that the transactions contemplated by
this Commitment Letter and the Fee Letter (including the exercise of rights
and remedies hereunder and thereunder) are arm's-length commercial
transactions between the Commitment Party Groups, on the one hand, and the
Company, on the other, and in connection therewith and with the process
leading thereto, (i) no Commitment Party Group has assumed (A) an advisory or
fiduciary responsibility in favor of the Company or the Merger Party or your
respective equity holders or affiliates with Company or the Merger Party or
your respective equity holders or affiliates with respect to the financing
transactions contemplated hereby, or in each case, the exercise of rights or
remedies with respect thereto or the process leading thereto (irrespective of
whether such Commitment Party has advised, is currently advising or will
advise the Company, its equity holders or its affiliates on other matters) or
any other obligation to the Company or the Merger Party except the obligations
expressly set forth in this Commitment Letter and the Fee Letter and (ii) each
Commitment Party Group is acting solely as a principal and not as the agent or
fiduciary of the Company, its management, equity holders, affiliates,
creditors or any other person. Each of you acknowledge and agree that you have
consulted your own legal and financial advisors to the extent you deemed
appropriate and that you are responsible for making your own independent
judgment with respect to such transactions and the process leading thereto.
You each agree that you will not claim that any Commitment Party Group has
rendered advisory services of any nature or respect, or owes a fiduciary or
similar duty to the Company or the Merger Party, in connection with such
transactions or the process leading thereto.

  

  

  

  

 

 

 

  

 

8  

  

 

 

 

  

  

  

Without limiting any other provision of this Section 8, the Company and the
Merger Party (i) expressly agree that this Commitment Letter and the Fee
Letter are being addressed to each of you solely at your mutual request, (ii)
acknowledge that circumstances may arise where the interests of the Company
and the Merger Party hereunder and/or under the Fee Letter are adverse to one
another and (iii) agree not to assert any claim that you might allege based on
any actual or potential conflict arising from the fact that both of you are
parties to this Commitment Letter and the Fee Letter including, but not
limited to, any such claim arising or resulting from the separate retention by
either of the Company or the Merger Party of any Commitment Party or any
affiliate thereof as an advisor in connection with the Merger and such
Commitment Party's or such affiliate's commitments, agreements and acts under
this Commitment Letter.

  

  

In addition, each Commitment Party may employ the services of its affiliates
in providing services and/or performing their obligations hereunder and may
exchange with such affiliates information concerning the Company, the Merger
Party and other companies that may be the subject of this arrangement, and
such affiliates will be entitled to the benefits afforded to the Commitment
Parties hereunder.

  

  

In addition, please note that the Commitment Parties do not provide
accounting, tax or legal advice. Notwithstanding anything herein to the
contrary, each of the Company and the Merger Party (and each employee,
representative or other agent of the Company and the Merger Party) may
disclose to any and all persons, without limitation of any kind, the tax
treatment and tax structure of the Senior Facilities and all materials of any
kind (including opinions or other tax analyses) that are provided to you
relating to such tax treatment and tax structure. However, any information
relating to the tax treatment or tax structure will remain subject to the
confidentiality provisions hereof (and the foregoing sentence will not apply)
to the extent reasonably necessary to enable the parties hereto, their
respective affiliates, and their and their respective affiliates' directors
and employees to comply with applicable securities laws. For this purpose,
"tax treatment" means U.S. federal or state income tax treatment, and "tax
structure" is limited to any facts relevant to the U.S. federal income tax
treatment of the transactions contemplated by this Commitment Letter but does
not include information relating to the identity of the parties hereto or any
of their respective affiliates.

  

  

9. Miscellaneous.

  

  

Each Commitment Party's commitments and agreements hereunder will terminate
upon the first to occur of (i) the consummation of the Merger, (ii) the
abandonment or termination of the definitive documentation for the Merger
(including the exhibits, schedules and all related documents) (the "Merger
Agreement"), (iii) a material breach by the Company or the Merger Party under
this Commitment Letter or the Fee Letter and (iv) February 28, 2011, unless
the closing of the Senior Facilities, on the terms and subject to the
conditions contained herein, has been consummated on or before such date.

  

  

The provisions set forth under Sections 3, 4, 5 (including Annex A) and 7
hereof and this Section 9 hereof will remain in full force and effect
regardless of whether definitive Loan Documents are executed and delivered.
The provisions set forth under Sections 5 (including Annex A) and 7 hereof and
this Section 9 will remain in full force and effect notwithstanding the
expiration or termination of this Commitment Letter or the Commitment Parties'
commitments and agreements hereunder.

  

  

  

  

 

 

 

  

 

9  

  

 

 

 

  

  

  

The Company and the Merger Party each agrees for itself and its affiliates
that any suit or proceeding arising in respect to this Commitment Letter or
the Commitment Parties' commitments or agreements hereunder or the Fee Letter
will be tried exclusively in the U.S. District Court for the Southern District
of New York or, if that court does not have subject matter jurisdiction, in
any state court located in the Borough of Manhattan in the City of New York,
and the Company and the Merger Party each agree to submit to the exclusive
jurisdiction of, and to venue in, such court. Any right to trial by jury with
respect to any action or proceeding arising in connection with or as a result
of either the Commitment Parties' commitments or agreements or any matter
referred to in this Commitment Letter or the Fee Letter is hereby waived by
the parties hereto. This Commitment Letter and the Fee Letter will be governed
by and construed in accordance with the laws of the State of New York without
regard to principles of conflicts of laws. The Merger Party shall provide
evidence that it has appointed CT Corporation, as its agent for service of
process for purpose of the submission to jurisdiction set forth above.

  

  

The Commitment Parties hereby notify the Company and the Merger Party that
pursuant to the requirements of the USA PATRIOT Act (Title III of Pub. L.
107-56 (signed into law October 26, 2001)) (the "Patriot Act") the Commitment
Parties and each Lender may be required to obtain, verify and record
information that identifies the Borrower and each of the Guarantors, which
information includes the name and address of the Borrower and each of the
Guarantors and other information that will allow the Commitment Parties and
each Lender to identify the Borrower and each of the Guarantors in accordance
with the Patriot Act. This notice is given in accordance with the requirements
of the Patriot Act and is effective for the Commitment Parties and each
Lender.

  

  

This Commitment Letter may be executed in any number of counterparts, each of
which when executed will be an original, and all of which, when taken
together, will constitute one agreement. Delivery of an executed counterpart
of a signature page of this Commitment Letter by facsimile transmission or
electronic transmission (in pdf or tif format) will be effective as delivery
of a manually executed counterpart hereof. This Commitment Letter and the Fee
Letter are the only agreements that have been entered into among the parties
hereto with respect to the Senior Facilities and set forth the entire
understanding of the parties with respect thereto and supersede any prior
written or oral agreements among the parties hereto with respect to the Senior
Facilities.

  

  

[Remainder of page intentionally left blank]

  

  

  

  

 

 

 

  

 

10  

  

 

 

 

  

  

  


 

  

Please confirm that the foregoing is in accordance with your understanding by
signing and returning to the Commitment Parties the enclosed copy of this
Commitment Letter, together, if not previously executed and delivered, with
the Fee Letter on or before the close of business on June 21, 2010, whereupon
this Commitment Letter and the Fee Letter will become binding agreements
between us. If the Commitment Letter and Fee Letter have not been signed and
returned as described in the preceding sentence by such date, this offer will
terminate on such date. We look forward to working with you on this
transaction.

  

  

     |  

Very truly yours,

  

   
---|--- 
   |  

GOLDMAN SACHS BANK USA

  

GOLDMAN SACHS LENDING PARTNERS LLC

  

   
   |   
   |   
   |  

By:

  | /s/ Alexis Maged |   
   |  |  

Authorized Signatory

   
 

  


 

  

  

  

  

 

 

 

  

 

Commitment Letter Signature Page  

  

 

 

 

  


 

  

  

    

MORGAN STANLEY SENIOR FUNDING, INC.

   
--- 
  

  

  

   
  

By:

  |  

/s/ Christy Silvester

  |  

   
   |  

Name: Christy Silvester

   
   |  

Title: Executive Director

   
 

  

  

  

  

  

  

 

 

 

  

 

Commitment Letter Signature Page  

  

 

 

 

  

  


 

  


 

  

    

JEFFERIES GROUP, INC.

   
--- 
  

  

  

   
  

By:

  |  

/s/ Charles J. Hendrickson

  |  

   
   |  

Name: Charles J. Hendrickson

   
   |  

Title: Managing Director

   
 

  

  

  

  

 

 

 

  

 

Commitment Letter Signature Page  

  

 

 

 

  

  


 

  

ACCEPTED AND AGREED AS OF

  

THE DATE FIRST WRITTEN ABOVE:

  

  

VALEANT PHARMACEUTICALS

  

INTERNATIONAL

  


 

  


 

  

    

By:

  | /s/ J. Michael Pearson  
---|--- 
   |  

Name: J. Michael Pearson

   
   |  

Title: Chief Executive Officer

   
 

  

  

  

  

 

 

 

  

 

Commitment Letter Signature Page  

  

 

 

 

  


 

  


 

  

    

BIOVAIL CORPORATION

   
--- 
    
    
  

By:

  |  

/s/ MJ Mulligan

   
   |  

Name: MJ Mulligan

   
   |  

Title: Chief Financial Officer

   
 

  

  

  

  

 

 

 

  

 

Commitment Letter Signature Page  

  

 

 

 

  

  


 

  

Annex A

  


 

  

In the event that any Commitment Party becomes involved in any capacity in any
action, proceeding or investigation brought by or against any person,
including shareholders, partners, members or other equity holders of the
Company or the Merger Party in connection with or as a result of either this
arrangement or any matter referred to in this Commitment Letter or the Fee
Letter (together, the "Letters'), the Company and the Merger Party each agree
to periodically reimburse each Commitment Party for its reasonable legal and
other expenses (including the cost of any investigation and preparation)
incurred in connection therewith. The Company and the Merger Party each also
agrees to indemnify and hold each Commitment Party harmless against any and
all losses, claims, damages or liabilities to any such person in connection
with or as a result of either this arrangement or any matter referred to in
the Letters (whether or not such investigation, litigation, claim or
proceeding is brought by you, your equity holders or creditors or an
indemnified person and whether or not any such indemnified person is otherwise
a party thereto), except to the extent that such loss, claim, damage or
liability has been found by a final, non-appealable judgment of a court of
competent jurisdiction to have resulted from the gross negligence or willful
misconduct of such Commitment Party in performing the services that are the
subject of the Letters. If for any reason the foregoing indemnification is
unavailable to any Commitment Party or insufficient to hold it harmless, then
the Company and the Merger Party will contribute to the amount paid or payable
by the Commitment Party as a result of such loss, claim, damage or liability
in such proportion as is appropriate to reflect the relative economic
interests of (:) the Company and the Merger Party and their respective
affiliates, shareholders, partners, members or other equity holders on the one
hand and (ii) the Commitment Parties on the other hand in the matters
contemplated by the Letters as well as the relative fault of (i) the Company
and the Merger Party and their respective affiliates, shareholders, partners,
members or other equity holders and (ii) the Commitment Parties with respect
to such loss, claim, damage or liability and any other relevant equitable
considerations. The reimbursement, indemnity and contribution obligations of
the Company and the Merger Party under this paragraph will be in addition to
any liability which the Company or the Merger Party may otherwise have, will
extend upon the same terms and conditions to any affiliate of a Commitment
Party and the partners, members, directors, agents, employees and controlling
persons (if any), as the case may be, of such Commitment Party and any such
affiliate, and will be binding upon and inure to the benefit of any
successors, assigns, heirs and personal representatives of the Company and the
Merger Party, each Commitment Party, any such affiliate and any such person.
The Company and the Merger Party each also agrees that neither any indemnified
party nor any of such affiliates, partners, members, directors, agents,
employees or controlling persons will have any liability to the Company or the
Merger Party or any person asserting claims on behalf of or in right of the
Company or the Merger Party or any other person in connection with or as a
result of either this arrangement or any matter referred to in the Letters,
except to the extent that any losses, claims, damages, liabilities or expenses
incurred by the Company, the Merger Party or their respective affiliates,
shareholders, partners or other equity holders have been found by a final,
non-appealable judgment of a court of competent jurisdiction to have resulted
from the gross negligence or willful misconduct of such indemnified party in
performing the services that are the subject of the Letters; provided,
however, that in no event will such indemnified party or such other parties
have any liability for any indirect, consequential, special or punitive
damages in connection with or as a result of such indemnified party's or such
other parties' activities related to the Letters. Each of the Company and the
Merger Party agree that, notwithstanding anything in this Commitment Letter to
the contrary and without limiting the Commitment Parties rights, remedies and
defenses thereunder, in no event shall the Commitment Parties or their
partners, members, directors, agents, employees, controlling persons or
affiliates be liable (in the aggregate) to the Company or the Merger Party (or
their respective shareholders, partners, members or other equity holders) for
damages under this Commitment Letter or the Fee Letter or related to the
financing contemplated thereby in an amount in excess of $100.0 million.

  

  

  

 

 

 

  

 

Annex A-1  

  

 

 

 

  

  

  

Neither the Company nor the Merger Party will be required to indemnify any
Commitment Parties for any amount paid or payable by such Commitment Party in
the settlement of any action, proceeding or investigation without such party's
consent, which consent will not be unreasonably withheld or delayed; provided
that the foregoing indemnity will apply to any such settlement in the event
that the Company or the Merger Party, as applicable, were offered the ability
to assume the defense of the action that was the subject matter of such
settlement and elected not to so assume. The provisions of this Annex A will
survive any termination or completion of the arrangement provided by the
Letters.

  

  

  

  

  

  

 

 

 

  

 

Annex A-2  

  

 

 

 

  

  

  


 

  

Annex B

  

  

Summary of the Senior Facilities

  

  

This Summary outlines certain terms of the Senior Facilities referred to in
the Commitment Letter, of which this Annex B is a part. Certain capitalized
terms used herein are defined in the Commitment Letter.

  

  

 

  

 

    

Borrower:

  |  

Valeant Pharmaceuticals International (the "Borrower").

  

   
---|--- 
  

Guarantors:

  |  

Biovail Corporation (the "Parent") and, subject to exclusions to be mutually
agreed upon by the Borrower and the Administrative Agent, each of the Parent's
existing and subsequently acquired or organized subsidiaries (other than
foreign subsidiaries of the Borrower) (collectively, the "Guarantors") will
guarantee (the "Guarantee") all obligations under the Senior Facilities;
provided that Parent and its existing subsidiaries immediately prior to the
Merger shall only be Guarantors upon and after the consummation of the Merger.

  

   
  

Purpose/Use of Proceeds:

  |  

The proceeds of the Term Facilities will be used to fund the Refinancing, the
Dividend, the Post-Merger Special Dividend and all fees and expenses in
connection with the Merger (such fees and expenses, the "Transaction
Expenses"). Amounts available under the Revolving Facility will be used to
finance transaction expenses related to the Merger, for permitted capital
expenditures and permitted acquisitions (subject to customary conditions and
pro forma financial tests to be agreed), to provide for the ongoing working
capital requirements of Parent and its subsidiaries following the Merger and
for general corporate purposes.

  

   
  

Joint Lead Arrangers, Joint Bookrunners and Syndication Agents:

  

  |  

Goldman Sachs Lending Partners LLC ("GSLP"), Jefferies Group, Inc.
("Jefferies") and Morgan Stanley Senior Funding, Inc. ("Morgan Stanley" and
together with GSLP and Jefferies, in their capacities as Joint Lead Arrangers,
Joint Bookrunners and Syndication Agents, the "Arrangers").

  

   
  

Administrative Agent:

  |  

Goldman Sachs Lending Partners LLC (in such capacity, the "Administrative
Agent").

  

   
  

Lenders:

  |  

Goldman Sachs Bank USA, Morgan Stanley and Jefferies and/or other financial
institutions selected by the Arrangers (each, a "Lender" and, collectively,
the "Lenders").

  

   
  

Amount of Senior Facilities:

  |  

Up to $3,022.0 million of senior secured bank financing to include:

  

   
   |  |  

(i)

  |  

$500.0 million of a senior secured term loan A (the "Term A Facility") which
will be available on the Closing Date to fund the Refinancing;

  

   
 

 

  

  

  

 

 

 

  

 

Annex B-1  

  

 

 

 

  

  

  

  

 

     |  |  

(ii)

  |  

up to $2,272.0 million of senior secured term loan B (the "Term B Facility"
and, together with the Term A Facility, the "Term Facilities"): (i) up to
$1,972.0 million of which will be available on the Closing Date to fund, in
part, the Refinancing and to fund the Dividend and (ii) $300.0 million of
which shall be available on a delayed-draw basis, each as set forth below
under "Availability"; and

   
---|---|---|--- 
   |  |  |   
   |  |  

(ii)

  |  

a $250.0 million senior secured revolving credit facility (the "Revolving
Facility" and, together with the Term Facilities, the "Senior Facilities").
The Revolving Facility (including any Letters of Credit issued thereunder)
shall be made available in U.S. dollars.

  

   
   |  

The amount of the Initial Draw under the Term B Facility (as defined below)
shall be reduced dollar-for-dollar by (i) the net proceeds of any Securities
issued after the date hereof and prior to the Closing Date, (ii) the aggregate
principal amount of the Existing Notes that will remain outstanding on and
after the Closing Date, after giving effect to the making of the loans under
the Senior Facilities and the Refinancing and (iii) 50% of the net proceeds
from the sale of properties or assets or any interests therein that,
individually or in a series of related transactions, generate net proceeds in
excess of $25.0 million, until the aggregate net proceeds after the date
hereof equals $400.0 million and then 100% of any additional asset sale
proceeds (except for sales of pharmaceutical products in the ordinary course
of business, which shall not be subject to this clause (iii)).

  

   
  

Incremental Facility:

  |  

On or before the final maturity date of each the Senior Facilities, the
Borrower will have the right, but not the obligation, to increase the amount
of the Term B Facility by incurring an incremental term loan facility (the
"Incremental Facility") in an aggregate principal amount not to exceed $250.0
million; provided that (i) no event of default or default exists or would
exist after giving effect thereto, (ii) all financial covenants would be
satisfied on a pro forma basis on the date of incurrence and for the most
recent determination period, after giving effect to such Incremental Facility
and (iii) (a) the yield applicable to the Incremental Facility will not be
more than 0.25% higher than the corresponding interest rate for the existing
Term B Facility, unless the interest rate margins with respect to the Term B
Facility is increased by an amount equal to the difference between the yield
with respect to the Incremental Facility and the corresponding interest rate
on the Term B Facility, minus 0.25%, (b) the maturity date applicable to the
Incremental Facility will not be earlier than the maturity date of the Term B
Facility, (c) the weighted average life to maturity of the Incremental
Facility will not be shorter than the then remaining weighted average life to
maturity of the Term B Facility and (d) all other terms (other than pricing
and amortization) of the Incremental Facility, if not consistent with the
terms of the existing Term B Facility (except as permitted by subclauses (a),
(b) and (c) of this clause (iii), must be reasonably acceptable to the
Administrative Agent. Such increased amounts will be provided by existing
Lenders or other persons who become Lenders in connection therewith; provided
that no existing Lender will be obligated to provide any such increased
portion of the Senior Facilities.

  

   
 

 

  

  

  

  

  

 

 

 

  

 

Annex B-2  

  

 

 

 

  

  

  

  

  

 

    

Availability:

  |  

Term A Facility: The entire $500.0 million of the Term A Facility will be
available on the Closing Date to fund, in part, the Refinancing and the
Transaction Expenses, upon satisfaction of the Initial Draw Conditions (as
defined in Annex C to the Commitment Letter).

  

  

Term B Facility: Two drawings may be made under the Term B Facility. The first
drawing under the Term Facility (the "Initial Draw") may be made on the
Closing Date to fund, in part, the Refinancing and the Transaction Expenses,
upon satisfaction of the Initial Draw Conditions. The second drawing under the
Term B Facility (the "Second Draw") may be made on the Closing Date to fund
the Dividend, upon satisfaction of the Second Draw Conditions (as defined in
Annex C to the Commitment Letter).

  

  

Delayed-Draw Term B Facility: $300.0 million of the Term B Facility (the
"Delayed-Draw Tranche") will be available to the Borrower on a delayed-draw
basis to fund the Post-Merger Special Dividend on or prior to the later of (i)
December 31, 2010 or (ii) 60 days after the Closing Date.

  

  

Revolving Facility: Amounts available under the Revolving Facility may be
borrowed, repaid and reborrowed on and after the Closing Date until the
maturity date thereof, including on the Closing Date to fund any original
issue discount or upfront fees resulting from the Commitment Party's exercise
of rights under the "Market Flex" provisions of the Fee Letter; provided that
after giving effect to all such borrowings on the Closing Date there remains
at least $100.0 million of undrawn availability under the Revolving Facility.

  

   
---|--- 
  

Maturities:

  |  

Term A Facility: 5 year anniversary of the Closing Date.

  

  

Term B Facility: 6 year anniversary of the Closing Date.

  

  

Revolving Facility: 4.5 year anniversary of the Closing Date.

  

   
  

Closing Date:

  |  

The date on or before February 28, 2011 on which the initial borrowings under
the Term Facilities are made, upon satisfaction of the Initial Draw Conditions
(the "Closing Date").

  

   
  

Amoritization:

  |  

Term A Facility: The outstanding principal amount of the Term A Facility will
be payable as follows: 10% in years 1 and 2, 20% in years 3 and 4, with the
remaining balance due at the maturity of the Term A Facility.

  

  

Term B Facility: The outstanding principal amount of the Term B Facility will
be payable in equal quarterly amounts of 1% per annum, with the remaining
balance due at the maturity of the Term B Facility.

  

  

Revolving Facility: None.

  

   
 

 

  

  

  

  

  

  

 

 

 

  

 

Annex B-3  

  

 

 

 

  

  

  

  

 

    

Swing Line Loans:

  |  

At the option of the Lender providing such swing line loans, a portion of the
Revolving Facility to be agreed upon may be made available as swing line
loans.

  

   
---|--- 
  

Letters of Credit:

  |  

At the option of the issuing bank providing such Letter of Credit, a portion
of the Revolving Facility to be agreed upon may be made available for the
issuance of letters of credit by an issuing bank to be agreed ("Letters of
Credit").

  

   
  

Interest Rate:

  |  

All amounts outstanding under the Senior Facilities will bear interest, at the
Borrower's option, as follows:

  

   
   |  |  

With respect to loans made under the Term A Facility and the Revolving
Facility:

  

   
   |  |  

(i)

  |  

at the Base Rate plus 3.50% per annum; or

  

   
   |  |  

(ii)

  |  

at the reserve adjusted Eurodollar Rate plus 4.50% per annum;

  

   
   |  |  

With respect to loans made under the Term B Facility:

  

   
   |  |  

(i)

  |  

at the Base Rate plus 3.75% per annum; or

  

   
   |  |  

(ii)

  |  

at the reserve adjusted Eurodollar Rate plus 4.75% per annum;

  

   
   |  

provided, that the interest rate margins for the Senior Facilities set forth
in clauses (i) and (ii) above with respect to each of the Term A Facility, the
Term B Facility and the Revolving Facility shall be (x) decreased by 0.25% if
the credit ratings for the Senior Facilities are at least Ba3 (stable) from
Moody's and BB- (stable) from SandP prior to the Closing Date and (y) increased
by 0.75% if the credit rating for the Senior Facilities is B2 (stable) or
lower from Moody's or B (stable) or lower from SandP prior to the Closing Date.

  

   
   |  

As used herein, the terms "Base Rate" and "reserve adjusted Eurodollar Rate"
will have meanings customary and appropriate for financings of this type, and
the basis for calculating accrued interest and the interest periods for loans
bearing interest at the reserve adjusted Eurodollar Rate will be customary and
appropriate for financings of this type subject, in the case of the Term B
Facility only, to a reserve adjusted Eurodollar Rate "floor" of 1.75% and a
Base Rate "floor" of 2.75%. In no event shall the Base Rate be less than the
sum of (i) the one-month reserve adjusted Eurodollar Rate (after giving effect
to any reserve adjusted Eurodollar Rate "floor") plus (ii) the difference
between the applicable stated margin for reserve adjusted Eurodollar Rate
loans and the applicable stated margin for Base Rate loans. After the
occurrence and during the continuance of an Event of Default, interest on all
amounts then outstanding will accrue at a rate equal to the rate on loans
bearing interest at the rate determined by reference to the Base Rate plus an
additional two percentage points (2.00%) per annum and will be payable on
demand.

  

   
 

 

  

  

  

  

  

  

 

 

 

  

 

Annex B-4  

  

 

 

 

  

  

  

 

    

Interest Payments:

  

  |  

Quarterly for loans bearing interest by reference to the Base Rate; except as
set forth below, on the last day of selected interest periods (which will be
one, two, three and six months and any other period mutually agreed upon by
the Borrower and the Lenders under the Revolving Facility) for loans bearing
interest by reference to the Eurodollar Rate (and at the end of every three
months, in the case of interest periods of longer than three months); and upon
prepayment, in each case payable in arrears and computed on the basis of a
360-day year (365/366 day year with respect to loans bearing interest by
reference to the Base Rate).

  

   
---|--- 
  

Interest Rate Protection:

  

  |  

Within 90 days after the Closing Date, the Borrower will obtain from a
counterparty satisfactory to the Administrative Agent interest rate protection
through interest rate swaps, caps or other agreements satisfactory to the
Administrative Agent against increases in the interest rates with respect to a
notional amount of indebtedness such that not less than 35% of the total
funded indebtedness of the Parent and its subsidiaries outstanding as of the
Closing Date will be either (i) subject to such interest rate protection
agreements or (ii) fixed rate indebtedness, in each case for a period of not
less than three years.

  

   
  

Funding Protection:

  

  |  

Customary for transactions of this type, including breakage costs, gross-up
for withholding, compensation for increased costs and compliance with capital
adequacy and other regulatory restrictions. The Loan Documents will contain
customary Lender mitigation and replacement provisions.

  

   
  

Commitment Fees:

  

  |  

Commitment fees equal to 0.75% per annum times the daily average undrawn
portion of the Revolving Facility (reduced by the amount of Letters of Credit
issued and outstanding) will accrue from the Closing Date and will be payable
quarterly in arrears.

  

   
  

Delayed Draw Fee:

  

  |  

Commitment fees equal to 0.75% per annum times the undrawn amount of
commitments under the Delayed-Draw Tranche will accrue from the Closing Date
and will be payable quarterly in arrears.

  

   
  

Letters of Credit Fees:

  |  

A fee equal to (i) the applicable margin then in effect for loans bearing
interest at the reserve adjusted Eurodollar Rate made under the Revolving
Facility, times (ii) the average daily maximum aggregate amount available to
be drawn under all Letters of Credit, will be payable quarterly in arrears to
the Lenders under the Revolving Facility. In addition, a fronting fee, to be
agreed upon between the issuer of each Letter of Credit and the Borrower, will
be payable to such issuer, as well as certain customary fees assessed thereby.

  

   
 Voluntary Prepayments | The Senior Facilities may be prepaid in whole or in
part without premium or penalty; provided that loans bearing interest with
reference to the reserve adjusted Eurodollar Rate will be prepayable only on
the last day of the related interest period unless the Borrower pays any
related breakage costs. Voluntary prepayments of the Term Facilities will be
applied to scheduled amortization payments as directed by the Borrower.  
 

 

  

  

  

 

 

 

  

 

Annex B-5  

  

 

 

 

 

  

  

  

  

 

    

Mandatory Prepayments:

  |  

The following mandatory prepayments will be required (subject to certain
customary basket amounts to be negotiated in the definitive Loan Documents):

  

   
---|--- 
   |  

1.

  |  

Asset Sales: Prepayments in an amount equal to 100% of the net cash proceeds
of the sale or other disposition of any property or assets of Parent or its
subsidiaries (in excess of certain thresholds and subject to certain
exceptions to be determined), other than net cash proceeds of sales or other
dispositions of inventory in the ordinary course of business and net cash
proceeds that are reinvested in other assets useful in the business of the
Parent and its subsidiaries within one year of receipt thereof.

  

   
   |  

2.

  |  

Insurance Proceeds: Prepayments in an amount equal to 100% of the net cash
proceeds of insurance paid on account of any loss of any property or assets of
the Parent or its subsidiaries, other than net cash proceeds that are
reinvested in other assets useful in the business of Parent and its
subsidiaries (or used to replace damaged or destroyed assets) within one year
of receipt thereof.

  

   
   |  

3.

  |  

Incurrence of Indebtedness: Prepayments in an amount equal to 100% of the net
cash proceeds received from the incurrence of indebtedness by the Parent or
its subsidiaries (other than indebtedness otherwise permitted under the Loan
Documents and other exceptions to be agreed), payable no later than the first
business day following the date of receipt.

  

   
   |  

4.

  |  

Equity Offerings: Prepayments in an amount equal to 50% (subject to reductions
to a lower percentage upon achievement of certain financial performance
measures to be determined) of the net cash proceeds received from the issuance
of equity securities of Parent, the Borrower or their respective subsidiaries
(other than issuances pursuant to employee stock plans and other exceptions to
be mutually agreed upon by the Borrower and the Administrative Agent).

  

   
   |  

5.

  |  

Excess Cash Flow: Prepayments in an amount equal to 50% (subject to reductions
to a lower percentage upon achievement of certain financial performance
measures to be determined) of "excess cash flow" (to be defined in the
applicable Loan Document), payable within 90 days of fiscal year-end
(commencing for the fiscal year ended December 31, 2011); provided that
voluntary prepayments of loans under the Revolving Facility (to the extent
accompanied by a permanent commitment reduction in like amount) or the Term
Facilities (other than, in each case, prepayments funded with the proceeds of
incurrences of indebtedness, equity issuances or contributions or asset
dispositions) shall be credited against excess cash flow prepayment
obligations on a dollar-for-dollar basis.

  

   
 

 

  

  

  


 

  

 

 

 

  

 

Annex B-6  

  

 

 

 

  

  

  

  

 

     |  

All mandatory prepayments will be applied without penalty or premium (except
for breakage costs, if any) and will be applied first pro rata to the Term
Facilities (and applied pro rata to remaining scheduled amortization payments
and the payments at final maturity); provided that, at the election of holders
of loans under the Term B Facility, the portion of proceeds otherwise
allocable thereto may be allocated to repay the loans under Term A Facility in
full prior to prepayment of the loans under the Term B Facility held by such
holders; and, second, to outstanding loans under the Revolving Facility.

  

   
---|--- 
  

Security:

  |  

The Senior Facilities, each Guarantee and any interest rate and currency
hedging obligations of the Borrower or any Guarantor owed to the
Administrative Agent, the Arrangers, any Lender or any affiliate of the
Administrative Agent, the Arrangers or any Lender (the "Hedging Obligations")
will be secured by first priority security interests in substantially all
assets, including, without limitation, substantially all personal, material
and owned real and mixed property of the Borrower and the Guarantors (except
as otherwise agreed to by the Arrangers or set forth below). In addition, the
Senior Facilities will be secured by a first priority security interest in
100% of the capital stock of the Borrower and each domestic subsidiary of the
Borrower, 65% of the capital stock of each foreign subsidiary of the Borrower,
and 100% of the capital stock of each subsidiary of the Parent that is not
also a subsidiary of the Borrower, and all intercompany debt. All security
arrangements relating to the Senior Facilities and the Hedging Obligations
will be in form and substance reasonably satisfactory to the Administrative
Agent and the Arrangers and, subject to the limitations set forth in the
Commitment Letter, will be perfected on the Closing Date; provided, that with
respect to guarantees and collateral documentation regarding the Merger Party,
such documentation shall be been delivered in escrow to counsel to the
Arrangers pursuant to instructions providing for the release and effectiveness
of such documentation concurrently with the effectiveness of the Merger as set
forth in the Merger Certificate (as defined in Annex C to the Commitment
Letter).

  

   
 

 

  

  

  

  

  

  

 

 

 

  

 

Annex B-7  

  

 

 

 

  

  

  

 

    

  |  

Notwithstanding the foregoing, the collateral shall not include: (a) motor
vehicles and other assets subject to certificates of title, (b) letter of
credit rights (other than letter of credit rights that are supporting
obligations), (c) deposit accounts the funds in which are used solely for the
payment of salaries and wages, workers' compensation and similar expenses, (d)
equity interests in any person that is not a direct or indirect wholly owned
subsidiary of the Parent (with subsidiaries the minority interest in which is
held by management, directors or employees of the Parent or its subsidiaries
or consists of rolled-over equity to be treated as wholly owned for purposes
of the foregoing) if the organizational or governance documents of such person
prohibit the grant of a security interest therein without the consent of any
third party, (e) any license, contract or agreement if the grant of a security
interest therein would result in a breach thereof (other than to the extent
that any such provision would be rendered ineffective pursuant to applicable
provisions of the UCC), (f) any equipment owned by the Borrower or any
Guarantor that is subject to a purchase money security interest if the
agreement pursuant to which such purchase money security interest has been
granted prohibits a grant of a security interest therein without the consent
of any third party, (g) leasehold interests and (f) other assets (including
owned real property and commercial tort claims) if the Administrative Agent,
in consultation with the Borrower, determines that the cost or burden of
creating or perfecting a security interest therein shall be excessive in view
of the benefits to be obtained by the Lenders therefrom.

  

   
---|--- 
  

Representations and Warranties:

  |  

The credit agreement for the Senior Facilities will contain representations
and warranties by the Borrower (with respect to the Parent, the Borrower and
their respective subsidiaries) as to the following matters: due organization;
requisite power and authority; qualification; equity interests and ownership;
due authorization, execution, delivery and enforceability of the Loan
Documents; creation, perfection and priority of security interests; no
conflicts; governmental consents; historical and projected financial
condition; no material adverse change; no restricted junior payments; absence
of material litigation; payment of taxes; title to properties; environmental
matters; no defaults under material agreements; Investment Company Act and
margin stock matters; ERISA and other employee matters; solvency of the
Parent, Borrower and each of the Guarantors, subject to customary assumptions
regarding credit support; compliance with laws; full disclosure; and Patriot
Act and other related matters.

  

   
  

Covenants:

  

  |  

The definitive Loan Documents for the Senior Facilities will contain
financial, affirmative and negative covenants by each of the Parent and the
Borrower (with respect to Parent and the Borrower and their subsidiaries) that
consist of the following:

  

   
  

\- financial covenants:

  |  

maximum total leverage ratio, minimum total interest coverage, maximum capital
expenditures, with financial definitions and covenant levels to be mutually
agreed upon by the Borrower and the Arrangers, and

  

   
 

 

  

  

  

  

 

 

 

  

 

Annex B-8  

  

 

 

 

  

  

  

 

    

\- affirmative covenants:

  

  |  

delivery of financial statements and other reports (including the
identification of information as suitable for distribution to Public Lenders);
maintenance of existence; payment of taxes and claims; maintenance of
properties; maintenance of insurance; cooperation with syndication efforts;
books and records; inspections; annual lender meetings; compliance with laws;
environmental matters; additional collateral and guarantors; maintenance of
corporate level and facility level ratings; and further assurances, including,
in each case, exceptions and baskets to be mutually agreed upon by the
Borrower and the Arrangers, and

  

   
---|--- 
  

\- negative covenants:

  |  

limitations with respect to other indebtedness; liens; negative pledges;
restricted junior payments (e.g., no dividends, redemptions or voluntary
payments on certain debt); restrictions on subsidiary distributions;
investments, mergers and acquisitions; sales of assets (including subsidiary
interests); sales and lease-backs; transactions with affiliates; conduct of
business; amendments and waivers of organizational documents, junior
indebtedness and other material agreements; and changes to fiscal year,
including, in each case, exceptions and baskets to be mutually agreed upon by
the Borrower and the Arrangers (including, without limitation, to the
limitation on restricted junior payments to permit the Dividend and the Post-
Merger Special Dividend).

  

   
  

Events of Default:

  

  |  

The definitive Loan Documents for the Senior Facilities will include events of
default (and usual and customary grace periods) that consist of the following:
failure to make payments when due, cross-default under material indebtedness,
noncompliance with covenants, breaches of representations and warranties,
bankruptcy, judgments in excess of specified amounts, ERISA, invalidity of
security interests in collateral, invalidity of guarantees and "change of
control" (to be defined in a manner to be mutually agreed upon by the Borrower
and the Arrangers).

  

   
  

Conditions Precedent to the Initial Draw and

  

the Second Draw:

  

  |  

The several obligations of the Lenders to make loans to the Borrower in
respect of the Initial Draw and the Second Draw will be subject to the
conditions precedent referred to in the Commitment Letter and listed on Annex
C attached to the Commitment Letter.

  

   
  

Conditions to All Borrowings:

  |  

The making of each extension of credit under the Senior Facilities will be
subject to (a) prior written notice of borrowing, (b) the accuracy of
representations and warranties that are qualified by materiality and the
accuracy in all material respects of the representations and warranties not so
qualified (subject to the limitations set forth in the Commitment Letter) and
(c) after the Closing Date, the absence of any default or event of default.

   
 

 

  

  

  

  

 

 

 

  

 

Annex B-9  

  

 

 

 

  

  

  

 

    

  |  

Notwithstanding the foregoing, any fact or matter that would cause a default
or event of default on the Closing Date had clause (c) been applicable on the
Closing Date shall not result in a failed condition to borrowing on the
Closing Date, but, unless cured or waived in accordance with the terms of the
Loan Documents, shall constitute a default or event of default, as applicable,
immediately thereafter.

  

  

In addition, as conditions to the funding of the Delayed-Draw Tranche, (i) the
Merger shall have been consummated and become effective and (ii) the Parent
shall have declared the Post-Merger Special Dividend to its shareholders.

  

   
---|--- 
  

Assignments and Participations:

  |  

The Lenders may assign all or, in an amount of not less than (x) $2.5 million
with respect to each of the Term A Facility and the Revolving Facility and (y)
$1.0 million with respect to the Term B Facility, any part of, their
respective shares of the Senior Facilities to their affiliates (other than
natural persons) or one or more banks, financial institutions or other
entities that are eligible assignees (to be defined in the Loan Documents)
which, in the case of assignments with respect to the Term A Facility and the
Revolving Facility (except in the case of assignments made by or to Goldman
Sachs), are reasonably acceptable to the Administrative Agent and (except
during the existence of an Event of Default) the Borrower, each such consent
not to be unreasonably withheld or delayed. Upon such assignment, such
affiliate, bank, financial institution or entity will become a Lender for all
purposes under the Loan Documents; provided, that assignments made to
affiliates and other Lenders will not be subject to the above described
consent or minimum assignment amount requirements. A $3,500 processing fee
will be required in connection with any such assignment. The Lenders will also
have the right to sell participations, subject to customary limitations on
voting rights, in their respective shares of the Senior Facilities.

  

   
  

Requisite Lenders:

  

  |  

Amendments and waivers will require the approval of Lenders holding more than
50% of total commitments or exposure under the Senior Facilities, except that
(x) any amendment that would disproportionately affect the obligation of the
Borrower to make payment of the loans under either the Revolving Facility or
the Term Facilities will not be effective without the approval of holders of
more than 50% of such class of loans and (y) with respect to matters relating
to the interest rates, maturity, amortization, certain collateral issues and
the definition of Requisite Lenders, consent of each Lender directly and
adversely affected thereby shall be required.

  

   
  

Taxes:

  

  |  

The Senior Facilities will provide that all payments are to be made free and
clear of any taxes (other than franchise taxes, taxes on overall net income),
imposts, assessments, withholdings or other deductions whatsoever not in
existence on the date on which the applicable institution became a Lender.
Lenders will furnish to the Administrative Agent appropriate certificates or
other evidence of exemption from U.S. federal tax withholding.

  

   
 

 

  

  

  

  

 

 

 

  

 

Annex B-10  

  

 

 

 

  

  

  

 

    

Indemnity:

  

  |  

The Senior Facilities will provide customary and appropriate provisions
relating to indemnity and related matters in a form reasonably satisfactory to
the Borrower, the Arrangers, the Administrative Agent and the Lenders.

  

   
---|--- 
  

Governing Law and Jurisdiction:

  |  

The Senior Facilities will provide that the Borrower will submit to the
exclusive jurisdiction and venue of the federal and state courts of the State
of New York (except to the extent the Collateral Agent requires submission to
any other jurisdiction in connection with the exercise of any rights under any
security document or the enforcement of any judgment) and will waive any right
to trial by jury. New York law will govern the Loan Documents, except with
respect to certain security documents where applicable local law is necessary
for enforceability or perfection.

  

   
  

Counsel to the Arrangers and Administrative Agent:

  

  |  

Cahill Gordon and Reindel LLP.

   
 

 

  

  

 

The foregoing is intended to summarize certain basic terms of the Senior
Facilities. It is not intended to be a definitive list of all of the
requirements of the Lenders in connection with the Senior Facilities. Any
terms to be set forth in the Loan Documents that are not otherwise set forth
in this Summary of Senior Facilities shall be reasonably acceptable to each of
the Borrower and the Administrative Agent.

  

 

  

  

 

 

 

  

 

Annex B-11  

  

 

 

 

  

  

  


 

  

Annex C

  

  

Summary of Conditions Precedent to the Senior Facilities

  

  

This Summary of Conditions Precedent outlines the conditions precedent to the
Senior Facilities referred to in the Commitment Letter, of which this Annex C
is a part. Certain capitalized terms used herein are defined in the Commitment
Letter.

  

  

    

A.

  |  

Initial Draw Conditions: The conditions to the Initial Draw (the "Initial Draw
Conditions") shall consist of the following (together with any other
conditions to funding expressly set forth in the Commitment Letter and in
Annex B thereto):

  

   
---|--- 
  

1.

  |  

Acquisition: The terms of the Merger Agreement (including the exhibits,
schedules, disclosure letters and all related documents) will be reasonably
satisfactory to the Arrangers; provided that the Arrangers acknowledge that
the Merger Agreement draft dated as of June 20, 2010 is reasonably acceptable
to the Arrangers. All conditions precedent to the consummation of the Merger
in the Merger Agreement dated as of June 20, 2010 shall have been satisfied or
waived, without giving effect to any amendments thereto or any waivers or
consents that are materially adverse to the Arrangers or the Lenders in their
capacities as Lenders, in each case without the consent of the Arrangers
(provided that any (i) change in the form of Merger consideration, (ii) any
increase in the Merger consideration or (iii) any decrease in the Merger
consideration that is not accompanied by a corresponding dollar-for-dollar
reduction in the Dividend and the amount of the Term B Facility, shall be
deemed to be materially adverse and require the consent of the Arrangers).

  

   
  

2.

  |  

Existing Indebtedness of the Company: There will not exist (pro forma for the
Merger and the financing thereof) any default or event of default under the
Company's 3.0% Convertible Subordinated Notes due 2010 or 4.0% Convertible
Subordinated Notes due 2013 (together, the "Convertible Notes"). Concurrently
with the consummation of the Merger and after giving effect to the financing
thereof, the Company shall not have any material indebtedness outstanding
other than (i) under the Senior Facilities, as contemplated by the Commitment
Letter, (ii) the Securities, if issued, and (iii) the Company's 3.0%
Convertible Subordinated Notes due 2010 and 4.0% Convertible Subordinated
Notes due 2013. On or prior to the Closing Date, the Company shall have:

  

   
   |  |  

a.

  |  

either (i) issued an irrevocable call notice with respect to all of the
Existing Notes in accordance with the terms of the indentures governing the
Existing Notes and on terms reasonably acceptable to the Commitment Parties or
(ii) (A) consummated a tender offer (the "Tender Offer") with respect to each
of the Existing Notes and solicited consents to amendments to the indentures
(the "Supplemental Indentures") related thereto that will eliminate
substantially all the covenants contained therein on terms reasonably
acceptable to the Commitment Parties, (B) accepted for purchase at least 50.1%
of each of the 2016 Notes and the 2020 Notes and (C) entered into the
Supplemental Indentures related to each of the 2016 Notes and the 2020 Notes
on terms reasonably acceptable to the Commitment Parties; and

  

   
   |  |  

b.

  |  

repaid in full, terminated and released all liens relating to the Company's
credit and guaranty agreement, dated as of May 26, 2010, between the Company,
the guarantors party thereto, GSLP as sole lead arranger and GS Bank, as
administrative agent and collateral agent (the "Existing GSLP Facility").

  

   
  

  

  

  

 

 

 

  

 

Annex C-1  

  

 

 

 

  

  

  

     

3.

  

  |  

Financial Statements. The Arrangers shall have received (i) at least 30 days
prior to the Closing Date, audited financial statements of the Company and the
Merger Party for each of the three fiscal years immediately preceding the
Merger ended more than 90 days prior to the Closing Date; (ii) as soon as
internal financial statements are available, and in any event at least 5 days
prior to the Closing Date, unaudited financial statements for any fiscal
quarter of the Company and the Merger Party ended after the date of the most
recent audited financial statements of such person and more than 45 days prior
to the Closing Date; and (iii) customary pro forma financial statements,
giving effect to the Merger, the Refinancing, the Dividend, the Senior
Facilities and/or Securities and any borrowings thereunder.

  

   
---|--- 
  

4.

  

  |  

Performance of Obligations. All costs, fees, expenses (including, without
limitation, legal fees and expenses, title premiums, survey charges and
recording taxes and fees) and other compensation contemplated by the
Commitment Letter and the Fee Letter payable to the Commitment Parties, the
Arrangers, the Administrative Agent or the Lenders on the Closing Date shall
have been paid to the extent due and the Company and the Merger Party shall
have complied in all material respects with all of their respective
obligations under the Commitment Letter and the Fee Letter.

  

   
  

5.

  

  |  

Customary Closing Documents. The Arrangers shall be satisfied that the Company
and the Merger Party have complied with the following closing conditions and
delivered the following customary documentation relating to the Borrower and
all of the Guarantors (including the Merger Party): (i) the delivery of
customary legal opinions, corporate records and documents from public
officials, lien searches and officer's certificates as to the Borrower and
each of the Guarantors; (ii) absence of pending or ongoing litigation seeking
to enjoin the Merger that could reasonably be expected to result in an
injunction of the Merger after the funding of the Senior Facilities; (iii)
obtaining material third party and governmental consents necessary in
connection with the Merger or the financings thereof; (iv) evidence of
authority; (v) subject to the limitations set forth in the Commitment Letter,
perfection of liens, pledges, and mortgages on the collateral securing the
Senior Facilities; (vi) delivery of satisfactory commitments for title
insurance; (vii) evidence of customary insurance; and (viii) delivery of a
solvency certificate from the chief financial officer of the Borrower in form
and substance, and with supporting documentation, reasonably satisfactory to
the Administrative Agent, as to the Borrower, Parent and each Guarantor. The
Arrangers will have received at least 10 days prior to the Closing Date all
documentation and other information required by bank regulatory authorities
under applicable "know-your-customer" and anti-money laundering rules and
regulations, including the Patriot Act, to the extent requested at least 15
days prior to the Closing Date; provided, that with respect to guarantees and
collateral documentation regarding Parent and each of the Guarantors that is
not a subsidiary of the Borrower, such documentation shall be been delivered
in escrow to counsel to the Arrangers pursuant to instructions providing for
the release and effectiveness of such documentation concurrently with the
effectiveness of the Merger as set forth in the Merger Certificate (as defined
below).

  

   
  

6.

  

  |  

Maximum Leverage Ratio. At the time of funding, the total amount of
indebtedness will be limited such that the ratio of (i) total indebtedness for
Parent and its subsidiaries as of the Closing Date (assuming the consummation
of the Merger) to (ii) pro forma consolidated adjusted EBITDA (calculated in
accordance with Regulation S-X together with such additional adjustments as
the Arrangers agree are appropriate, but not including any synergies relating
to the Merger) for the latest four-quarter period for which financial
statements are then publicly available will not be greater than 3.75:1.00.

  

   
  

  

  

  

  

 

 

 

  

 

Annex C-2  

  

 

 

 

  

  

  

     

B.

  |  

Second Draw Conditions: In addition to the continued satisfaction of the
Initial Draw Conditions, the Second Draw shall be subject to the following
additional conditions (collectively with the Initial Draw Conditions, the
"Second Draw Conditions"):

  

   
---|--- 
  

1.

  

  |  

Merger Certificate: The certificate relating to the Merger (the "Merger
Certificate") shall be filed with the Delaware Secretary of State
substantially concurrently with the funding of the Second Draw. The Merger
Certificate shall provide that the Merger shall become automatically effective
at 12:01 a.m. (Eastern time) on the date following the filing of the Merger
Certificate (without any additional conditions to effectiveness).

  

   
  

2.

  |  

Existing Indebtedness of the Merger Party: There will not exist (pro forma for
the Merger and the financing thereof) any default or event of default under
any material indebtedness of the Parent or its subsidiaries. Pro forma for the
consummation of the Merger, all material pre-existing indebtedness of the
Merger Party (other than indebtedness outstanding under the Senior Facilities,
any Securities, the Convertible Notes and the Parent's 5.375% Convertible
Notes due 2014) shall have been repaid or repurchased in full, all commitments
relating thereto shall have been terminated, and all liens or security
interests related thereto shall have been terminated or released, in each case
on terms satisfactory to the Arrangers and subject to exceptions to be
mutually agreed upon.

   
 

 

 

  

  

  

  

  

  

  

  

Annex C-3     

 

         '

